



Study results
Risk of subsequent cardiovascular events in patients
discharged after myocardial infarction - Perseus
(1 of 3)
Primary objectives

Study #9502
April 21st 2016
Version 1.0

Prepared for
AstraZeneca Nordic Baltic

By EPID Research Oy

Contents

1	Primary objectives	4
1.1	Population Description	4
1.1.1	Population flowchart	4
1.1.2	Index MI event characterization	5
1.1.3	Patients baseline characteristics at index date for group 1 and at the 1 year baseline check for groups 2-5	10
1.1.4	Type of invasive procedure stratified by age	20
1.1.5	Type of invasive procedure stratified by sex	20
1.1.6	Type of invasive procedure stratified by type of index MI	20
1.1.7	Gender distribution in STEMI patients with a PCI	21
1.1.8	Secondary prevention drugs use	22
1.2	Stratified incidence rates of primary outcomes	24
1.2.1	Stratified incidence rates for group 1	24
	Myocardial infarction	24
	Stroke (total)	26
	Cardiovascular mortality	28
	Composite end-point	30
	Overall mortality	32
1.2.2	Stratified incidence rates for group 2	34
	Myocardial infarction	34
	Stroke (total)	36
	Cardiovascular mortality	38
	Composite end-point	40
	Overall mortality	42
1.2.3	Stratified incidence rates for group 3	44
	Myocardial infarction	44
	Stroke (total)	46
	Cardiovascular mortality	48
	Composite end-point	50
	Overall mortality	52
1.2.4	Stratified incidence rates for group 4	54
	Myocardial infarction	54
	Stroke (total)	56
	Cardiovascular mortality	58
	Composite end-point	60
	Overall mortality	62
1.2.5	Stratified incidence rates for group 5	64
	Myocardial infarction	64
	Stroke (total)	66
	Cardiovascular mortality	68
	Composite end-point	70

	Overall mortality	72
1.3	Explored risk factors for primary outcomes	74
1.3.1	Explored risk factors for group 1	74
	Myocardial infarction	74
	Stroke (total)	77
	Cardiovascular mortality	81
	Composite end-point	85
	Overall mortality	89
1.3.2	Explored risk factors for group 2	94
	Myocardial infarction	94
	Stroke (total)	97
	Cardiovascular mortality	101
	Composite end-point	105
	Overall mortality	109
1.3.3	Explored risk factors for group 3	114
	Myocardial infarction	114
	Stroke (total)	117
	Cardiovascular mortality	120
	Composite end-point	124
	Overall mortality	128
1.3.4	Explored risk factors for group 4	133
	Myocardial infarction	133
	Stroke (total)	136
	Cardiovascular mortality	139
	Composite end-point	143
	Overall mortality	147
1.3.5	Explored risk factors for group 5	152
	Myocardial infarction	152
	Stroke (total)	155
	Cardiovascular mortality	158
	Composite end-point	161
	Overall mortality	164
1.3.6	Explored risk factors for group 1 (first year only)	168
	Myocardial infarction	168
	Stroke (total)	171
	Cardiovascular mortality	174
	Composite end-point	178
	Overall mortality	182
1.4	Cumulative incidence rates for the primary outcomes	187
1.4.1	cumulative incidence of primary outcomes for group 1	187
	Myocardial infarction	187
	Stroke (total)	190
	Cardiovascular mortality	192
	Composite end-point	195
	Overall mortality	197
1.4.2	Cumulative incidence of primary outcomes for group 2	201
	Myocardial infarction	201
	Stroke (total)	206
	Cardiovascular mortality	211
	Composite end-point	216
	Overall mortality	221


1.4.3	Cumulative incidence of primary outcomes for group 3	227
	Myocardial infarction	227
	Stroke (total)	232
	Cardiovascular mortality	237
	Composite end-point	242
	Overall mortality	247
1.4.4	Cumulative incidence of primary outcomes for group 4	253
	Myocardial infarction	253
	Stroke (total)	257
	Cardiovascular mortality	261
	Composite end-point	265
	Overall mortality	269
1.4.5	Cumulative incidence of primary outcomes for group 5	274
	Myocardial infarction	274
	Stroke (total)	277
	Cardiovascular mortality	280
	Composite end-point	283
	Overall mortality	286

Chapter 1

Primary objectives

1.1 Population Description

1.1.1 Population flowchart



1.1.2 Index MI event characterization

Table 1.1: Index MI event characterization for the study groups.

	Group 1 patients N = 35238	Group 2 patients N = 27188	Group 3 patients N = 22041	Group 4 patients N = 19194	Group 5 patients N = 8942
Type of index MI*					
MI at index (Total)	35238(100.00%)	27188(100.00%)	22041(100.00%)	19194(100.00%)	8942(100.00%)
ST elevation MI	11788(33.45%)	9874(36.32%)	7267(32.97%)	6463(33.67%)	2433(27.21%)
Non-ST elevation MI (or unspecified MI)	23450(66.55%)	17314(63.68%)	14774(67.03%)	12731(66.33%)	6509(72.79%)
Invasive procedure related to index event					
No invasive procedure	15424(43.77%)	9890(36.38%)	9101(41.29%)	7629(39.75%)	5111(57.16%)
Coronary angiography only	4934(14.00%)	4099(15.08%)	3141(14.25%)	2731(14.23%)	1445(16.16%)
PCI	12626(35.83%)	11167(41.07%)	8091(36.71%)	7389(38.50%)	2386(26.68%)
CABG	2254(6.40%)	2032(7.47%)	1708(7.75%)	1445(7.53%)	0(0.00%)
Time spent in hospital for index event					
[0,1) days	195(0.55%)	130(0.48%)	105(0.48%)	83(0.43%)	47(0.53%)
[1,3) days	2800(7.95%)	2314(8.51%)	1666(7.56%)	1494(7.78%)	716(8.01%)
[3,7) days	15206(43.15%)	12739(46.86%)	9434(42.80%)	8578(44.69%)	3745(41.88%)
[7,14) days	8939(25.37%)	6502(23.91%)	5744(26.06%)	4888(25.47%)	2432(27.20%)
[14,21) days	3552(10.08%)	2498(9.19%)	2265(10.28%)	1882(9.81%)	855(9.56%)
[21,30) days	1892(5.37%)	1280(4.71%)	1196(5.43%)	949(4.94%)	439(4.91%)
30 and over	2654(7.53%)	1725(6.34%)	1631(7.40%)	1320(6.88%)	708(7.92%)
range (min,max)	(0.00, 1390.00)	(0.00, 1390.00)	(0.00, 1390.00)	(0.00, 1390.00)	(0.00, 1390.00)
mean (+/-sd)	12.91 (29.89)	11.72 (28.09)	12.93 (30.46)	12.50 (30.89)	13.63 (33.73)
median (Q1,Q3)	6.00 (4.00, 13.00)	6.00 (4.00, 11.00)	6.00 (4.00, 13.00)	6.00 (4.00, 12.00)	6.00 (4.00, 12.00)
Type of hospital (at index event)					
University	13244(37.58%)	10965(40.33%)	8421(38.21%)	7379(38.44%)	2700(30.19%)
Central	13906(39.46%)	10737(39.49%)	8665(39.31%)	7548(39.32%)	3776(42.23%)
Other	8088(22.95%)	5486(20.18%)	4955(22.48%)	4267(22.23%)	2466(27.58%)

Each column corresponds to one of the study groups

The percentages for each variable correspond to the proportion of patients within each of the study groups.

** - For this group, each row is a separate variable, the numbers and proportions correspond to the proportion of yes in each variable. (Percentages will not sum up to 100%).*

Table 1.1: (continued)

	Group 1 patients N = 35238	Group 2 patients N = 27188	Group 3 patients N = 22041	Group 4 patients N = 19194	Group 5 patients N = 8942
University or Central hospital stay during index event					
No	5790(16.43%)	3640(13.39%)	3383(15.35%)	2889(15.05%)	1926(21.54%)
Yes	29448(83.57%)	23548(86.61%)	18658(84.65%)	16305(84.95%)	7016(78.46%)
Hospital region(at index event)					
Ahvenanmaa	0(0.00%)	0(0.00%)	0(0.00%)	0(0.00%)	0(0.00%)
HYKS	9049(25.68%)	7227(26.58%)	5765(26.16%)	5160(26.88%)	2038(22.79%)
KYS	7044(19.99%)	5324(19.58%)	4322(19.61%)	3642(18.97%)	1784(19.95%)
OYS	6314(17.92%)	4861(17.88%)	3893(17.66%)	3394(17.68%)	1459(16.32%)
TAYS	6927(19.66%)	5275(19.40%)	4289(19.46%)	3701(19.28%)	1883(21.06%)
TYKS	5904(16.75%)	4501(16.56%)	3772(17.11%)	3297(17.18%)	1778(19.88%)

Each column corresponds to one of the study groups

The percentages for each variable correspond to the proportion of patients within each of the study groups.

* - For this group, each row is a separate variable, the numbers and proportions correspond to the proportion of yes in each variable. (Percentages will not sum up to 100%).

Table 1.1: (continued)

	Group 1 patients N = 35238	Group 2 patients N = 27188	Group 3 patients N = 22041	Group 4 patients N = 19194	Group 5 patients N = 8942
Hospital region (at index event)					
Ahvenanmaa	0(0.00%)	0(0.00%)	0(0.00%)	0(0.00%)	0(0.00%)
Etelä-Karjala	1263(3.58%)	928(3.41%)	766(3.48%)	671(3.50%)	310(3.47%)
Etelä-Pohjanmaa	1181(3.35%)	861(3.17%)	702(3.18%)	613(3.19%)	290(3.24%)
Etelä-Savo	1128(3.20%)	823(3.03%)	667(3.03%)	557(2.90%)	283(3.16%)
Helsinki and Uusimaa	6599(18.73%)	5381(19.79%)	4197(19.04%)	3756(19.57%)	1407(15.73%)
Itä-Savo	478(1.36%)	344(1.27%)	270(1.22%)	240(1.25%)	142(1.59%)
Kainuu	886(2.51%)	656(2.41%)	529(2.40%)	456(2.38%)	223(2.49%)
Kanta-Häme	976(2.77%)	678(2.49%)	577(2.62%)	502(2.62%)	306(3.42%)
Keski-Pohjanmaa	759(2.15%)	583(2.14%)	473(2.15%)	407(2.12%)	245(2.74%)
Keski-Suomi	1898(5.39%)	1431(5.26%)	1180(5.35%)	1005(5.24%)	451(5.04%)
Kymenlaakso	1187(3.37%)	918(3.38%)	802(3.64%)	733(3.82%)	321(3.59%)
Länsi-Pohja	529(1.50%)	406(1.49%)	324(1.47%)	268(1.40%)	103(1.15%)
Lappi	866(2.46%)	668(2.46%)	514(2.33%)	470(2.45%)	198(2.21%)
Päijät-Häme	1336(3.79%)	1019(3.75%)	834(3.78%)	716(3.73%)	361(4.04%)
Pirkanmaa	3434(9.75%)	2717(9.99%)	2176(9.87%)	1870(9.74%)	926(10.36%)
Pohjois-Karjala	1131(3.21%)	887(3.26%)	699(3.17%)	598(3.12%)	408(4.56%)
Pohjois-Pohjanmaa	3274(9.29%)	2548(9.37%)	2053(9.31%)	1793(9.34%)	690(7.72%)
Pohjois-Savo	2409(6.84%)	1839(6.76%)	1506(6.83%)	1242(6.47%)	500(5.59%)
Satakunta	1706(4.84%)	1343(4.94%)	1143(5.19%)	981(5.11%)	653(7.30%)
Vaasa	1113(3.16%)	812(2.99%)	671(3.04%)	609(3.17%)	285(3.19%)
Varsinais-Suomi	3085(8.75%)	2346(8.63%)	1958(8.88%)	1707(8.89%)	840(9.39%)
Type of hospital (at discharge)					
University	8574(24.33%)	7375(27.13%)	5421(24.60%)	4833(25.18%)	1692(18.92%)
Central	11695(33.19%)	9566(35.18%)	7376(33.46%)	6511(33.92%)	2965(33.16%)
Other	14969(42.48%)	10247(37.69%)	9244(41.94%)	7850(40.90%)	4285(47.92%)

Each column corresponds to one of the study groups

The percentages for each variable correspond to the proportion of patients within each of the study groups.

* - For this group, each row is a separate variable, the numbers and proportions correspond to the proportion of yes in each variable. (Percentages will not sum up to 100%).

Table 1.1: (continued)

	Group 1 patients N = 35238	Group 2 patients N = 27188	Group 3 patients N = 22041	Group 4 patients N = 19194	Group 5 patients N = 8942
Hospital region(at discharge)					
Ahvenanmaa	0(0.00%)	0(0.00%)	0(0.00%)	0(0.00%)	0(0.00%)
HYKS	8850(25.11%)	7047(25.92%)	5648(25.62%)	5054(26.33%)	2003(22.40%)
KYS	7032(19.96%)	5316(19.55%)	4321(19.60%)	3644(18.99%)	1780(19.91%)
OYS	6324(17.95%)	4874(17.93%)	3900(17.69%)	3393(17.68%)	1460(16.33%)
TAYS	7106(20.17%)	5434(19.99%)	4390(19.92%)	3797(19.78%)	1920(21.47%)
TYKS	5926(16.82%)	4517(16.61%)	3782(17.16%)	3306(17.22%)	1779(19.89%)
Hospital region (at discharge)					
Ahvenanmaa	0(0.00%)	0(0.00%)	0(0.00%)	0(0.00%)	0(0.00%)
Etelä-Karjala	1270(3.60%)	936(3.44%)	760(3.45%)	663(3.45%)	303(3.39%)
Etelä-Pohjanmaa	1367(3.88%)	1020(3.75%)	825(3.74%)	720(3.75%)	330(3.69%)
Etelä-Savo	1135(3.22%)	822(3.02%)	671(3.04%)	556(2.90%)	282(3.15%)
Helsinki and Uusimaa	6304(17.89%)	5110(18.80%)	4019(18.23%)	3594(18.72%)	1374(15.37%)
Itä-Savo	478(1.36%)	347(1.28%)	272(1.23%)	240(1.25%)	141(1.58%)
Kainuu	904(2.57%)	676(2.49%)	547(2.48%)	475(2.47%)	228(2.55%)
Kanta-Häme	1222(3.47%)	895(3.29%)	729(3.31%)	639(3.33%)	353(3.95%)
Keski-Pohjanmaa	732(2.08%)	565(2.08%)	455(2.06%)	391(2.04%)	232(2.59%)
Keski-Suomi	1966(5.58%)	1487(5.47%)	1229(5.58%)	1047(5.45%)	462(5.17%)
Kymenlaakso	1276(3.62%)	1001(3.68%)	869(3.94%)	797(4.15%)	326(3.65%)
Länsi-Pohja	539(1.53%)	415(1.53%)	336(1.52%)	276(1.44%)	104(1.16%)
Lappi	914(2.59%)	710(2.61%)	549(2.49%)	491(2.56%)	210(2.35%)
Päijät-Häme	1506(4.27%)	1167(4.29%)	940(4.26%)	813(4.24%)	388(4.34%)
Pirkanmaa	3011(8.54%)	2352(8.65%)	1896(8.60%)	1625(8.47%)	849(9.49%)
Pohjois-Karjala	1142(3.24%)	898(3.30%)	712(3.23%)	610(3.18%)	413(4.62%)
Pohjois-Pohjanmaa	3235(9.18%)	2508(9.22%)	2013(9.13%)	1760(9.17%)	686(7.67%)
Pohjois-Savo	2311(6.56%)	1762(6.48%)	1437(6.52%)	1191(6.21%)	482(5.39%)
Satakunta	1731(4.91%)	1358(4.99%)	1158(5.25%)	990(5.16%)	658(7.36%)
Vaasa	1145(3.25%)	834(3.07%)	690(3.13%)	628(3.27%)	292(3.27%)
Varsinais-Suomi	3050(8.66%)	2325(8.55%)	1934(8.77%)	1688(8.79%)	829(9.27%)

Each column corresponds to one of the study groups

The percentages for each variable correspond to the proportion of patients within each of the study groups.

* - For this group, each row is a separate variable, the numbers and proportions correspond to the proportion of yes in each variable. (Percentages will not sum up to 100%).

Table 1.1: *(continued)*

	Group 1 patients N = 35238	Group 2 patients N = 27188	Group 3 patients N = 22041	Group 4 patients N = 19194	Group 5 patients N = 8942
Index year					
2009	9010(25.57%)	6747(24.82%)	5474(24.84%)	4806(25.04%)	2387(26.69%)
2010	8701(24.69%)	6703(24.65%)	5422(24.60%)	4753(24.76%)	2182(24.40%)
2011	8772(24.89%)	6870(25.27%)	5552(25.19%)	4818(25.10%)	2180(24.38%)
2012	8755(24.85%)	6868(25.26%)	5593(25.38%)	4817(25.10%)	2193(24.52%)

Each column corresponds to one of the study groups

The percentages for each variable correspond to the proportion of patients within each of the study groups.

** - For this group, each row is a separate variable, the numbers and proportions correspond to the proportion of yes in each variable. (Percentages will not sum up to 100%).*

1.1.3 Patients baseline characteristics at index date for group 1 and at the 1 year baseline check for groups 2-5

Table 1.2: Patient characteristics for the study groups at hospital discharge for group 1 and at the 1 year baseline check for groups 2-5.

	Group 1 patients N = 35238	Group 2 patients N = 27188	Group 3 patients N = 22041	Group 4 patients N = 19194	Group 5 patients N = 8942
Age (years)					
0-17	0(0.00%)	0(0.00%)	0(0.00%)	0(0.00%)	0(0.00%)
18-49	1973(5.60%)	1554(5.72%)	558(2.53%)	537(2.80%)	0(0.00%)
50-64	8531(24.21%)	7171(26.38%)	3020(13.70%)	2805(14.61%)	854(9.55%)
65-69	3704(10.51%)	3202(11.78%)	3202(14.53%)	2891(15.06%)	1075(12.02%)
70-74	4350(12.34%)	3450(12.69%)	3450(15.65%)	3009(15.68%)	1196(13.38%)
75-79	4930(13.99%)	3684(13.55%)	3684(16.71%)	3122(16.27%)	1401(15.67%)
80-84	5396(15.31%)	3788(13.93%)	3788(17.19%)	3132(16.32%)	1773(19.83%)
85 and over	6354(18.03%)	4339(15.96%)	4339(19.69%)	3698(19.27%)	2643(29.56%)
range (min,max)	(18.52, 102.83)	(19.50, 103.12)	(22.25, 103.12)	(22.25, 103.12)	(50.10, 103.12)
mean (+/-sd)	72.33 (12.97)	71.47 (12.86)	75.09 (11.09)	74.69 (11.30)	78.47 (10.03)
median (Q1,Q3)	73.94 (62.95, 82.69)	72.61 (62.34, 81.77)	76.08 (67.96, 83.43)	75.57 (67.38, 83.22)	79.85 (71.44, 86.13)
Sex					
Male	21261(60.34%)	16904(62.17%)	12783(58.00%)	11153(58.11%)	4394(49.14%)
Female	13977(39.66%)	10284(37.83%)	9258(42.00%)	8041(41.89%)	4548(50.86%)
History of myocardial infarction*					
MI (Total)	2329(6.61%)	1047(3.85%)	1047(4.75%)	907(4.73%)	439(4.91%)
ST elevation MI	648(1.84%)	326(1.20%)	326(1.48%)	298(1.55%)	129(1.44%)
Non-ST elevation MI	1319(3.74%)	568(2.09%)	568(2.58%)	486(2.53%)	233(2.61%)
Unspecified acute MI	733(2.08%)	303(1.11%)	303(1.37%)	260(1.35%)	145(1.62%)
MI complications	39(0.11%)	31(0.11%)	25(0.11%)	15(0.08%)	8(0.09%)

Each column corresponds to one of the study groups

The percentages for each variable correspond to the proportion of patients within each of the study groups.

* - For this group, each row is a separate variable, the numbers and proportions correspond to the proportion of yes in each variable. (Percentages will not sum up to 100%).

Table 1.2: (continued)

	Group 1 patients N = 35238	Group 2 patients N = 27188	Group 3 patients N = 22041	Group 4 patients N = 19194	Group 5 patients N = 8942
Number of previous MI in history					
0	32909(93.39%)	26141(96.15%)	20994(95.25%)	18287(95.27%)	8503(95.09%)
1	1271(3.61%)	628(2.31%)	628(2.85%)	541(2.82%)	268(3.00%)
2	658(1.87%)	276(1.02%)	276(1.25%)	235(1.22%)	109(1.22%)
3	231(0.66%)	88(0.32%)	88(0.40%)	81(0.42%)	36(0.40%)
4	97(0.28%)	36(0.13%)	36(0.16%)	34(0.18%)	16(0.18%)
5 and over	72(0.20%)	19(0.07%)	19(0.09%)	16(0.08%)	10(0.11%)
range (min,max)	(0.00, 15.00)	(0.00, 9.00)	(0.00, 9.00)	(0.00, 9.00)	(0.00, 9.00)
mean (+/-sd)	0.12 (0.53)	0.06 (0.37)	0.08 (0.41)	0.08 (0.41)	0.08 (0.43)
median (Q1,Q3)	0.00 (0.00, 0.00)	0.00 (0.00, 0.00)	0.00 (0.00, 0.00)	0.00 (0.00, 0.00)	0.00 (0.00, 0.00)
Prior cardiovascular comorbidities*					
Heart failure	7311(20.75%)	5394(19.84%)	5128(23.27%)	3966(20.66%)	2326(26.01%)
Hypertension	32236(91.48%)	26644(98.00%)	21688(98.40%)	18851(98.21%)	8682(97.09%)
Hyperlipidemia	26020(73.84%)	24054(88.47%)	19260(87.38%)	16811(87.58%)	7017(78.47%)
Unstable angina pectoris	3156(8.96%)	2817(10.36%)	2412(10.94%)	2059(10.73%)	526(5.88%)
Stroke (Total)	2353(6.68%)	1265(4.65%)	1250(5.67%)	958(4.99%)	1(0.01%)
Haemorrhagic stroke	204(0.58%)	116(0.43%)	101(0.46%)	94(0.49%)	0(0.00%)
Ischaemic stroke	2172(6.16%)	1157(4.26%)	1157(5.25%)	873(4.55%)	0(0.00%)
Other stroke (not sub-classified)	22(0.06%)	10(0.04%)	10(0.05%)	5(0.03%)	1(0.01%)
Transient ischemic attack	1053(2.99%)	734(2.70%)	692(3.14%)	547(2.85%)	242(2.71%)
Major bleedings	1955(5.55%)	1579(5.81%)	1452(6.59%)	1207(6.29%)	537(6.01%)
Arrhythmia	7028(19.94%)	5390(19.82%)	4930(22.37%)	3043(15.85%)	1745(19.51%)
Atrial fibrillation	5359(15.21%)	3961(14.57%)	3754(17.03%)	2021(10.53%)	1275(14.26%)
Bleeding disorder	88(0.25%)	74(0.27%)	69(0.31%)	55(0.29%)	0(0.00%)
Other acute ischaemic heart diseases	155(0.44%)	116(0.43%)	104(0.47%)	87(0.45%)	41(0.46%)

Each column corresponds to one of the study groups

The percentages for each variable correspond to the proportion of patients within each of the study groups.

* - For this group, each row is a separate variable, the numbers and proportions correspond to the proportion of yes in each variable. (Percentages will not sum up to 100%).

Table 1.2: (continued)

	Group 1 patients N = 35238	Group 2 patients N = 27188	Group 3 patients N = 22041	Group 4 patients N = 19194	Group 5 patients N = 8942
Other prior comorbidities*					
Diabetes mellitus	9156(25.98%)	7081(26.04%)	6875(31.19%)	5875(30.61%)	2446(27.35%)
Chronic renal dysfunction	827(2.35%)	557(2.05%)	557(2.53%)	482(2.51%)	251(2.81%)
Severe liver disease	105(0.30%)	88(0.32%)	77(0.35%)	65(0.34%)	0(0.00%)
Severe renal failure requiring dialysis	106(0.30%)	61(0.22%)	61(0.28%)	57(0.30%)	0(0.00%)
COPD	1346(3.82%)	988(3.63%)	902(4.09%)	787(4.10%)	441(4.93%)
Dementia/Alzheimer's disease	1765(5.01%)	1302(4.79%)	1292(5.86%)	1143(5.95%)	875(9.79%)
Cancer	2435(6.91%)	1748(6.43%)	1625(7.37%)	1414(7.37%)	808(9.04%)
Ongoing OAP use*					
OAP use (Total)	1458(4.14%)	10287(37.84%)	7673(34.81%)	7382(38.46%)	0(0.00%)
Clopidogrel	1456(4.13%)	9748(35.85%)	7326(33.24%)	7042(36.69%)	0(0.00%)
Prasugrel	1(0.00%)	287(1.06%)	174(0.79%)	169(0.88%)	0(0.00%)
Ticagrelor	1(0.00%)	252(0.93%)	173(0.78%)	171(0.89%)	0(0.00%)

Each column corresponds to one of the study groups

The percentages for each variable correspond to the proportion of patients within each of the study groups.

* - For this group, each row is a separate variable, the numbers and proportions correspond to the proportion of yes in each variable. (Percentages will not sum up to 100%).

Table 1.2: (continued)

	Group 1 patients N = 35238	Group 2 patients N = 27188	Group 3 patients N = 22041	Group 4 patients N = 19194	Group 5 patients N = 8942
Ongoing medication*					
Anticoagulation medication	2885(8.19%)	3143(11.56%)	2950(13.38%)	103(0.54%)	69(0.77%)
Antithrombotic medication	6992(19.84%)	13489(49.61%)	10717(48.62%)	7870(41.00%)	334(3.74%)
ARB	6022(17.09%)	5623(20.68%)	4714(21.39%)	4040(21.05%)	1715(19.18%)
ACE inhibitor	7519(21.34%)	11440(42.08%)	9034(40.99%)	7781(40.54%)	3076(34.40%)
Nitrate	10683(30.32%)	9377(34.49%)	8686(39.41%)	7157(37.29%)	3806(42.56%)
Beta-blocker	14857(42.16%)	20652(75.96%)	16784(76.15%)	14511(75.60%)	6230(69.67%)
Calcium channel blocker	6532(18.54%)	4990(18.35%)	4436(20.13%)	3828(19.94%)	1746(19.53%)
Antidiabetic drugs	6866(19.48%)	5649(20.78%)	5649(25.63%)	4829(25.16%)	1872(20.93%)
Insulin	3163(8.98%)	2503(9.21%)	2503(11.36%)	2137(11.13%)	856(9.57%)
Oral antidiabetic	5049(14.33%)	4169(15.33%)	4168(18.91%)	3555(18.52%)	1340(14.99%)
LMWH	113(0.32%)	71(0.26%)	68(0.31%)	9(0.05%)	6(0.07%)
NOAC	10(0.03%)	30(0.11%)	28(0.13%)	1(0.01%)	1(0.01%)
Proton pump inhibitor	5793(16.44%)	6380(23.47%)	5627(25.53%)	4710(24.54%)	2341(26.18%)
Statin	12245(34.75%)	19453(71.55%)	15492(70.29%)	13487(70.27%)	5191(58.05%)
Fibrate	55(0.16%)	51(0.19%)	42(0.19%)	36(0.19%)	13(0.15%)
NSAID	2389(6.78%)	982(3.61%)	770(3.49%)	748(3.90%)	361(4.04%)
SSRI	1514(4.30%)	1336(4.91%)	1104(5.01%)	936(4.88%)	487(5.45%)
Warfarin	2728(7.74%)	3043(11.19%)	2856(12.96%)	90(0.47%)	60(0.67%)
Additinal risk factors*					
Age ≥ 65 years	24734(70.19%)	18463(67.91%)	18463(83.77%)	15852(82.59%)	8088(90.45%)
Diabetes with ongoing medication	6866(19.48%)	5649(20.78%)	5649(25.63%)	4829(25.16%)	1872(20.93%)
≥ 1 MI in addition to index MI	2329(6.61%)	1047(3.85%)	1047(4.75%)	907(4.73%)	439(4.91%)
Multivessel CAD	8037(22.81%)	7629(28.06%)	7629(34.61%)	6671(34.76%)	2485(27.79%)
Chronic renal dysfunction	827(2.35%)	557(2.05%)	557(2.53%)	482(2.51%)	251(2.81%)
Ischaemic stroke	2172(6.16%)	1157(4.26%)	1157(5.25%)	873(4.55%)	0(0.00%)

Each column corresponds to one of the study groups

The percentages for each variable correspond to the proportion of patients within each of the study groups.

* - For this group, each row is a separate variable, the numbers and proportions correspond to the proportion of yes in each variable. (Percentages will not sum up to 100%).

Table 1.2: (continued)

	Group 1 patients N = 35238	Group 2 patients N = 27188	Group 3 patients N = 22041	Group 4 patients N = 19194	Group 5 patients N = 8942
Number of additional risk factors					
0	6819(19.35%)	5147(18.93%)	0(0.00%)	0(0.00%)	0(0.00%)
1	15969(45.32%)	12284(45.18%)	12284(55.73%)	10966(57.13%)	5475(61.23%)
2	9021(25.60%)	7395(27.20%)	7395(33.55%)	6307(32.86%)	2805(31.37%)
3	2821(8.01%)	2045(7.52%)	2045(9.28%)	1673(8.72%)	602(6.73%)
4	549(1.56%)	292(1.07%)	292(1.32%)	225(1.17%)	56(0.63%)
5	59(0.17%)	25(0.09%)	25(0.11%)	23(0.12%)	4(0.04%)
6	0(0.00%)	0(0.00%)	0(0.00%)	0(0.00%)	0(0.00%)
range (min,max)	(0.00, 5.00)	(0.00, 5.00)	(1.00, 5.00)	(1.00, 5.00)	(1.00, 5.00)
mean (+/-sd)	1.28 (0.93)	1.27 (0.90)	1.57 (0.72)	1.54 (0.71)	1.47 (0.65)
median (Q1,Q3)	1.00 (1.00, 2.00)	1.00 (1.00, 2.00)	1.00 (1.00, 2.00)	1.00 (1.00, 2.00)	1.00 (1.00, 2.00)
Duration of anticoagulation medication exposure					
<90 days	31651(89.82%)	22935(84.36%)	18107(82.15%)	18106(94.33%)	8271(92.50%)
≥ 90 days	3587(10.18%)	4253(15.64%)	3934(17.85%)	1088(5.67%)	671(7.50%)
range (min,max)	(0.00, 360.00)	(0.00, 360.00)	(0.00, 360.00)	(0.00, 360.00)	(0.00, 360.00)
mean (+/-sd)	29.83 (87.92)	43.75 (100.24)	49.86 (105.80)	14.37 (47.85)	18.57 (54.80)
median (Q1,Q3)	0.00 (0.00, 0.00)	0.00 (0.00, 0.00)	0.00 (0.00, 0.00)	0.00 (0.00, 0.00)	0.00 (0.00, 0.00)
Chronic use of anticoagulation medication					
No	32583(92.47%)	24153(88.84%)	19194(87.08%)	19194(100.00%)	8942(100.00%)
Yes	2655(7.53%)	3035(11.16%)	2847(12.92%)	0(0.00%)	0(0.00%)

Each column corresponds to one of the study groups

The percentages for each variable correspond to the proportion of patients within each of the study groups.

* - For this group, each row is a separate variable, the numbers and proportions correspond to the proportion of yes in each variable. (Percentages will not sum up to 100%).

Table 1.2: (continued)

	Group 1 patients N = 35238	Group 2 patients N = 27188	Group 3 patients N = 22041	Group 4 patients N = 19194	Group 5 patients N = 8942
Pegasus exclusion criteria*					
Age <50	1973(5.60%)	1554(5.72%)	558(2.53%)	537(2.80%)	0(0.00%)
Use of OAP	1458(4.14%)	10287(37.84%)	7673(34.81%)	7382(38.46%)	0(0.00%)
Bleeding disorder	88(0.25%)	74(0.27%)	69(0.31%)	55(0.29%)	0(0.00%)
Increased bleeding risk (Total)	961(2.73%)	542(1.99%)	491(2.23%)	427(2.22%)	0(0.00%)
Intracranial bleeding	442(1.25%)	307(1.13%)	277(1.26%)	250(1.30%)	0(0.00%)
Central nervous tumour	17(0.05%)	11(0.04%)	9(0.04%)	8(0.04%)	0(0.00%)
Intracranial vascular abnormality	175(0.50%)	117(0.43%)	106(0.48%)	85(0.44%)	0(0.00%)
Gastrointestinal bleeding	354(1.00%)	114(0.42%)	105(0.48%)	89(0.46%)	0(0.00%)
Ischaemic stroke	2172(6.16%)	1157(4.26%)	1157(5.25%)	873(4.55%)	0(0.00%)
CABG	2722(7.72%)	2725(10.02%)	2337(10.60%)	1979(10.31%)	0(0.00%)
Severe liver disease	105(0.30%)	88(0.32%)	77(0.35%)	65(0.34%)	0(0.00%)
Severe renal failure requiring dialysis	106(0.30%)	61(0.22%)	61(0.28%)	57(0.30%)	0(0.00%)

Each column corresponds to one of the study groups

The percentages for each variable correspond to the proportion of patients within each of the study groups.

* - For this group, each row is a separate variable, the numbers and proportions correspond to the proportion of yes in each variable. (Percentages will not sum up to 100%).

Table 1.3: Characteristics of group 1 patients experiencing a subsequent MI, stroke or death within 1 year after discharge for the index MI event. Variables are evaluated at discharge for index MI event.

	group 1 patients experiencing a subsequent MI, stroke or death within 1 year after discharge N = 8050
Age at index (years)	
0-17	0(0.00%)
18-49	165(2.05%)
50-64	951(11.81%)
65-69	591(7.34%)
70-74	768(9.54%)
75-79	1214(15.08%)
80-84	1707(21.20%)
85 and over	2654(32.97%)
range (min,max)	(27.85, 102.83)
mean (+/-sd)	78.56 (11.30)
median (Q1,Q3)	81.11 (72.17, 86.80)
Sex	
Male	4357(54.12%)
Female	3693(45.88%)
History of myocardial infarction*	
MI (Total)	968(12.02%)
ST elevation MI	207(2.57%)
Non-ST elevation MI	586(7.28%)
Unspecified acute MI	350(4.35%)
MI complications	10(0.12%)
Number of previous MI in history	
0	7082(87.98%)
1	465(5.78%)
2	297(3.69%)
3	108(1.34%)
4	50(0.62%)
5 and over	48(0.60%)
range (min,max)	(0.00, 15.00)
mean (+/-sd)	0.23 (0.78)
median (Q1,Q3)	0.00 (0.00, 0.00)

Each column corresponds to one of the study groups

The percentages for each variable correspond to the proportion of patients within each of the study groups.

* - For this group, each row is a separate variable, the numbers and proportions correspond to the proportion of yes in each variable. (Percentages will not sum up to 100%).

Table 1.3: (continued)

	group 1 patients experiencing a subsequent MI, stroke or death within 1 year after discharge N = 8050
Prior cardiovascular comorbidities*	
Heart failure	2950(36.65%)
Hypertension	7528(93.52%)
Hyperlipidemia	5322(66.11%)
Unstable angina pectoris	677(8.41%)
Stroke (Total)	936(11.63%)
Haemorrhagic stroke	77(0.96%)
Ischaemic stroke	871(10.82%)
Other stroke (not sub-classified)	9(0.11%)
Transient ischemic attack	369(4.58%)
Major bleedings	702(8.72%)
Arrhythmia	2283(28.36%)
Atrial fibrillation	1858(23.08%)
Bleeding disorder	24(0.30%)
Other acute ischaemic heart diseases	49(0.61%)
Other prior comorbidities*	
Diabetes mellitus	2745(34.10%)
Chronic renal dysfunction	391(4.86%)
Severe liver disease	41(0.51%)
Severe renal failure requiring dialysis	55(0.68%)
COPD	473(5.88%)
Dementia/Alzheimer's disease	756(9.39%)
Cancer	939(11.66%)
Ongoing OAP use*	
OAP use (Total)	472(5.86%)
Clopidogrel	472(5.86%)
Prasugrel	0(0.00%)
Ticagrelor	0(0.00%)

Each column corresponds to one of the study groups

The percentages for each variable correspond to the proportion of patients within each of the study groups.

* - For this group, each row is a separate variable, the numbers and proportions correspond to the proportion of yes in each variable. (Percentages will not sum up to 100%).

Table 1.3: (continued)

	group 1 patients experiencing a subsequent MI, stroke or death within 1 year after discharge N = 8050
Ongoing medication*	
Anticoagulation medication	969(12.04%)
Antithrombotic medication	2092(25.99%)
ARB	1379(17.13%)
ACE inhibitor	2075(25.78%)
Nitrate	3434(42.66%)
Beta-blocker	4147(51.52%)
Calcium channel blocker	1757(21.83%)
Antidiabetic drugs	2025(25.16%)
Insulin	1123(13.95%)
Oral antidiabetic	1298(16.12%)
LMWH	43(0.53%)
NOAC	3(0.04%)
Proton pump inhibitor	1843(22.89%)
Statin	3039(37.75%)
Fibrate	9(0.11%)
NSAID	443(5.50%)
SSRI	449(5.58%)
Warfarin	913(11.34%)
Additinal risk factors*	
Age \geq 65 years	6934(86.14%)
Diabetes with ongoing medication	2025(25.16%)
\geq 1 MI in addition to index MI	968(12.02%)
Multivessel CAD	2029(25.20%)
Chronic renal dysfunction	391(4.86%)
Ischaemic stroke	871(10.82%)
Number of additional risk factors	
0	561(6.97%)
1	3476(43.18%)
2	2648(32.89%)
3	1052(13.07%)
4	275(3.42%)
5	38(0.47%)
6	0(0.00%)
range (min,max)	(0.00, 5.00)
mean (+/-sd)	1.64 (0.94)
median (Q1,Q3)	1.00 (1.00, 2.00)

Each column corresponds to one of the study groups

The percentages for each variable correspond to the proportion of patients within each of the study groups.

* - For this group, each row is a separate variable, the numbers and proportions correspond to the proportion of yes in each variable. (Percentages will not sum up to 100%).

Table 1.3: (continued)

group 1 patients experiencing a subsequent MI, stroke or death within 1 year after discharge N = 8050	
Duration of anticoagulation medication exposure	
<90 days	6760(83.98%)
≥ 90 days	1290(16.02%)
range (min,max)	(0.00, 360.00)
mean (+/-sd)	46.34 (105.79)
median (Q1,Q3)	0.00 (0.00, 0.00)
Chronic use of anticoagulation medication	
No	7141(88.71%)
Yes	909(11.29%)
Pegasus exclusion criteria*	
Age <50	165(2.05%)
Use of OAP	472(5.86%)
Bleeding disorder	24(0.30%)
Increased bleeding risk (Total)	344(4.27%)
Intracranial bleeding	148(1.84%)
Central nervous tumour	9(0.11%)
Intracranial vascular abnormality	59(0.73%)
Gastrointestinal bleeding	136(1.69%)
Ischaemic stroke	871(10.82%)
CABG	311(3.86%)
Severe liver disease	41(0.51%)
Severe renal failure requiring dialysis	55(0.68%)

Each column corresponds to one of the study groups

The percentages for each variable correspond to the proportion of patients within each of the study groups.

* - For this group, each row is a separate variable, the numbers and proportions correspond to the proportion of yes in each variable. (Percentages will not sum up to 100%).

1.1.4 Type of invasive procedure stratified by age

Table 1.4: Type of invasive procedure related to the index MI event for group 1 patients stratified by age at discharge.

	Age under 80 years at discharge N = 23488	Age 80 and over at discharge N = 11750
Invasive procedure related to index event		
No invasive procedure	6563(27.94%)	8861(75.41%)
Coronary angiography only	4083(17.38%)	851(7.24%)
PCI	10800(45.98%)	1826(15.54%)
CABG	2042(8.69%)	212(1.80%)

Each column corresponds to one of the study groups

The percentages for each variable correspond to the proportion of patients within each of the groups.

* - For this group, each row is a separate variable, the numbers and proportions correspond to the proportion of yes in each variable. (Percentages will not sum up to 100%).

1.1.5 Type of invasive procedure stratified by sex

Table 1.5: Type of invasive procedure related to the index MI event for group 1 patients stratified by sex.

	Sex : Male N = 21261	Sex : Female N = 13977
Invasive procedure related to index event		
No invasive procedure	7471(35.14%)	7953(56.90%)
Coronary angiography only	2942(13.84%)	1992(14.25%)
PCI	9090(42.75%)	3536(25.30%)
CABG	1758(8.27%)	496(3.55%)

Each column corresponds to one of the study groups

The percentages for each variable correspond to the proportion of patients within each of the groups.

* - For this group, each row is a separate variable, the numbers and proportions correspond to the proportion of yes in each variable. (Percentages will not sum up to 100%).

1.1.6 Type of invasive procedure stratified by type of index MI

Table 1.6: Type of invasive procedure related to the index MI event for group 1 patients stratified by type of index Myocardial infarction.

	Non-ST elevation MI (and unspecified MI) at discharge N = 23450	ST elevation MI at discharge N = 11788
Invasive procedure related to index event		
No invasive procedure	12228(52.14%)	3196(27.11%)
Coronary angiography only	3378(14.41%)	1556(13.20%)
PCI	6328(26.99%)	6298(53.43%)
CABG	1516(6.46%)	738(6.26%)

Each column corresponds to one of the study groups

The percentages for each variable correspond to the proportion of patients within each of the groups.

* - For this group, each row is a separate variable, the numbers and proportions correspond to the proportion of yes in each variable. (Percentages will not sum up to 100%).

1.1.7 Gender distribution in STEMI patients with a PCI

Table 1.7: Sex distribution for patients in group 1 with STEMI as index event by type of invasive treatment associated with the index event.

	Sex : Male N = 7971	Sex : Female N = 3817
Invasive procedure related to index event		
No invasive procedure	1725(21.64%)	1471(38.54%)
Coronary angiography only	996(12.50%)	560(14.67%)
PCI	4661(58.47%)	1637(42.89%)
CABG	589(7.39%)	149(3.90%)

Each column corresponds to one of the study groups

The percentages for each variable correspond to the proportion of patients within each of the groups.

** - For this group, each row is a separate variable, the numbers and proportions correspond to the proportion of yes in each variable. (Percentages will not sum up to 100%).*

1.1.8 Secondary prevention drugs use

Table 1.8: Secondary prevention drugs use at discharge in group 1, group 2 and group 1.b patients.

	Group 1 Patients	Group 1.b patients	Group 2 patients
New users			
OAP (Total)	17161(50.4%)	2363(31.0%)	14798(56.0%)
Clopidogrel	16219(47.6%)	2289(30.0%)	13930(52.7%)
Prasugrel	591(1.7%)	59(0.7%)	532(2.0%)
Ticagrelor	469(1.3%)	45(0.6%)	424(1.6%)
ARB	1421(4.8%)	293(4.4%)	1128(5.0%)
ACE inhibitors	10117(35.8%)	1502(24.6%)	8615(38.8%)
ACE inhibitors or ARB	10965(48.6%)	1680(35.2%)	9285(52.1%)
Beta-blocker	15517(71.2%)	2386(56.3%)	13131(74.7%)
Statin	15960(63.6%)	2183(40.7%)	13777(69.9%)
Old users			
OAP (Total)	742(62.3%)	233(54.8%)	509(66.4%)
Clopidogrel	710(59.7%)	227(53.4%)	483(63.2%)
Prasugrel	1(100.0%)	0(<i>NaN</i> %)	1(100.0%)
Ticagrelor	2(100.0%)	0(<i>NaN</i> %)	2(100.0%)
ARB	3815(64.9%)	759(55.5%)	3056(67.7%)
ACE inhibitors	4535(65.1%)	1045(53.5%)	3490(69.7%)
ACE inhibitors or ARB	8848(69.9%)	1907(58.2%)	6941(74.0%)
Beta-blocker	9997(74.4%)	2520(66.1%)	7477(77.7%)
Statin	7372(72.6%)	1641(61.1%)	5731(76.8%)

New users: Each cell corresponds to the number and proportion of patients in a given study group with no prior use of the corresponding drug claiming a new purchase within 30 days after index date. i.e. proportion of initiation among non prior users in each of the study groups.

Old users: Each cell corresponds to the number and proportion of patients in a given study group with a prior use of the corresponding drug claiming a purchase within 90 days after index date. i.e. proportion continuing among prior users in each of the study groups.

All: Each cell corresponds to the number and proportion of patients in a given study group claiming a purchase within 90 days for old users and 30 days for new users in each of the study groups.

Table 1.8: (continued)

	Group 1 Patients	Group 1.b patients	Group 2 patients
All			
OAP (Total)	17903(50.8%)	2596(32.2%)	15307(56.3%)
Clopidogrel	16929(48.0%)	2516(31.3%)	14413(53.0%)
Prasugrel	592(1.7%)	59(0.7%)	533(2.0%)
Ticagrelor	471(1.3%)	45(0.6%)	426(1.6%)
ARB	5236(14.9%)	1052(13.1%)	4184(15.4%)
ACE inhibitors	14652(41.6%)	2547(31.6%)	12105(44.5%)
ACE inhibitors or ARB	19813(56.2%)	3587(44.6%)	16226(59.7%)
Beta-blocker	25514(72.4%)	4906(60.9%)	20608(75.8%)
Statin	23332(66.2%)	3824(47.5%)	19508(71.8%)
Number of secondary prevention drugs			
0	4648(13.2%)	1886(23.4%)	2762(10.2%)
1	4816(13.7%)	1701(21.1%)	3115(11.5%)
2	7108(20.2%)	1809(22.5%)	5299(19.5%)
3	9597(27.2%)	1611(20.0%)	7986(29.4%)
4	9069(25.7%)	1043(13.0%)	8026(29.5%)
range (min,max)	(0.0, 4.0)	(0.0, 4.0)	(0.0, 4.0)
mean (+/-sd)	2.4 (1.3)	1.8 (1.3)	2.6 (1.3)
median (Q1,Q3)	3.0 (1.0, 4.0)	2.0 (1.0, 3.0)	3.0 (2.0, 4.0)

New users: Each cell corresponds to the number and proportion of patients in a given study group with no prior use of the corresponding drug claiming a new purchase within 30 days after index date. i.e. proportion of initiation among non prior users in each of the study groups.

Old users: Each cell corresponds to the number and proportion of patients in a given study group with a prior use of the corresponding drug claiming a purchase within 90 days after index date. i.e. proportion continuing among prior users in each of the study groups.

All: Each cell corresponds to the number and proportion of patients in a given study group claiming a purchase within 90 days for old users and 30 days for new users in each of the study groups.

1.2 Stratified incidence rates of primary outcomes

1.2.1 Stratified incidence rates for group 1

Myocardial infarction

Table 1.9: Stratified incidence rates per 1000 patient years of Myocardial infarction with 95% confidence intervals (CIs) in Group 1 . The number of patients in each strata, the number of events and the total number of person years are also presented. Variables are evaluated at index date. Stratification was done separately for each variable.

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
No strata (All)						
Group 1 patients	35238	6299	77893	80.87	78.89	82.89
Type of index MI						
Non-ST elevation MI (and unspecified MI)	23450	4712	48996	96.17	93.46	98.96
ST elevation MI	11788	1587	28898	54.92	52.28	57.69
Age at index (years)						
18-49	1973	194	5326	36.43	31.64	41.93
50-64	8531	905	22424	40.36	37.81	43.08
65-69	3704	511	8959	57.04	52.30	62.20
70-74	4350	643	10402	61.82	57.22	66.78
75-79	4930	963	10717	89.86	84.36	95.72
80-84	5396	1292	10325	125.14	118.50	132.15
85 and over	6354	1791	9741	183.86	175.54	192.57
Sex						
Male	21261	3460	48803	70.90	68.57	73.30
Female	13977	2839	29090	97.59	94.07	101.25
Bleeding disorder						
No	35150	6287	77730	80.88	78.91	82.91
Yes	88	12	163	73.72	41.86	129.80
Ischaemic stroke						
No	33066	5782	73834	78.31	76.32	80.36
Yes	2172	517	4059	127.37	116.86	138.84
Chronic use of anticoagulation medication						
No	32583	5664	72985	77.60	75.61	79.65
Yes	2655	635	4908	129.39	119.71	139.85
Use of OAP						
No	33780	5838	75118	77.72	75.75	79.74
Yes	1458	461	2775	166.15	151.65	182.03

Table 1.9: (continued)

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
Increased bleeding risk (Total)						
No	34277	6076	76154	79.79	77.80	81.82
Yes	961	223	1739	128.26	112.48	146.25
CABG						
No	32516	6056	70702	85.66	83.53	87.84
Yes	2722	243	7191	33.79	29.80	38.32
Severe liver disease						
No	35133	6275	77717	80.74	78.77	82.76
Yes	105	24	176	136.17	91.27	203.16
Severe renal failure requiring dialysis						
No	35132	6258	77764	80.47	78.50	82.49
Yes	106	41	129	317.58	233.84	431.31

Stroke (total)

Table 1.10: Stratified incidence rates per 1000 patient years of Stroke (total) with 95% confidence intervals (CIs) in Group 1 . The number of patients in each strata, the number of events and the total number of person years are also presented. Variables are evaluated at index date. Stratification was done separately for each variable.

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
No strata (All)						
Group 1 patients	35238	1985	84817	23.4	22.4	24.46
Type of index MI						
Non-ST elevation MI (and unspecified MI)	23450	1408	53886	26.13	24.80	27.53
ST elevation MI	11788	577	30931	18.65	17.19	20.24
Age at index (years)						
18-49	1973	28	5725	4.89	3.38	7.08
50-64	8531	246	23803	10.33	9.12	11.71
65-69	3704	180	9677	18.60	16.07	21.53
70-74	4350	249	11222	22.19	19.60	25.12
75-79	4930	346	11704	29.56	26.61	32.85
80-84	5396	433	11500	37.65	34.27	41.37
85 and over	6354	503	11187	44.96	41.20	49.07
Sex						
Male	21261	1085	52800	20.55	19.36	21.81
Female	13977	900	32017	28.11	26.33	30.01
Bleeding disorder						
No	35150	1977	84636	23.36	22.35	24.41
Yes	88	8	181	44.20	22.10	88.38
Ischaemic stroke						
No	33066	1472	80852	18.21	17.30	19.16
Yes	2172	513	3965	129.39	118.66	141.08
Chronic use of anticoagulation medication						
No	32583	1774	79282	22.38	21.36	23.44
Yes	2655	211	5535	38.12	33.31	43.63
Use of OAP						
No	33780	1879	81562	23.04	22.02	24.10
Yes	1458	106	3255	32.56	26.92	39.39

Table 1.10: (continued)

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
Increased bleeding risk (Total)						
No	34277	1890	82933	22.79	21.78	23.84
Yes	961	95	1884	50.43	41.24	61.66
CABG						
No	32516	1856	77376	23.99	22.92	25.1
Yes	2722	129	7440	17.34	14.59	20.6
Severe liver disease						
No	35133	1975	84625	23.34	22.33	24.39
Yes	105	10	191	52.28	28.13	97.17
Severe renal failure requiring dialysis						
No	35132	1974	84654	23.32	22.31	24.37
Yes	106	11	163	67.38	37.32	121.67

Cardiovascular mortality

Table 1.11: Stratified incidence rates per 1000 patient years of Cardiovascular mortality with 95% confidence intervals (CIs) in Group 1 . The number of patients in each strata, the number of events and the total number of person years are also presented. Variables are evaluated at index date. Stratification was done separately for each variable.

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
No strata (All)						
Group 1 patients	35238	2644	87222	30.31	29.18	31.49
Type of index MI						
Non-ST elevation MI (and unspecified MI)	23450	2157	55527	38.85	37.24	40.52
ST elevation MI	11788	487	31694	15.37	14.06	16.79
Age at index (years)						
18-49	1973	16	5767	2.77	1.70	4.53
50-64	8531	152	24238	6.27	5.35	7.35
65-69	3704	118	9942	11.87	9.91	14.22
70-74	4350	208	11535	18.03	15.74	20.66
75-79	4930	389	12163	31.98	28.96	35.32
80-84	5396	631	11980	52.67	48.72	56.95
85 and over	6354	1130	11597	97.44	91.92	103.29
Sex						
Male	21261	1265	54219	23.33	22.08	24.65
Female	13977	1379	33003	41.78	39.64	44.05
Bleeding disorder						
No	35150	2637	87036	30.30	29.16	31.48
Yes	88	7	186	37.67	17.96	79.02
Ischaemic stroke						
No	33066	2319	82553	28.09	26.97	29.26
Yes	2172	325	4669	69.61	62.44	77.61
Chronic use of anticoagulation medication						
No	32583	2330	81466	28.60	27.46	29.79
Yes	2655	314	5755	54.56	48.84	60.94
Use of OAP						
No	33780	2439	83846	29.09	27.96	30.27
Yes	1458	205	3376	60.72	52.95	69.63

Table 1.11: (continued)

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
Increased bleeding risk (Total)						
No	34277	2533	85207	29.73	28.59	30.91
Yes	961	111	2014	55.10	45.75	66.37
CABG						
No	32516	2571	79594	32.30	31.08	33.57
Yes	2722	73	7628	9.57	7.61	12.04
Severe liver disease						
No	35133	2636	87019	30.29	29.16	31.47
Yes	105	8	203	39.38	19.70	78.75
Severe renal failure requiring dialysis						
No	35132	2626	87048	30.17	29.04	31.34
Yes	106	18	173	103.83	65.42	164.80

Composite end-point

Table 1.12: Stratified incidence rates per 1000 patient years of Composite end-point with 95% confidence intervals (CIs) in Group 1 . The number of patients in each strata, the number of events and the total number of person years are also presented. Variables are evaluated at index date. Stratification was done separately for each variable.

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
No strata (All)						
Group 1 patients	35238	8551	76054	112.43	110.08	114.84
Type of index MI						
Non-ST elevation MI (and unspecified MI)	23450	6365	47744	133.32	130.08	136.63
ST elevation MI	11788	2186	28310	77.22	74.05	80.52
Age at index (years)						
18-49	1973	223	5287	42.18	36.99	48.09
50-64	8531	1159	22077	52.50	49.56	55.61
65-69	3704	687	8758	78.44	72.79	84.53
70-74	4350	896	10167	88.13	82.54	94.09
75-79	4930	1329	10361	128.27	121.56	135.36
80-84	5396	1770	9968	177.57	169.48	186.03
85 and over	6354	2487	9436	263.57	253.41	274.14
Sex						
Male	21261	4669	47729	97.82	95.06	100.67
Female	13977	3882	28325	137.05	132.81	141.43
Bleeding disorder						
No	35150	8529	75895	112.38	110.02	114.79
Yes	88	22	158	138.86	91.43	210.89
Ischaemic stroke						
No	33066	7602	72516	104.83	102.50	107.22
Yes	2172	949	3538	268.25	251.71	285.87
Chronic use of anticoagulation medication						
No	32583	7665	71317	107.48	105.10	109.91
Yes	2655	886	4737	187.04	175.12	199.77
Use of OAP						
No	33780	7984	73354	108.84	106.48	111.26
Yes	1458	567	2700	210.00	193.41	228.02

Table 1.12: (continued)

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
Increased bleeding risk (Total)						
No	34277	8230	74400	110.62	108.25	113.03
Yes	961	321	1654	194.12	174.01	216.56
CABG						
No	32516	8168	69029	118.33	115.79	120.92
Yes	2722	383	7025	54.52	49.32	60.26
Severe liver disease						
No	35133	8519	75884	112.26	109.9	114.67
Yes	105	32	169	188.92	133.6	267.15
Severe renal failure requiring dialysis						
No	35132	8499	75932	111.93	109.57	114.33
Yes	106	52	122	427.58	325.82	561.12

Overall mortality

Table 1.13: Stratified incidence rates per 1000 patient years of Overall mortality with 95% confidence intervals (CIs) in Group 1 . The number of patients in each strata, the number of events and the total number of person years are also presented. Variables are evaluated at index date. Stratification was done separately for each variable.

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
No strata (All)						
Group 1 patients	35238	9326	87222	106.92	104.77	109.12
Type of index MI						
Non-ST elevation MI (and unspecified MI)	23450	7424	55527	133.70	130.69	136.78
ST elevation MI	11788	1902	31694	60.01	57.37	62.77
Age at index (years)						
18-49	1973	65	5767	11.27	8.84	14.37
50-64	8531	699	24238	28.84	26.78	31.06
65-69	3704	508	9942	51.10	46.84	55.74
70-74	4350	791	11535	68.58	63.96	73.53
75-79	4930	1420	12163	116.75	110.83	122.98
80-84	5396	2156	11980	179.97	172.53	187.73
85 and over	6354	3687	11597	317.94	307.84	328.37
Sex						
Male	21261	4801	54219	88.55	86.08	91.09
Female	13977	4525	33003	137.11	133.17	141.16
Bleeding disorder						
No	35150	9289	87036	106.73	104.58	108.92
Yes	88	37	186	199.12	144.27	274.83
Ischaemic stroke						
No	33066	8359	82553	101.26	99.11	103.45
Yes	2172	967	4669	207.13	194.48	220.60
Chronic use of anticoagulation medication						
No	32583	8189	81466	100.52	98.37	102.72
Yes	2655	1137	5755	197.55	186.39	209.37
Use of OAP						
No	33780	8811	83846	105.09	102.91	107.3
Yes	1458	515	3376	152.54	139.92	166.3

Table 1.13: (continued)

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
Increased bleeding risk (Total)						
No	34277	8894	85207	104.38	102.23	106.57
Yes	961	432	2014	214.45	195.16	235.66
CABG						
No	32516	9006	79594	113.15	110.84	115.51
Yes	2722	320	7628	41.95	37.60	46.81
Severe liver disease						
No	35133	9276	87019	106.60	104.45	108.79
Yes	105	50	203	246.16	186.57	324.78
Severe renal failure requiring dialysis						
No	35132	9257	87048	106.34	104.20	108.53
Yes	106	69	173	398.03	314.37	503.95

1.2.2 Stratified incidence rates for group 2

Myocardial infarction

Table 1.14: Stratified incidence rates per 1000 patient years of Myocardial infarction with 95% confidence intervals (CIs) in Group 2 . The number of patients in each strata, the number of events and the total number of person years are also presented. Variables are evaluated the 1 year baseline check. Stratification was done separately for each variable.

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
No strata (All)						
Group 2 patients	27188	1807	47258	38.24	36.51	40.04
Type of index MI						
Non-ST elevation MI (and unspecified MI)	17314	1371	29043	47.21	44.77	49.77
ST elevation MI	9874	436	18215	23.94	21.79	26.29
Age at 1 year baseline check (years)						
18-49	1554	52	2981	17.44	13.29	22.89
50-64	7171	266	13713	19.40	17.20	21.87
65-69	3202	125	5691	21.97	18.43	26.18
70-74	3450	173	6302	27.45	23.65	31.86
75-79	3684	263	6463	40.69	36.06	45.92
80-84	3788	359	6126	58.60	52.84	64.99
85 and over	4339	569	5983	95.11	87.61	103.26
Sex						
Male	16904	977	30026	32.54	30.56	34.64
Female	10284	830	17233	48.16	45.00	51.55
Ischaemic stroke						
No	26031	1672	45375	36.85	35.12	38.66
Yes	1157	135	1883	71.69	60.56	84.86
Bleeding disorder						
No	27114	1800	47153	38.17	36.45	39.98
Yes	74	7	105	66.36	31.64	139.20
Severe renal failure requiring dialysis						
No	27127	1797	47197	38.07	36.35	39.88
Yes	61	10	61	162.72	87.55	302.42
OAP use (Total)						
No	16901	1246	28925	43.08	40.75	45.54
Yes	10287	561	18333	30.60	28.17	33.24

Table 1.14: (continued)

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
Chronic use of anticoagulation medication						
No	24153	1579	42370	37.27	35.47	39.15
Yes	3035	228	4888	46.64	40.97	53.11
Increased bleeding risk (Total)						
No	26646	1762	46412	37.96	36.23	39.78
Yes	542	45	846	53.18	39.70	71.22
CABG						
No	24463	1737	41985	41.37	39.47	43.36
Yes	2725	70	5273	13.27	10.50	16.78
Severe liver disease						
No	27100	1803	47132	38.25	36.53	40.06
Yes	88	4	126	31.74	11.91	84.57
Severe renal failure requiring dialysis						
No	27127	1797	47197	38.07	36.35	39.88
Yes	61	10	61	162.72	87.55	302.42

Stroke (total)

Table 1.15: Stratified incidence rates per 1000 patient years of Stroke (total) with 95% confidence intervals (CIs) in Group 2 . The number of patients in each strata, the number of events and the total number of person years are also presented. Variables are evaluated the 1 year baseline check. Stratification was done separately for each variable.

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
No strata (All)						
Group 2 patients	27188	798	48224	16.55	15.44	17.74
Type of index MI						
Non-ST elevation MI (and unspecified MI)	17314	544	29776	18.27	16.80	19.87
ST elevation MI	9874	254	18449	13.77	12.17	15.57
Age at 1 year baseline check (years)						
18-49	1554	9	3044	2.96	1.54	5.68
50-64	7171	95	13930	6.82	5.58	8.34
65-69	3202	67	5758	11.64	9.16	14.78
70-74	3450	108	6390	16.90	14.00	20.41
75-79	3684	140	6598	21.22	17.98	25.04
80-84	3788	156	6305	24.74	21.15	28.95
85 and over	4339	223	6198	35.98	31.55	41.02
Sex						
Male	16904	437	30553	14.30	13.02	15.71
Female	10284	361	17671	20.43	18.43	22.65
Ischaemic stroke						
No	26031	658	46369	14.19	13.15	15.32
Yes	1157	140	1855	75.45	63.94	89.05
Bleeding disorder						
No	27114	795	48116	16.52	15.41	17.71
Yes	74	3	109	27.60	8.90	85.57
Severe renal failure requiring dialysis						
No	27127	794	48157	16.49	15.38	17.68
Yes	61	4	67	59.72	22.41	159.12
OAP use (Total)						
No	16901	585	29533	19.81	18.27	21.48
Yes	10287	213	18691	11.40	9.96	13.03

Table 1.15: (continued)

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
Chronic use of anticoagulation medication						
No	24153	678	43262	15.67	14.54	16.90
Yes	3035	120	4963	24.18	20.22	28.92
Increased bleeding risk (Total)						
No	26646	772	47370	16.30	15.19	17.49
Yes	542	26	854	30.43	20.72	44.69
CABG						
No	24463	734	42946	17.09	15.90	18.37
Yes	2725	64	5279	12.12	9.49	15.49
Severe liver disease						
No	27100	793	48099	16.49	15.38	17.68
Yes	88	5	125	40.02	16.66	96.14
Severe renal failure requiring dialysis						
No	27127	794	48157	16.49	15.38	17.68
Yes	61	4	67	59.72	22.41	159.12

Cardiovascular mortality

Table 1.16: Stratified incidence rates per 1000 patient years of Cardiovascular mortality with 95% confidence intervals (CIs) in Group 2 . The number of patients in each strata, the number of events and the total number of person years are also presented. Variables are evaluated the 1 year baseline check. Stratification was done separately for each variable.

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
No strata (All)						
Group 2 patients	27188	913	48936	18.66	17.49	19.91
Type of index MI						
Non-ST elevation MI (and unspecified MI)	17314	720	30261	23.79	22.12	25.6
ST elevation MI	9874	193	18676	10.33	8.97	11.9
Age at 1 year baseline check (years)						
18-49	1554	5	3052	1.64	0.68	3.94
50-64	7171	56	14044	3.99	3.07	5.18
65-69	3202	39	5826	6.69	4.89	9.16
70-74	3450	73	6496	11.24	8.93	14.14
75-79	3684	125	6732	18.57	15.58	22.12
80-84	3788	202	6427	31.43	27.38	36.08
85 and over	4339	413	6359	64.94	58.97	71.52
Sex						
Male	16904	418	30954	13.50	12.27	14.86
Female	10284	495	17982	27.53	25.21	30.06
Ischaemic stroke						
No	26031	821	46955	17.48	16.33	18.72
Yes	1157	92	1982	46.42	37.84	56.95
Bleeding disorder						
No	27114	909	48824	18.62	17.45	19.87
Yes	74	4	112	35.74	13.42	95.24
Severe renal failure requiring dialysis						
No	27127	906	48866	18.54	17.37	19.79
Yes	61	7	71	98.82	47.11	207.28
OAP use (Total)						
No	16901	732	30029	24.38	22.67	26.21
Yes	10287	181	18908	9.57	8.28	11.07

Table 1.16: (continued)

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
Chronic use of anticoagulation medication						
No	24153	759	43870	17.3	16.11	18.58
Yes	3035	154	5066	30.4	25.96	35.60
Increased bleeding risk (Total)						
No	26646	888	48061	18.48	17.3	19.73
Yes	542	25	875	28.57	19.3	42.28
CABG						
No	24463	875	43591	20.07	18.79	21.45
Yes	2725	38	5345	7.11	5.17	9.77
Severe liver disease						
No	27100	912	48806	18.69	17.51	19.94
Yes	88	1	130	7.68	1.08	54.53
Severe renal failure requiring dialysis						
No	27127	906	48866	18.54	17.37	19.79
Yes	61	7	71	98.82	47.11	207.28

Composite end-point

Table 1.17: Stratified incidence rates per 1000 patient years of Composite end-point with 95% confidence intervals (CIs) in Group 2 . The number of patients in each strata, the number of events and the total number of person years are also presented. Variables are evaluated the 1 year baseline check. Stratification was done separately for each variable.

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
No strata (All)						
Group 2 patients	27188	2806	46626	60.18	58	62.45
Type of index MI						
Non-ST elevation MI (and unspecified MI)	17314	2074	28617	72.47	69.42	75.66
ST elevation MI	9874	732	18008	40.65	37.81	43.70
Age at 1 year baseline check (years)						
18-49	1554	63	2974	21.18	16.55	27.12
50-64	7171	377	13617	27.69	25.03	30.63
65-69	3202	207	5624	36.81	32.12	42.18
70-74	3450	299	6207	48.17	43.01	53.95
75-79	3684	430	6339	67.83	61.71	74.56
80-84	3788	556	6015	92.43	85.06	100.45
85 and over	4339	874	5849	149.42	139.84	159.67
Sex						
Male	16904	1504	29666	50.70	48.20	53.33
Female	10284	1302	16960	76.77	72.71	81.06
Ischaemic stroke						
No	26031	2536	44851	56.54	54.38	58.79
Yes	1157	270	1774	152.16	135.05	171.43
Bleeding disorder						
No	27114	2795	46523	60.08	57.89	62.35
Yes	74	11	103	107.29	59.42	193.74
Severe renal failure requiring dialysis						
No	27127	2792	46567	59.96	57.77	62.22
Yes	61	14	59	239.11	141.61	403.72
OAP use (Total)						
No	16901	2010	28484	70.57	67.55	73.72
Yes	10287	796	18141	43.88	40.93	47.03

Table 1.17: (continued)

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
Chronic use of anticoagulation medication						
No	24153	2427	41834	58.01	55.75	60.37
Yes	3035	379	4791	79.10	71.53	87.48
Increased bleeding risk (Total)						
No	26646	2728	45796	59.57	57.37	61.85
Yes	542	78	829	94.05	75.33	117.41
CABG						
No	24463	2657	41417	64.15	61.76	66.64
Yes	2725	149	5209	28.61	24.36	33.59
Severe liver disease						
No	27100	2798	46502	60.17	57.98	62.44
Yes	88	8	123	64.93	32.47	129.84
Severe renal failure requiring dialysis						
No	27127	2792	46567	59.96	57.77	62.22
Yes	61	14	59	239.11	141.61	403.72

Overall mortality

Table 1.18: Stratified incidence rates per 1000 patient years of Overall mortality with 95% confidence intervals (CIs) in Group 2 . The number of patients in each strata, the number of events and the total number of person years are also presented. Variables are evaluated the 1 year baseline check. Stratification was done separately for each variable.

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
No strata (All)						
Group 2 patients	27188	3862	48936	78.92	76.47	81.45
Type of index MI						
Non-ST elevation MI (and unspecified MI)	17314	3006	30261	99.34	95.85	102.95
ST elevation MI	9874	856	18676	45.83	42.86	49.01
Age at 1 year baseline check (years)						
18-49	1554	25	3052	8.19	5.54	12.12
50-64	7171	282	14044	20.08	17.87	22.57
65-69	3202	206	5826	35.36	30.85	40.53
70-74	3450	338	6496	52.03	46.77	57.89
75-79	3684	568	6732	84.37	77.71	91.60
80-84	3788	831	6427	129.30	120.80	138.39
85 and over	4339	1612	6359	253.49	241.41	266.17
Sex						
Male	16904	1997	30954	64.52	61.75	67.41
Female	10284	1865	17982	103.71	99.11	108.53
Ischaemic stroke						
No	26031	3565	46955	75.92	73.47	78.46
Yes	1157	297	1982	149.87	133.76	167.92
Bleeding disorder						
No	27114	3840	48824	78.65	76.20	81.18
Yes	74	22	112	196.59	129.45	298.57
Severe renal failure requiring dialysis						
No	27127	3839	48866	78.56	76.12	81.09
Yes	61	23	71	324.68	215.76	488.59
OAP use (Total)						
No	16901	3171	30029	105.60	101.99	109.34
Yes	10287	691	18908	36.55	33.92	39.38

Table 1.18: (continued)

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
Chronic use of anticoagulation medication						
No	24153	3277	43870	74.70	72.18	77.30
Yes	3035	585	5066	115.46	106.48	125.21
Increased bleeding risk (Total)						
No	26646	3705	48061	77.09	74.65	79.61
Yes	542	157	875	179.40	153.42	209.77
CABG						
No	24463	3675	43591	84.31	81.62	87.08
Yes	2725	187	5345	34.99	30.31	40.38
Severe liver disease						
No	27100	3835	48806	78.58	76.13	81.10
Yes	88	27	130	207.41	142.24	302.44
Severe renal failure requiring dialysis						
No	27127	3839	48866	78.56	76.12	81.09
Yes	61	23	71	324.68	215.76	488.59

1.2.3 Stratified incidence rates for group 3

Myocardial infarction

Table 1.19: Stratified incidence rates per 1000 patient years of Myocardial infarction with 95% confidence intervals (CIs) in Group 3 . The number of patients in each strata, the number of events and the total number of person years are also presented. Variables are evaluated the 1 year baseline check. Stratification was done separately for each variable.

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
No strata (All)						
Group 3 patients	22041	1653	37298	44.32	42.23	46.51
Type of index MI						
Non-ST elevation MI (and unspecified MI)	14774	1290	24161	53.39	50.56	56.39
ST elevation MI	7267	363	13137	27.63	24.93	30.63
Age at 1 year baseline check (years)						
18-49	558	24	1064	22.56	15.12	33.66
50-64	3020	140	5670	24.69	20.92	29.14
65-69	3202	125	5691	21.97	18.43	26.18
70-74	3450	173	6302	27.45	23.65	31.86
75-79	3684	263	6463	40.69	36.06	45.92
80-84	3788	359	6126	58.60	52.84	64.99
85 and over	4339	569	5983	95.11	87.61	103.26
Sex						
Male	12783	849	22022	38.55	36.05	41.24
Female	9258	804	15277	52.63	49.11	56.40
Ischaemic stroke						
No	20884	1518	35415	42.86	40.76	45.07
Yes	1157	135	1883	71.69	60.56	84.86
Bleeding disorder						
No	21972	1646	37199	44.25	42.16	46.44
Yes	69	7	99	70.70	33.71	148.31
Severe renal failure requiring dialysis						
No	21980	1643	37237	44.12	42.04	46.31
Yes	61	10	61	162.72	87.55	302.42
OAP use (Total)						
No	14368	1162	23905	48.61	45.89	51.49
Yes	7673	491	13393	36.66	33.56	40.05

Table 1.19: (continued)

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
Chronic use of anticoagulation medication						
No	19194	1429	32768	43.61	41.41	45.93
Yes	2847	224	4530	49.45	43.38	56.37
Increased bleeding risk (Total)						
No	21550	1612	36554	44.10	42.00	46.31
Yes	491	41	744	55.11	40.58	74.84
CABG						
No	19704	1586	32829	48.31	45.99	50.75
Yes	2337	67	4469	14.99	11.80	19.05
Severe liver disease						
No	21964	1650	37189	44.37	42.28	46.56
Yes	77	3	109	27.44	8.85	85.07
Severe renal failure requiring dialysis						
No	21980	1643	37237	44.12	42.04	46.31
Yes	61	10	61	162.72	87.55	302.42

Stroke (total)

Table 1.20: Stratified incidence rates per 1000 patient years of Stroke (total) with 95% confidence intervals (CIs) in Group 3 . The number of patients in each strata, the number of events and the total number of person years are also presented. Variables are evaluated the 1 year baseline check. Stratification was done separately for each variable.

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
No strata (All)						
Group 3 patients	22041	749	38123	19.65	18.29	21.11
Type of index MI						
Non-ST elevation MI (and unspecified MI)	14774	520	24822	20.95	19.22	22.83
ST elevation MI	7267	229	13300	17.22	15.13	19.60
Age at 1 year baseline check (years)						
18-49	558	7	1093	6.40	3.05	13.43
50-64	3020	48	5780	8.30	6.26	11.02
65-69	3202	67	5758	11.64	9.16	14.78
70-74	3450	108	6390	16.90	14.00	20.41
75-79	3684	140	6598	21.22	17.98	25.04
80-84	3788	156	6305	24.74	21.15	28.95
85 and over	4339	223	6198	35.98	31.55	41.02
Sex						
Male	12783	397	22433	17.70	16.04	19.53
Female	9258	352	15689	22.44	20.21	24.91
Ischaemic stroke						
No	20884	609	36267	16.79	15.51	18.18
Yes	1157	140	1855	75.45	63.94	89.05
Bleeding disorder						
No	21972	746	38020	19.62	18.26	21.08
Yes	69	3	102	29.35	9.46	90.99
Severe renal failure requiring dialysis						
No	21980	745	38056	19.58	18.22	21.03
Yes	61	4	67	59.72	22.41	159.12
OAP use (Total)						
No	14368	553	24448	22.62	20.81	24.59
Yes	7673	196	13675	14.33	12.46	16.49

Table 1.20: (continued)

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
Chronic use of anticoagulation medication						
No	19194	634	33516	18.92	17.50	20.45
Yes	2847	115	4607	24.96	20.79	29.97
Increased bleeding risk (Total)						
No	21550	724	37375	19.37	18.01	20.83
Yes	491	25	747	33.46	22.61	49.51
CABG						
No	19704	688	33647	20.45	18.98	22.03
Yes	2337	61	4476	13.63	10.60	17.52
Severe liver disease						
No	21964	745	38014	19.60	18.24	21.06
Yes	77	4	108	36.92	13.86	98.37
Severe renal failure requiring dialysis						
No	21980	745	38056	19.58	18.22	21.03
Yes	61	4	67	59.72	22.41	159.12

Cardiovascular mortality

Table 1.21: Stratified incidence rates per 1000 patient years of Cardiovascular mortality with 95% confidence intervals (CIs) in Group 3 . The number of patients in each strata, the number of events and the total number of person years are also presented. Variables are evaluated the 1 year baseline check. Stratification was done separately for each variable.

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
No strata (All)						
Group 3 patients	22041	896	38776	23.11	21.64	24.67
Type of index MI						
Non-ST elevation MI (and unspecified MI)	14774	709	25278	28.05	26.06	30.19
ST elevation MI	7267	187	13498	13.85	12.00	15.99
Age at 1 year baseline check (years)						
18-49	558	3	1100	2.73	0.88	8.45
50-64	3020	41	5836	7.03	5.17	9.54
65-69	3202	39	5826	6.69	4.89	9.16
70-74	3450	73	6496	11.24	8.93	14.14
75-79	3684	125	6732	18.57	15.58	22.12
80-84	3788	202	6427	31.43	27.38	36.08
85 and over	4339	413	6359	64.94	58.97	71.52
Sex						
Male	12783	408	22790	17.90	16.25	19.73
Female	9258	488	15986	30.53	27.93	33.36
Ischaemic stroke						
No	20884	804	36795	21.85	20.39	23.41
Yes	1157	92	1982	46.42	37.84	56.95
Bleeding disorder						
No	21972	892	38671	23.07	21.60	24.63
Yes	69	4	105	37.94	14.24	101.09
Severe renal failure requiring dialysis						
No	21980	889	38706	22.97	21.51	24.53
Yes	61	7	71	98.82	47.11	207.28
OAP use (Total)						
No	14368	716	24902	28.75	26.72	30.94
Yes	7673	180	13874	12.97	11.21	15.01

Table 1.21: (continued)

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
Chronic use of anticoagulation medication						
No	19194	743	34074	21.81	20.29	23.43
Yes	2847	153	4702	32.54	27.77	38.13
Increased bleeding risk (Total)						
No	21550	871	38010	22.92	21.44	24.49
Yes	491	25	767	32.61	22.03	48.26
CABG						
No	19704	858	34238	25.06	23.44	26.79
Yes	2337	38	4538	8.37	6.09	11.51
Severe liver disease						
No	21964	895	38664	23.15	21.68	24.72
Yes	77	1	112	8.93	1.26	63.38
Severe renal failure requiring dialysis						
No	21980	889	38706	22.97	21.51	24.53
Yes	61	7	71	98.82	47.11	207.28

Composite end-point

Table 1.22: Stratified incidence rates per 1000 patient years of Composite end-point with 95% confidence intervals (CIs) in Group 3 . The number of patients in each strata, the number of events and the total number of person years are also presented. Variables are evaluated the 1 year baseline check. Stratification was done separately for each variable.

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
No strata (All)						
Group 3 patients	22041	2600	36718	70.81	68.14	73.59
Type of index MI						
Non-ST elevation MI (and unspecified MI)	14774	1968	23759	82.83	79.25	86.57
ST elevation MI	7267	632	12958	48.77	45.11	52.73
Age at 1 year baseline check (years)						
18-49	558	32	1057	30.28	21.41	42.82
50-64	3020	202	5626	35.91	31.28	41.21
65-69	3202	207	5624	36.81	32.12	42.18
70-74	3450	299	6207	48.17	43.01	53.95
75-79	3684	430	6339	67.83	61.71	74.56
80-84	3788	556	6015	92.43	85.06	100.45
85 and over	4339	874	5849	149.42	139.84	159.67
Sex						
Male	12783	1338	21701	61.66	58.44	65.05
Female	9258	1262	15016	84.04	79.53	88.81
Ischaemic stroke						
No	20884	2330	34943	66.68	64.03	69.44
Yes	1157	270	1774	152.16	135.05	171.43
Bleeding disorder						
No	21972	2589	36622	70.70	68.02	73.47
Yes	69	11	96	114.53	63.43	206.80
Severe renal failure requiring dialysis						
No	21980	2586	36659	70.54	67.87	73.31
Yes	61	14	59	239.11	141.61	403.72
OAP use (Total)						
No	14368	1889	23502	80.38	76.83	84.08
Yes	7673	711	13215	53.80	49.99	57.90

Table 1.22: (continued)

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
Chronic use of anticoagulation medication						
No	19194	2230	32276	69.09	66.28	72.02
Yes	2847	370	4442	83.30	75.23	92.24
Increased bleeding risk (Total)						
No	21550	2526	35991	70.19	67.50	72.98
Yes	491	74	727	101.77	81.04	127.81
CABG						
No	19704	2457	32309	76.05	73.10	79.11
Yes	2337	143	4408	32.44	27.54	38.22
Severe liver disease						
No	21964	2593	36611	70.83	68.15	73.60
Yes	77	7	107	65.67	31.30	137.74
Severe renal failure requiring dialysis						
No	21980	2586	36659	70.54	67.87	73.31
Yes	61	14	59	239.11	141.61	403.72

Overall mortality

Table 1.23: Stratified incidence rates per 1000 patient years of Overall mortality with 95% confidence intervals (CIs) in Group 3 . The number of patients in each strata, the number of events and the total number of person years are also presented. Variables are evaluated the 1 year baseline check. Stratification was done separately for each variable.

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
No strata (All)						
Group 3 patients	22041	3724	38776	96.04	93	99.17
Type of index MI						
Non-ST elevation MI (and unspecified MI)	14774	2923	25278	115.63	111.52	119.9
ST elevation MI	7267	801	13498	59.34	55.37	63.6
Age at 1 year baseline check (years)						
18-49	558	9	1100	8.18	4.26	15.72
50-64	3020	160	5836	27.42	23.48	32.01
65-69	3202	206	5826	35.36	30.85	40.53
70-74	3450	338	6496	52.03	46.77	57.89
75-79	3684	568	6732	84.37	77.71	91.60
80-84	3788	831	6427	129.30	120.80	138.39
85 and over	4339	1612	6359	253.49	241.41	266.17
Sex						
Male	12783	1887	22790	82.80	79.15	86.62
Female	9258	1837	15986	114.91	109.78	120.29
Ischaemic stroke						
No	20884	3427	36795	93.14	90.07	96.31
Yes	1157	297	1982	149.87	133.76	167.92
Bleeding disorder						
No	21972	3703	38671	95.76	92.72	98.89
Yes	69	21	105	199.18	129.87	305.49
Severe renal failure requiring dialysis						
No	21980	3701	38706	95.62	92.59	98.75
Yes	61	23	71	324.68	215.76	488.59
OAP use (Total)						
No	14368	3064	24902	123.04	118.76	127.48
Yes	7673	660	13874	47.57	44.08	51.34

Table 1.23: (continued)

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
Chronic use of anticoagulation medication						
No	19194	3147	34074	92.36	89.19	95.64
Yes	2847	577	4702	122.71	113.10	133.15
Increased bleeding risk (Total)						
No	21550	3571	38010	93.95	90.92	97.08
Yes	491	153	767	199.55	170.31	233.82
CABG						
No	19704	3544	34238	103.51	100.16	106.97
Yes	2337	180	4538	39.66	34.27	45.90
Severe liver disease						
No	21964	3699	38664	95.67	92.64	98.80
Yes	77	25	112	223.19	150.81	330.31
Severe renal failure requiring dialysis						
No	21980	3701	38706	95.62	92.59	98.75
Yes	61	23	71	324.68	215.76	488.59

1.2.4 Stratified incidence rates for group 4

Myocardial infarction

Table 1.24: Stratified incidence rates per 1000 patient years of Myocardial infarction with 95% confidence intervals (CIs) in Group 4 . The number of patients in each strata, the number of events and the total number of person years are also presented. Variables are evaluated the 1 year baseline check. Stratification was done separately for each variable.

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
No strata (All)						
Group 4 patients	19194	1429	32768	43.61	41.41	45.93
Type of index MI						
Non-ST elevation MI (and unspecified MI)	12731	1109	20990	52.83	49.82	56.04
ST elevation MI	6463	320	11778	27.17	24.35	30.31
Age at 1 year baseline check (years)						
18-49	537	22	1022	21.53	14.18	32.70
50-64	2805	128	5279	24.25	20.39	28.84
65-69	2891	114	5152	22.13	18.42	26.59
70-74	3009	147	5564	26.42	22.47	31.05
75-79	3122	220	5525	39.82	34.89	45.44
80-84	3132	305	5122	59.55	53.23	66.63
85 and over	3698	493	5104	96.58	88.42	105.50
Sex						
Male	11153	723	19386	37.30	34.67	40.12
Female	8041	706	13383	52.75	49.00	56.79
Ischaemic stroke						
No	18321	1327	31338	42.34	40.13	44.69
Yes	873	102	1430	71.33	58.75	86.61
Bleeding disorder						
No	19139	1422	32683	43.51	41.30	45.83
Yes	55	7	85	82.42	39.29	172.89
Severe renal failure requiring dialysis						
No	19137	1419	32712	43.38	41.18	45.69
Yes	57	10	56	178.86	96.24	332.42
OAP use (Total)						
No	11812	956	19837	48.19	45.23	51.35
Yes	7382	473	12931	36.58	33.43	40.03

Table 1.24: (continued)

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
Increased bleeding risk (Total)						
No	18767	1391	32115	43.31	41.10	45.65
Yes	427	38	653	58.18	42.34	79.96
CABG						
No	17215	1371	28946	47.36	44.92	49.94
Yes	1979	58	3823	15.17	11.73	19.63
Severe liver disease						
No	19129	1426	32671	43.65	41.44	45.97
Yes	65	3	97	31.01	10.00	96.15
Severe renal failure requiring dialysis						
No	19137	1419	32712	43.38	41.18	45.69
Yes	57	10	56	178.86	96.24	332.42

Stroke (total)

Table 1.25: Stratified incidence rates per 1000 patient years of Stroke (total) with 95% confidence intervals (CIs) in Group 4 . The number of patients in each strata, the number of events and the total number of person years are also presented. Variables are evaluated the 1 year baseline check. Stratification was done separately for each variable.

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
No strata (All)						
Group 4 patients	19194	634	33516	18.92	17.5	20.45
Type of index MI						
Non-ST elevation MI (and unspecified MI)	12731	441	21581	20.44	18.61	22.43
ST elevation MI	6463	193	11935	16.17	14.04	18.62
Age at 1 year baseline check (years)						
18-49	537	6	1050	5.71	2.57	12.71
50-64	2805	45	5380	8.36	6.24	11.20
65-69	2891	61	5213	11.70	9.10	15.04
70-74	3009	88	5642	15.60	12.66	19.22
75-79	3122	115	5646	20.37	16.97	24.45
80-84	3132	124	5283	23.47	19.68	27.99
85 and over	3698	195	5300	36.79	31.97	42.34
Sex						
Male	11153	327	19767	16.54	14.84	18.44
Female	8041	307	13749	22.33	19.97	24.97
Ischaemic stroke						
No	18321	525	32108	16.35	15.01	17.81
Yes	873	109	1408	77.44	64.18	93.43
Bleeding disorder						
No	19139	631	33428	18.88	17.46	20.41
Yes	55	3	88	34.03	10.98	105.52
Severe renal failure requiring dialysis						
No	19137	630	33454	18.83	17.42	20.36
Yes	57	4	61	65.11	24.44	173.49
OAP use (Total)						
No	11812	450	20307	22.16	20.20	24.3
Yes	7382	184	13209	13.93	12.06	16.1

Table 1.25: (continued)

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
Increased bleeding risk (Total)						
No	18767	612	32857	18.63	17.21	20.16
Yes	427	22	659	33.40	22.00	50.73
CABG						
No	17215	585	29681	19.71	18.18	21.37
Yes	1979	49	3835	12.78	9.66	16.91
Severe liver disease						
No	19129	631	33420	18.88	17.46	20.41
Yes	65	3	96	31.33	10.10	97.13
Severe renal failure requiring dialysis						
No	19137	630	33454	18.83	17.42	20.36
Yes	57	4	61	65.11	24.44	173.49

Cardiovascular mortality

Table 1.26: Stratified incidence rates per 1000 patient years of Cardiovascular mortality with 95% confidence intervals (CIs) in Group 4 . The number of patients in each strata, the number of events and the total number of person years are also presented. Variables are evaluated the 1 year baseline check. Stratification was done separately for each variable.

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
No strata (All)						
Group 4 patients	19194	743	34074	21.81	20.29	23.43
Type of index MI						
Non-ST elevation MI (and unspecified MI)	12731	593	21963	27.00	24.91	29.26
ST elevation MI	6463	150	12111	12.39	10.55	14.53
Age at 1 year baseline check (years)						
18-49	537	3	1055	2.84	0.92	8.82
50-64	2805	37	5435	6.81	4.93	9.40
65-69	2891	35	5275	6.64	4.76	9.24
70-74	3009	60	5731	10.47	8.13	13.48
75-79	3122	101	5760	17.54	14.43	21.31
80-84	3132	166	5380	30.85	26.50	35.92
85 and over	3698	341	5439	62.70	56.38	69.72
Sex						
Male	11153	327	20065	16.3	14.62	18.16
Female	8041	416	14009	29.7	26.97	32.69
Ischaemic stroke						
No	18321	674	32571	20.69	19.19	22.32
Yes	873	69	1504	45.89	36.24	58.10
Bleeding disorder						
No	19139	740	33983	21.78	20.26	23.40
Yes	55	3	91	32.84	10.59	101.82
Severe renal failure requiring dialysis						
No	19137	736	34009	21.64	20.13	23.26
Yes	57	7	65	107.21	51.11	224.88
OAP use (Total)						
No	11812	577	20677	27.91	25.72	30.28
Yes	7382	166	13397	12.39	10.64	14.43

Table 1.26: (continued)

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
Increased bleeding risk (Total)						
No	18767	719	33399	21.53	20.01	23.16
Yes	427	24	675	35.54	23.82	53.02
CABG						
No	17215	711	30190	23.55	21.88	25.35
Yes	1979	32	3885	8.24	5.83	11.65
Severe liver disease						
No	19129	742	33975	21.84	20.32	23.47
Yes	65	1	99	10.06	1.42	71.41
Severe renal failure requiring dialysis						
No	19137	736	34009	21.64	20.13	23.26
Yes	57	7	65	107.21	51.11	224.88

Composite end-point

Table 1.27: Stratified incidence rates per 1000 patient years of Composite end-point with 95% confidence intervals (CIs) in Group 4 . The number of patients in each strata, the number of events and the total number of person years are also presented. Variables are evaluated the 1 year baseline check. Stratification was done separately for each variable.

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
No strata (All)						
Group 4 patients	19194	2230	32276	69.09	66.28	72.02
Type of index MI						
Non-ST elevation MI (and unspecified MI)	12731	1686	20655	81.63	77.82	85.62
ST elevation MI	6463	544	11621	46.81	43.04	50.91
Age at 1 year baseline check (years)						
18-49	537	29	1017	28.51	19.81	41.03
50-64	2805	185	5236	35.33	30.59	40.81
65-69	2891	187	5091	36.73	31.82	42.39
70-74	3009	250	5487	45.56	40.25	51.57
75-79	3122	356	5422	65.66	59.18	72.85
80-84	3132	466	5033	92.59	84.55	101.39
85 and over	3698	757	4989	151.73	141.29	162.93
Sex						
Male	11153	1128	19119	59.00	55.66	62.55
Female	8041	1102	13157	83.76	78.96	88.85
Ischaemic stroke						
No	18321	2024	30926	65.45	62.66	68.36
Yes	873	206	1349	152.65	133.17	174.99
Bleeding disorder						
No	19139	2220	32194	68.96	66.15	71.89
Yes	55	10	82	122.00	65.64	226.74
Severe renal failure requiring dialysis						
No	19137	2216	32223	68.77	65.97	71.69
Yes	57	14	53	264.13	156.43	445.97
OAP use (Total)						
No	11812	1551	19513	79.49	75.63	83.54
Yes	7382	679	12763	53.20	49.35	57.36

Table 1.27: (continued)

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
Increased bleeding risk (Total)						
No	18767	2161	31637	68.31	65.49	71.25
Yes	427	69	639	108.04	85.33	136.79
CABG						
No	17215	2111	28502	74.07	70.97	77.29
Yes	1979	119	3774	31.53	26.34	37.73
Severe liver disease						
No	19129	2224	32182	69.11	66.29	72.04
Yes	65	6	94	63.81	28.67	142.04
Severe renal failure requiring dialysis						
No	19137	2216	32223	68.77	65.97	71.69
Yes	57	14	53	264.13	156.43	445.97

Overall mortality

Table 1.28: Stratified incidence rates per 1000 patient years of Overall mortality with 95% confidence intervals (CIs) in Group 4 . The number of patients in each strata, the number of events and the total number of person years are also presented. Variables are evaluated the 1 year baseline check. Stratification was done separately for each variable.

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
No strata (All)						
Group 4 patients	19194	3147	34074	92.36	89.19	95.64
Type of index MI						
Non-ST elevation MI (and unspecified MI)	12731	2472	21963	112.55	108.20	117.08
ST elevation MI	6463	675	12111	55.73	51.68	60.10
Age at 1 year baseline check (years)						
18-49	537	9	1055	8.53	4.44	16.39
50-64	2805	145	5435	26.68	22.67	31.40
65-69	2891	173	5275	32.80	28.26	38.07
70-74	3009	272	5731	47.46	42.15	53.45
75-79	3122	479	5760	83.16	76.04	90.96
80-84	3132	683	5380	126.94	117.77	136.83
85 and over	3698	1386	5439	254.83	241.76	268.60
Sex						
Male	11153	1566	20065	78.05	74.27	82.01
Female	8041	1581	14009	112.86	107.43	118.56
Ischaemic stroke						
No	18321	2917	32571	89.56	86.37	92.87
Yes	873	230	1504	152.96	134.42	174.06
Bleeding disorder						
No	19139	3127	33983	92.02	88.85	95.30
Yes	55	20	91	218.93	141.24	339.34
Severe renal failure requiring dialysis						
No	19137	3124	34009	91.86	88.69	95.14
Yes	57	23	65	352.26	234.09	530.10
OAP use (Total)						
No	11812	2528	20677	122.26	117.59	127.12
Yes	7382	619	13397	46.20	42.70	49.99

Table 1.28: (continued)

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
Increased bleeding risk (Total)						
No	18767	3009	33399	90.09	86.93	93.37
Yes	427	138	675	204.34	172.94	241.44
CABG						
No	17215	2994	30190	99.17	95.68	102.79
Yes	1979	153	3885	39.38	33.61	46.15
Severe liver disease						
No	19129	3126	33975	92.01	88.84	95.29
Yes	65	21	99	211.24	137.73	323.99
Severe renal failure requiring dialysis						
No	19137	3124	34009	91.86	88.69	95.14
Yes	57	23	65	352.26	234.09	530.10

1.2.5 Stratified incidence rates for group 5

Myocardial infarction

Table 1.29: Stratified incidence rates per 1000 patient years of Myocardial infarction with 95% confidence intervals (CIs) in Group 5 . The number of patients in each strata, the number of events and the total number of person years are also presented. Variables are evaluated the 1 year baseline check. Stratification was done separately for each variable.

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
No strata (All)						
Group 5 patients	8942	788	14618	53.91	50.27	57.8
Type of index MI						
Non-ST elevation MI (and unspecified MI)	6509	630	10297	61.18	56.59	66.15
ST elevation MI	2433	158	4321	36.56	31.28	42.73
Age at index (years)						
18-49	17	0	27			
50-64	1042	50	1964	25.46	19.29	33.59
65-69	1069	48	1990	24.12	18.18	32.01
70-74	1262	70	2284	30.65	24.25	38.74
75-79	1442	125	2405	51.97	43.61	61.93
80-84	1818	193	2858	67.52	58.64	77.75
85 and over	2292	302	3090	97.74	87.32	109.41
Sex						
Male	4394	356	7322	48.62	43.82	53.94
Female	4548	432	7297	59.21	53.88	65.06
Number of additional risk factors						
0	315	6	599	10.01	4.50	22.29
1	5561	416	9313	44.67	40.57	49.17
2	2430	259	3790	68.34	60.50	77.19
3	560	91	824	110.42	89.91	135.61
4	71	16	87	183.59	112.48	299.68
5	5	0	4			
Chronic use of anticoagulation medication						
No	8629	750	14164	52.95	49.29	56.88
Yes	313	38	454	83.68	60.89	115.00
Use of OAP						
No	8758	770	14347	53.67	50.01	57.60
Yes	184	18	271	66.30	41.77	105.23

Table 1.29: (continued)

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
Age at 1 year baseline check (years)						
50-64	854	41	1609	25.48	18.76	34.60
65-69	1075	50	1957	25.55	19.37	33.72
70-74	1196	59	2227	26.50	20.53	34.20
75-79	1401	115	2388	48.15	40.11	57.81
80-84	1773	182	2836	64.17	55.49	74.20
85 and over	2643	341	3601	94.69	85.16	105.30
Sex						
Male	4394	356	7322	48.62	43.82	53.94
Female	4548	432	7297	59.21	53.88	65.06

Stroke (total)

Table 1.30: Stratified incidence rates per 1000 patient years of Stroke (total) with 95% confidence intervals (CIs) in Group 5 . The number of patients in each strata, the number of events and the total number of person years are also presented. Variables are evaluated the 1 year baseline check. Stratification was done separately for each variable.

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
No strata (All)						
Group 5 patients	8942	304	15073	20.17	18.02	22.57
Type of index MI						
Non-ST elevation MI (and unspecified MI)	6509	223	10680	20.88	18.31	23.81
ST elevation MI	2433	81	4393	18.44	14.83	22.93
Age at index (years)						
18-49	17	0	27			
50-64	1042	15	2006	7.48	4.51	12.40
65-69	1069	22	2017	10.90	7.18	16.56
70-74	1262	39	2333	16.71	12.21	22.88
75-79	1442	51	2489	20.49	15.57	26.96
80-84	1818	77	2967	25.95	20.76	32.45
85 and over	2292	100	3232	30.94	25.43	37.64
Sex						
Male	4394	145	7507	19.32	16.41	22.73
Female	4548	159	7566	21.02	17.99	24.55
Number of additional risk factors						
0	315	2	604	3.31	0.83	13.24
1	5561	164	9569	17.14	14.71	19.97
2	2430	94	3934	23.90	19.52	29.25
3	560	38	871	43.61	31.73	59.94
4	71	5	91	55.03	22.90	132.21
5	5	1	4	268.96	37.89	1909.36
Chronic use of anticoagulation medication						
No	8629	290	14604	19.86	17.70	22.28
Yes	313	14	469	29.85	17.68	50.41
Use of OAP						
No	8758	299	14790	20.22	18.05	22.64
Yes	184	5	283	17.70	7.37	42.52

Table 1.30: *(continued)*

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
Age at 1 year baseline check (years)						
50-64	854	12	1646	7.29	4.14	12.84
65-69	1075	24	1978	12.13	8.13	18.10
70-74	1196	33	2271	14.53	10.33	20.44
75-79	1401	47	2466	19.06	14.32	25.37
80-84	1773	63	2956	21.31	16.65	27.28
85 and over	2643	125	3755	33.29	27.94	39.67
Sex						
Male	4394	145	7507	19.32	16.41	22.73
Female	4548	159	7566	21.02	17.99	24.55

Cardiovascular mortality

Table 1.31: Stratified incidence rates per 1000 patient years of Cardiovascular mortality with 95% confidence intervals (CIs) in Group 5 . The number of patients in each strata, the number of events and the total number of person years are also presented. Variables are evaluated the 1 year baseline check. Stratification was done separately for each variable.

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
No strata (All)						
Group 5 patients	8942	470	15316	30.69	28.03	33.59
Type of index MI						
Non-ST elevation MI (and unspecified MI)	6509	382	10848	35.21	31.85	38.93
ST elevation MI	2433	88	4468	19.70	15.98	24.27
Age at index (years)						
18-49	17	0	27			
50-64	1042	19	2026	9.38	5.98	14.70
65-69	1069	17	2041	8.33	5.18	13.40
70-74	1262	35	2376	14.73	10.57	20.51
75-79	1442	56	2536	22.09	17.00	28.70
80-84	1818	122	3017	40.44	33.86	48.29
85 and over	2292	221	3292	67.13	58.84	76.59
Sex						
Male	4394	188	7632	24.63	21.35	28.42
Female	4548	282	7684	36.70	32.66	41.24
Number of additional risk factors						
0	315	3	607	4.94	1.59	15.32
1	5561	225	9700	23.20	20.35	26.43
2	2430	164	4014	40.85	35.06	47.61
3	560	62	894	69.33	54.05	88.92
4	71	13	95	136.29	79.14	234.71
5	5	3	4	679.32	219.10	2106.29
Chronic use of anticoagulation medication						
No	8629	435	14841	29.31	26.68	32.20
Yes	313	35	475	73.68	52.90	102.62
Use of OAP						
No	8758	456	15031	30.34	27.68	33.25
Yes	184	14	284	49.25	29.17	83.16

Table 1.31: (continued)

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
Age at 1 year baseline check (years)						
50-64	854	14	1661	8.43	4.99	14.23
65-69	1075	20	2007	9.97	6.43	15.45
70-74	1196	28	2307	12.14	8.38	17.58
75-79	1401	51	2513	20.29	15.42	26.70
80-84	1773	107	2996	35.71	29.55	43.16
85 and over	2643	250	3832	65.25	57.64	73.86
Sex						
Male	4394	188	7632	24.63	21.35	28.42
Female	4548	282	7684	36.70	32.66	41.24

Composite end-point

Table 1.32: Stratified incidence rates per 1000 patient years of Composite end-point with 95% confidence intervals (CIs) in Group 5 . The number of patients in each strata, the number of events and the total number of person years are also presented. Variables are evaluated the 1 year baseline check. Stratification was done separately for each variable.

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
No strata (All)						
Group 5 patients	8942	1221	14406	84.75	80.13	89.64
Type of index MI						
Non-ST elevation MI (and unspecified MI)	6509	957	10152	94.27	88.48	100.43
ST elevation MI	2433	264	4254	62.06	55.00	70.01
Age at index (years)						
18-49	17	0	27			
50-64	1042	77	1949	39.51	31.60	49.40
65-69	1069	75	1967	38.14	30.41	47.82
70-74	1262	121	2245	53.90	45.10	64.41
75-79	1442	185	2364	78.24	67.74	90.37
80-84	1818	303	2816	107.60	96.14	120.43
85 and over	2292	460	3038	151.39	138.17	165.88
Sex						
Male	4394	551	7209	76.43	70.31	83.08
Female	4548	670	7197	93.09	86.30	100.42
Number of additional risk factors						
0	315	10	598	16.71	8.99	31.06
1	5561	644	9195	70.04	64.83	75.66
2	2430	399	3723	107.18	97.16	118.23
3	560	143	802	178.36	151.40	210.13
4	71	22	85	259.43	170.82	394.00
5	5	3	4	806.89	260.24	2501.80
Chronic use of anticoagulation medication						
No	8629	1156	13957	82.82	78.19	87.74
Yes	313	65	449	144.68	113.46	184.50
Use of OAP						
No	8758	1192	14137	84.32	79.67	89.24
Yes	184	29	270	107.50	74.71	154.70

Table 1.32: (continued)

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
Age at 1 year baseline check (years)						
50-64	854	62	1599	38.79	30.24	49.75
65-69	1075	81	1929	41.99	33.77	52.21
70-74	1196	102	2196	46.45	38.26	56.40
75-79	1401	172	2345	73.35	63.17	85.17
80-84	1773	278	2802	99.23	88.22	111.61
85 and over	2643	526	3537	148.73	136.55	162.00
Sex						
Male	4394	551	7209	76.43	70.31	83.08
Female	4548	670	7197	93.09	86.30	100.42

Overall mortality

Table 1.33: Stratified incidence rates per 1000 patient years of Overall mortality with 95% confidence intervals (CIs) in Group 5 . The number of patients in each strata, the number of events and the total number of person years are also presented. Variables are evaluated the 1 year baseline check. Stratification was done separately for each variable.

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
No strata (All)						
Group 5 patients	8942	2059	15316	134.44	128.75	140.37
Type of index MI						
Non-ST elevation MI (and unspecified MI)	6509	1665	10848	153.48	146.29	161.04
ST elevation MI	2433	394	4468	88.19	79.90	97.34
Age at index (years)						
18-49	17	0	27			
50-64	1042	63	2026	31.10	24.29	39.81
65-69	1069	87	2041	42.62	34.54	52.58
70-74	1262	157	2376	66.07	56.50	77.25
75-79	1442	298	2536	117.53	104.91	131.66
80-84	1818	493	3017	163.40	149.59	178.48
85 and over	2292	961	3292	291.91	274.03	310.96
Sex						
Male	4394	913	7632	119.63	112.11	127.64
Female	4548	1146	7684	149.15	140.76	158.04
Number of additional risk factors						
0	315	12	607	19.77	11.23	34.81
1	5561	1143	9700	117.83	111.20	124.87
2	2430	650	4014	161.92	149.94	174.86
3	560	214	894	239.29	209.29	273.60
4	71	36	95	377.41	272.24	523.22
5	5	4	4	905.77	339.95	2413.33
Chronic use of anticoagulation medication						
No	8629	1934	14841	130.32	124.64	136.26
Yes	313	125	475	263.15	220.84	313.57
Use of OAP						
No	8758	2023	15031	134.58	128.85	140.58
Yes	184	36	284	126.65	91.35	175.57

Table 1.33: (continued)

Variable and strata	N patients	N events	Person years	Rate	Lower 95%CI	Upper 95%CI
Age at 1 year baseline check (years)						
50-64	854	47	1661	28.29	21.26	37.66
65-69	1075	86	2007	42.86	34.69	52.94
70-74	1196	135	2307	58.53	49.44	69.28
75-79	1401	266	2513	105.84	93.85	119.35
80-84	1773	448	2996	149.52	136.30	164.03
85 and over	2643	1077	3832	281.08	264.78	298.38
Sex						
Male	4394	913	7632	119.63	112.11	127.64
Female	4548	1146	7684	149.15	140.76	158.04

1.3 Explored risk factors for primary outcomes

1.3.1 Explored risk factors for group 1

Myocardial infarction

Table 1.34: The effect of pre-defined and explored risk factors on the risk of Myocardial infarction estimated using the Cox proportional hazards model in Group 1 . Table shows the hazard ratios (HRs) for several factors with the corresponding 95% CI and p-value. Only those explored risk factors that indicated 20% effect on the hazard of the outcome with $p < 0.15$ are presented. Variables are evaluated at index date, medication use variables refer to ongoing use and comorbidities were searched in a 5 years history period.

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Age at index (years) : 18-49	reference	reference	reference	reference	reference	reference
Age at index (years) : 50-64	0.067	0.079	1.07	0.916	1.249	0.397
Age at index (years) : 65-69	0.349	0.085	1.417	1.201	1.672	<0.001
Age at index (years) : 70-74	0.413	0.082	1.511	1.286	1.775	<0.001
Age at index (years) : 75-79	0.719	0.079	2.053	1.758	2.398	<0.001
Age at index (years) : 80-84	1.006	0.078	2.734	2.347	3.185	<0.001
Age at index (years) : 85 and over	1.304	0.077	3.684	3.167	4.284	<0.001
Sex : Male	reference	reference	reference	reference	reference	reference
Sex : Female	-0.062	0.027	0.94	0.891	0.991	0.022
Diabetes with ongoing medication : No	reference	reference	reference	reference	reference	reference
Diabetes with ongoing medication : Yes	0.431	0.029	1.538	1.454	1.627	<0.001
≥ 1 MI in addition to index MI : No	reference	reference	reference	reference	reference	reference
≥ 1 MI in addition to index MI : Yes	0.596	0.039	1.815	1.683	1.957	<0.001
Multivessel CAD : No	reference	reference	reference	reference	reference	reference
Multivessel CAD : Yes	0.106	0.029	1.112	1.05	1.178	<0.001
Chronic renal dysfunction : No	reference	reference	reference	reference	reference	reference
Chronic renal dysfunction : Yes	0.648	0.062	1.911	1.691	2.159	<0.001
Ischaemic stroke : No	reference	reference	reference	reference	reference	reference
Ischaemic stroke : Yes	0.162	0.046	1.176	1.075	1.288	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Antithrombotic medication : No	reference	reference	reference	reference	reference	reference
Antithrombotic medication : Yes	0.25	0.029	1.284	1.212	1.359	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Beta-blocker : No	reference	reference	reference	reference	reference	reference
Beta-blocker : Yes	0.283	0.027	1.327	1.26	1.398	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
CABG : No	reference	reference	reference	reference	reference	reference
CABG : Yes	-0.715	0.066	0.489	0.43	0.557	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Calcium channel blocker : No	reference	reference	reference	reference	reference	reference
Calcium channel blocker : Yes	0.228	0.03	1.256	1.185	1.332	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Diabetes mellitus : No	reference	reference	reference	reference	reference	reference
Diabetes mellitus : Yes	0.27	0.048	1.309	1.191	1.44	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Heart failure : No	reference	reference	reference	reference	reference	reference
Heart failure : Yes	0.361	0.029	1.434	1.355	1.519	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Hypertension : No	reference	reference	reference	reference	reference	reference
Hypertension : Yes	0.189	0.055	1.209	1.085	1.346	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Insulin : No	reference	reference	reference	reference	reference	reference
Insulin : Yes	0.487	0.049	1.627	1.479	1.791	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Major bleedings : No	reference	reference	reference	reference	reference	reference
Major bleedings : Yes	0.219	0.048	1.245	1.134	1.367	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Nitrate : No	reference	reference	reference	reference	reference	reference
Nitrate : Yes	0.448	0.028	1.565	1.483	1.652	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
OAP use (Total) : No	reference	reference	reference	reference	reference	reference
OAP use (Total) : Yes	0.322	0.051	1.38	1.248	1.527	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Oral antidiabetic : No	reference	reference	reference	reference	reference	reference
Oral antidiabetic : Yes	-0.365	0.05	0.694	0.63	0.766	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Proton pump inhibitor : No	reference	reference	reference	reference	reference	reference
Proton pump inhibitor : Yes	0.237	0.031	1.267	1.192	1.346	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Severe liver disease : No	reference	reference	reference	reference	reference	reference
Severe liver disease : Yes	0.383	0.205	1.466	0.982	2.19	0.062

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Severe renal failure requiring dialysis : No	reference	reference	reference	reference	reference	reference
Severe renal failure requiring dialysis : Yes	0.53	0.17	1.699	1.218	2.37	0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Invasive procedure related to index event : No invasive procedure	reference	reference	reference	reference	reference	reference
Invasive procedure related to index event : Coronary angiography only	-0.264	0.041	0.768	0.708	0.832	<0.001
Invasive procedure related to index event : PCI	-0.508	0.034	0.602	0.563	0.643	<0.001
Invasive procedure related to index event : CABG	-1.14	0.083	0.32	0.272	0.376	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Type of index MI : Non-ST elevation MI (and unspecified MI)	reference	reference	reference	reference	reference	reference
Type of index MI : ST elevation MI	-0.228	0.03	0.796	0.751	0.844	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Gastrointestinal bleeding : No	reference	reference	reference	reference	reference	reference
Gastrointestinal bleeding : Yes	0.475	0.1	1.607	1.321	1.955	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
PCI or CABG related to index event : No	reference	reference	reference	reference	reference	reference
PCI or CABG related to index event : Yes	-0.505	0.031	0.603	0.568	0.641	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Increased bleeding risk (Total) : No	reference	reference	reference	reference	reference	reference
Increased bleeding risk (Total) : Yes	0.208	0.069	1.231	1.076	1.408	0.003

Stroke (total)

Table 1.55: The effect of pre-defined and explored risk factors on the risk of Stroke (total) estimated using the Cox proportional hazards model in Group 1 . Table shows the hazard ratios (HRs) for several factors with the corresponding 95% CI and p-value. Only those explored risk factors that indicated 20% effect on the hazard of the outcome with $p < 0.15$ are presented. Variables are evaluated at index date, medication use variables refer to ongoing use and comorbidities were searched in a 5 years history period.

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Age at index (years) : 18-49	reference	reference	reference	reference	reference	reference
Age at index (years) : 50-64	0.68	0.2	1.975	1.336	2.92	<0.001
Age at index (years) : 65-69	1.184	0.203	3.266	2.192	4.867	<0.001
Age at index (years) : 70-74	1.309	0.2	3.702	2.502	5.478	<0.001
Age at index (years) : 75-79	1.519	0.197	4.569	3.103	6.729	<0.001
Age at index (years) : 80-84	1.745	0.196	5.727	3.897	8.417	<0.001
Age at index (years) : 85 and over	1.866	0.196	6.465	4.4	9.501	<0.001
Sex : Male	reference	reference	reference	reference	reference	reference
Sex : Female	-0.067	0.048	0.935	0.852	1.027	0.161
Diabetes with ongoing medication : No	reference	reference	reference	reference	reference	reference
Diabetes with ongoing medication : Yes	0.214	0.053	1.238	1.116	1.373	<0.001
≥ 1 MI in addition to index MI : No	reference	reference	reference	reference	reference	reference
≥ 1 MI in addition to index MI : Yes	0.251	0.076	1.286	1.108	1.491	0.001
Multivessel CAD : No	reference	reference	reference	reference	reference	reference
Multivessel CAD : Yes	-0.041	0.054	0.96	0.863	1.068	0.453
Chronic renal dysfunction : No	reference	reference	reference	reference	reference	reference
Chronic renal dysfunction : Yes	0.285	0.134	1.329	1.023	1.728	0.043
Ischaemic stroke : No	reference	reference	reference	reference	reference	reference
Ischaemic stroke : Yes	1.685	0.052	5.394	4.87	5.975	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Atrial fibrillation : No	reference	reference	reference	reference	reference	reference
Atrial fibrillation : Yes	0.341	0.054	1.406	1.265	1.562	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Antithrombotic medication : No	reference	reference	reference	reference	reference	reference
Antithrombotic medication : Yes	0.219	0.051	1.245	1.126	1.376	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Arrhythmia : No	reference	reference	reference	reference	reference	reference
Arrhythmia : Yes	0.319	0.05	1.376	1.247	1.519	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Bleeding disorder : No	reference	reference	reference	reference	reference	reference

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Bleeding disorder : Yes	0.538	0.355	1.712	0.854	3.435	0.144

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Diabetes mellitus : No	reference	reference	reference	reference	reference	reference
Diabetes mellitus : Yes	0.24	0.084	1.271	1.079	1.497	0.005

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Haemorrhagic stroke : No	reference	reference	reference	reference	reference	reference
Haemorrhagic stroke : Yes	0.94	0.169	2.559	1.837	3.563	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Insulin : No	reference	reference	reference	reference	reference	reference
Insulin : Yes	0.292	0.092	1.339	1.119	1.603	0.002

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Intracranial vascular abnormality : No	reference	reference	reference	reference	reference	reference
Intracranial vascular abnormality : Yes	0.34	0.211	1.405	0.929	2.126	0.13

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Intracranial bleeding : No	reference	reference	reference	reference	reference	reference
Intracranial bleeding : Yes	0.471	0.141	1.601	1.214	2.112	0.002

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
LMWH : No	reference	reference	reference	reference	reference	reference
LMWH : Yes	0.784	0.269	2.189	1.293	3.708	0.005

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Oral antidiabetic : No	reference	reference	reference	reference	reference	reference
Oral antidiabetic : Yes	-0.267	0.095	0.766	0.636	0.923	0.005

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Other acute ischaemic heart diseases : No	reference	reference	reference	reference	reference	reference
Other acute ischaemic heart diseases : Yes	0.453	0.268	1.573	0.929	2.662	0.096

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Proton pump inhibitor : No	reference	reference	reference	reference	reference	reference
Proton pump inhibitor : Yes	0.193	0.055	1.213	1.088	1.352	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
SSRI : No	reference	reference	reference	reference	reference	reference
SSRI : Yes	0.264	0.093	1.303	1.086	1.562	0.005

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Stroke (Total) : No	reference	reference	reference	reference	reference	reference
Stroke (Total) : Yes	1.402	0.188	4.061	2.811	5.869	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Severe liver disease : No	reference	reference	reference	reference	reference	reference
Severe liver disease : Yes	0.764	0.318	2.147	1.152	4	0.013

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Severe renal failure requiring dialysis : No	reference	reference	reference	reference	reference	reference
Severe renal failure requiring dialysis : Yes	0.908	0.336	2.48	1.285	4.786	0.011

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Transient ischemic attack : No	reference	reference	reference	reference	reference	reference
Transient ischemic attack : Yes	0.215	0.096	1.239	1.026	1.497	0.033

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Index year : 2009	reference	reference	reference	reference	reference	reference
Index year : 2010	-0.146	0.059	0.864	0.77	0.97	0.015
Index year : 2011	-0.228	0.065	0.796	0.701	0.904	<0.001
Index year : 2012	-0.094	0.071	0.91	0.792	1.046	0.185

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Invasive procedure related to index event : No invasive procedure	reference	reference	reference	reference	reference	reference
Invasive procedure related to index event : Coronary angiography only	-0.271	0.073	0.763	0.661	0.88	<0.001
Invasive procedure related to index event : PCI	-0.577	0.063	0.562	0.496	0.635	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Invasive procedure related to index event : CABG	-0.419	0.108	0.658	0.532	0.813	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
PCI or CABG related to index event : No	reference	reference	reference	reference	reference	reference
PCI or CABG related to index event : Yes	-0.468	0.055	0.626	0.562	0.698	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Increased bleeding risk (Total) : No	reference	reference	reference	reference	reference	reference
Increased bleeding risk (Total) : Yes	0.33	0.106	1.391	1.13	1.712	0.003

Cardiovascular mortality

Table 1.78: The effect of pre-defined and explored risk factors on the risk of Cardiovascular mortality estimated using the Cox proportional hazards model in Group 1 . Table shows the hazard ratios (HRs) for several factors with the corresponding 95% CI and p-value. Only those explored risk factors that indicated 20% effect on the hazard of the outcome with $p < 0.15$ are presented. Variables are evaluated at index date, medication use variables refer to ongoing use and comorbidities were searched in a 5 years history period.

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Age at index (years) : 18-49	reference	reference	reference	reference	reference	reference
Age at index (years) : 50-64	0.772	0.263	2.165	1.293	3.624	0.003
Age at index (years) : 65-69	1.356	0.267	3.88	2.301	6.543	<0.001
Age at index (years) : 70-74	1.753	0.26	5.771	3.469	9.6	<0.001
Age at index (years) : 75-79	2.274	0.256	9.719	5.89	16.037	<0.001
Age at index (years) : 80-84	2.766	0.254	15.889	9.662	26.131	<0.001
Age at index (years) : 85 and over	3.363	0.253	28.876	17.593	47.396	<0.001
Sex : Male	reference	reference	reference	reference	reference	reference
Sex : Female	-0.063	0.041	0.939	0.867	1.017	0.122
Diabetes with ongoing medication : No	reference	reference	reference	reference	reference	reference
Diabetes with ongoing medication : Yes	0.477	0.043	1.611	1.48	1.753	<0.001
≥ 1 MI in addition to index MI : No	reference	reference	reference	reference	reference	reference
≥ 1 MI in addition to index MI : Yes	0.566	0.055	1.762	1.582	1.962	<0.001
Multivessel CAD : No	reference	reference	reference	reference	reference	reference
Multivessel CAD : Yes	0.163	0.044	1.177	1.079	1.284	<0.001
Chronic renal dysfunction : No	reference	reference	reference	reference	reference	reference
Chronic renal dysfunction : Yes	0.831	0.087	2.295	1.935	2.723	<0.001
Ischaemic stroke : No	reference	reference	reference	reference	reference	reference
Ischaemic stroke : Yes	0.502	0.059	1.653	1.471	1.857	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Atrial fibrillation : No	reference	reference	reference	reference	reference	reference
Atrial fibrillation : Yes	0.322	0.045	1.38	1.264	1.506	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Arrhythmia : No	reference	reference	reference	reference	reference	reference
Arrhythmia : Yes	0.291	0.042	1.338	1.232	1.454	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Beta-blocker : No	reference	reference	reference	reference	reference	reference
Beta-blocker : Yes	0.28	0.041	1.323	1.221	1.434	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
CABG : No	reference	reference	reference	reference	reference	reference
CABG : Yes	-0.799	0.12	0.45	0.355	0.569	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
COPD : No	reference	reference	reference	reference	reference	reference
COPD : Yes	0.472	0.088	1.604	1.35	1.905	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Diabetes mellitus : No	reference	reference	reference	reference	reference	reference
Diabetes mellitus : Yes	0.488	0.069	1.629	1.424	1.863	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Dementia/Alzheimer's disease : No	reference	reference	reference	reference	reference	reference
Dementia/Alzheimer's disease : Yes	0.351	0.065	1.421	1.25	1.615	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Heart failure : No	reference	reference	reference	reference	reference	reference
Heart failure : Yes	0.69	0.041	1.993	1.837	2.162	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Hyperlipidemia : No	reference	reference	reference	reference	reference	reference
Hyperlipidemia : Yes	-0.274	0.043	0.76	0.699	0.827	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Hypertension : No	reference	reference	reference	reference	reference	reference
Hypertension : Yes	0.309	0.096	1.362	1.128	1.645	0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Insulin : No	reference	reference	reference	reference	reference	reference
Insulin : Yes	0.618	0.074	1.854	1.605	2.142	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Major bleedings : No	reference	reference	reference	reference	reference	reference
Major bleedings : Yes	0.271	0.068	1.311	1.148	1.498	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Nitrate : No	reference	reference	reference	reference	reference	reference
Nitrate : Yes	0.298	0.042	1.346	1.241	1.461	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
OAP use (Total) : No	reference	reference	reference	reference	reference	reference
OAP use (Total) : Yes	0.256	0.077	1.292	1.111	1.503	0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Oral antidiabetic : No	reference	reference	reference	reference	reference	reference
Oral antidiabetic : Yes	-0.548	0.073	0.578	0.501	0.668	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Other acute ischaemic heart diseases : No	reference	reference	reference	reference	reference	reference
Other acute ischaemic heart diseases : Yes	0.474	0.214	1.606	1.055	2.444	0.027

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
SSRI : No	reference	reference	reference	reference	reference	reference
SSRI : Yes	0.286	0.079	1.331	1.141	1.553	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Severe renal failure requiring dialysis : No	reference	reference	reference	reference	reference	reference
Severe renal failure requiring dialysis : Yes	0.73	0.253	2.076	1.264	3.411	0.006

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Invasive procedure related to index event : No invasive procedure	reference	reference	reference	reference	reference	reference
Invasive procedure related to index event : Coronary angiography only	-0.671	0.073	0.511	0.443	0.59	<0.001
Invasive procedure related to index event : PCI	-1.127	0.065	0.324	0.285	0.368	<0.001
Invasive procedure related to index event : CABG	-1.476	0.157	0.228	0.168	0.311	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Type of index MI : Non-ST elevation MI (and unspecified MI)	reference	reference	reference	reference	reference	reference
Type of index MI : ST elevation MI	-0.431	0.051	0.65	0.588	0.718	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Gastrointestinal bleeding : No	reference	reference	reference	reference	reference	reference
Gastrointestinal bleeding : Yes	0.602	0.138	1.826	1.394	2.392	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
PCI or CABG related to index event : No	reference	reference	reference	reference	reference	reference
PCI or CABG related to index event : Yes	-1.018	0.06	0.361	0.321	0.406	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Increased bleeding risk (Total) : No	reference	reference	reference	reference	reference	reference
Increased bleeding risk (Total) : Yes	0.269	0.097	1.309	1.081	1.585	0.008

Composite end-point

Table 1.102: The effect of pre-defined and explored risk factors on the risk of Composite end-point estimated using the Cox proportional hazards model in Group 1 . Table shows the hazard ratios (HRs) for several factors with the corresponding 95% CI and p-value. Only those explored risk factors that indicated 20% effect on the hazard of the outcome with $p < 0.15$ are presented. Variables are evaluated at index date, medication use variables refer to ongoing use and comorbidities were searched in a 5 years history period.

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Age at index (years) : 18-49	reference	reference	reference	reference	reference	reference
Age at index (years) : 50-64	0.178	0.073	1.195	1.035	1.379	0.016
Age at index (years) : 65-69	0.514	0.077	1.672	1.437	1.945	<0.001
Age at index (years) : 70-74	0.608	0.075	1.837	1.585	2.128	<0.001
Age at index (years) : 75-79	0.915	0.073	2.497	2.165	2.88	<0.001
Age at index (years) : 80-84	1.203	0.072	3.329	2.892	3.833	<0.001
Age at index (years) : 85 and over	1.52	0.071	4.571	3.976	5.254	<0.001
Sex : Male	reference	reference	reference	reference	reference	reference
Sex : Female	-0.072	0.023	0.93	0.889	0.973	0.002
Diabetes with ongoing medication : No	reference	reference	reference	reference	reference	reference
Diabetes with ongoing medication : Yes	0.38	0.025	1.462	1.393	1.535	<0.001
≥ 1 MI in addition to index MI : No	reference	reference	reference	reference	reference	reference
≥ 1 MI in addition to index MI : Yes	0.536	0.034	1.71	1.6	1.827	<0.001
Multivessel CAD : No	reference	reference	reference	reference	reference	reference
Multivessel CAD : Yes	0.097	0.025	1.102	1.049	1.157	<0.001
Chronic renal dysfunction : No	reference	reference	reference	reference	reference	reference
Chronic renal dysfunction : Yes	0.555	0.056	1.743	1.561	1.946	<0.001
Ischaemic stroke : No	reference	reference	reference	reference	reference	reference
Ischaemic stroke : Yes	0.574	0.035	1.775	1.659	1.9	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Antithrombotic medication : No	reference	reference	reference	reference	reference	reference
Antithrombotic medication : Yes	0.226	0.025	1.253	1.193	1.317	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Beta-blocker : No	reference	reference	reference	reference	reference	reference
Beta-blocker : Yes	0.253	0.023	1.287	1.231	1.346	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
CABG : No	reference	reference	reference	reference	reference	reference
CABG : Yes	-0.549	0.053	0.577	0.52	0.641	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
COPD : No	reference	reference	reference	reference	reference	reference
COPD : Yes	0.225	0.053	1.252	1.13	1.388	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Diabetes mellitus : No	reference	reference	reference	reference	reference	reference
Diabetes mellitus : Yes	0.277	0.041	1.32	1.218	1.43	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Haemorrhagic stroke : No	reference	reference	reference	reference	reference	reference
Haemorrhagic stroke : Yes	0.268	0.12	1.307	1.033	1.654	0.032

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Heart failure : No	reference	reference	reference	reference	reference	reference
Heart failure : Yes	0.373	0.025	1.452	1.382	1.524	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Insulin : No	reference	reference	reference	reference	reference	reference
Insulin : Yes	0.482	0.043	1.62	1.49	1.761	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
LMWH : No	reference	reference	reference	reference	reference	reference
LMWH : Yes	0.323	0.169	1.382	0.991	1.926	0.048

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Major bleedings : No	reference	reference	reference	reference	reference	reference
Major bleedings : Yes	0.21	0.041	1.233	1.138	1.336	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Nitrate : No	reference	reference	reference	reference	reference	reference
Nitrate : Yes	0.33	0.024	1.39	1.327	1.457	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
OAP use (Total) : No	reference	reference	reference	reference	reference	reference
OAP use (Total) : Yes	0.213	0.046	1.238	1.131	1.354	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Oral antidiabetic : No	reference	reference	reference	reference	reference	reference
Oral antidiabetic : Yes	-0.354	0.044	0.702	0.644	0.765	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Proton pump inhibitor : No	reference	reference	reference	reference	reference	reference
Proton pump inhibitor : Yes	0.222	0.027	1.249	1.185	1.316	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Stroke (Total) : No	reference	reference	reference	reference	reference	reference
Stroke (Total) : Yes	0.388	0.131	1.474	1.141	1.905	0.004

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Severe liver disease : No	reference	reference	reference	reference	reference	reference
Severe liver disease : Yes	0.392	0.177	1.481	1.046	2.096	0.027

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Severe renal failure requiring dialysis : No	reference	reference	reference	reference	reference	reference
Severe renal failure requiring dialysis : Yes	0.663	0.151	1.94	1.442	2.61	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Transient ischemic attack : No	reference	reference	reference	reference	reference	reference
Transient ischemic attack : Yes	0.183	0.052	1.201	1.083	1.33	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Invasive procedure related to index event : No invasive procedure	reference	reference	reference	reference	reference	reference
Invasive procedure related to index event : Coronary angiography only	-0.289	0.036	0.749	0.698	0.803	<0.001
Invasive procedure related to index event : PCI	-0.573	0.03	0.564	0.532	0.597	<0.001
Invasive procedure related to index event : CABG	-0.955	0.065	0.385	0.339	0.437	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Gastrointestinal bleeding : No	reference	reference	reference	reference	reference	reference
Gastrointestinal bleeding : Yes	0.412	0.088	1.51	1.271	1.793	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
PCI or CABG related to index event : No	reference	reference	reference	reference	reference	reference
PCI or CABG related to index event : Yes	-0.538	0.027	0.584	0.554	0.615	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Increased bleeding risk (Total) : No	reference	reference	reference	reference	reference	reference
Increased bleeding risk (Total) : Yes	0.236	0.057	1.266	1.132	1.416	<0.001

Overall mortality

Table 1.125: The effect of pre-defined and explored risk factors on the risk of Overall mortality estimated using the Cox proportional hazards model in Group 1 . Table shows the hazard ratios (HRs) for several factors with the corresponding 95% CI and p-value. Only those explored risk factors that indicated 20% effect on the hazard of the outcome with $p < 0.15$ are presented. Variables are evaluated at index date, medication use variables refer to ongoing use and comorbidities were searched in a 5 years history period.

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Age at index (years) : 18-49	reference	reference	reference	reference	reference	reference
Age at index (years) : 50-64	0.92	0.13	2.509	1.946	3.235	<0.001
Age at index (years) : 65-69	1.472	0.132	4.359	3.367	5.644	<0.001
Age at index (years) : 70-74	1.759	0.129	5.807	4.509	7.48	<0.001
Age at index (years) : 75-79	2.27	0.127	9.678	7.544	12.415	<0.001
Age at index (years) : 80-84	2.711	0.126	15.044	11.746	19.267	<0.001
Age at index (years) : 85 and over	3.285	0.126	26.697	20.867	34.156	<0.001
Sex : Male	reference	reference	reference	reference	reference	reference
Sex : Female	-0.166	0.022	0.847	0.811	0.884	<0.001
Diabetes with ongoing medication : No	reference	reference	reference	reference	reference	reference
Diabetes with ongoing medication : Yes	0.275	0.024	1.317	1.256	1.381	<0.001
≥ 1 MI in addition to index MI : No	reference	reference	reference	reference	reference	reference
≥ 1 MI in addition to index MI : Yes	0.448	0.031	1.565	1.472	1.664	<0.001
Multivessel CAD : No	reference	reference	reference	reference	reference	reference
Multivessel CAD : Yes	0.09	0.024	1.094	1.043	1.147	<0.001
Chronic renal dysfunction : No	reference	reference	reference	reference	reference	reference
Chronic renal dysfunction : Yes	0.895	0.047	2.447	2.233	2.681	<0.001
Ischaemic stroke : No	reference	reference	reference	reference	reference	reference
Ischaemic stroke : Yes	0.348	0.034	1.417	1.325	1.515	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Atrial fibrillation : No	reference	reference	reference	reference	reference	reference
Atrial fibrillation : Yes	0.333	0.024	1.395	1.331	1.463	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Anticoagulation medication : No	reference	reference	reference	reference	reference	reference
Anticoagulation medication : Yes	0.236	0.031	1.267	1.192	1.346	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Arrhythmia : No	reference	reference	reference	reference	reference	reference
Arrhythmia : Yes	0.316	0.023	1.371	1.312	1.434	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Bleeding disorder : No	reference	reference	reference	reference	reference	reference
Bleeding disorder : Yes	0.539	0.165	1.714	1.241	2.368	0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
CABG : No	reference	reference	reference	reference	reference	reference
CABG : Yes	-0.635	0.058	0.53	0.473	0.593	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
COPD : No	reference	reference	reference	reference	reference	reference
COPD : Yes	0.814	0.04	2.257	2.085	2.442	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Cancer : No	reference	reference	reference	reference	reference	reference
Cancer : Yes	0.635	0.031	1.887	1.776	2.005	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Chronic use of anticoagulation medication : No	reference	reference	reference	reference	reference	reference
Chronic use of anticoagulation medication : Yes	0.239	0.032	1.269	1.192	1.352	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Central nervous tumour : No	reference	reference	reference	reference	reference	reference
Central nervous tumour : Yes	1.215	0.268	3.372	1.995	5.699	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Diabetes mellitus : No	reference	reference	reference	reference	reference	reference
Diabetes mellitus : Yes	0.504	0.036	1.655	1.542	1.775	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Dementia/Alzheimer's disease : No	reference	reference	reference	reference	reference	reference
Dementia/Alzheimer's disease : Yes	0.56	0.033	1.75	1.64	1.868	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Haemorrhagic stroke : No	reference	reference	reference	reference	reference	reference

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Haemorrhagic stroke : Yes	0.358	0.108	1.43	1.158	1.767	0.002

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Heart failure : No	reference	reference	reference	reference	reference	reference
Heart failure : Yes	0.731	0.022	2.077	1.989	2.17	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Hyperlipidemia : No	reference	reference	reference	reference	reference	reference
Hyperlipidemia : Yes	-0.459	0.022	0.632	0.605	0.66	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Insulin : No	reference	reference	reference	reference	reference	reference
Insulin : Yes	0.436	0.042	1.546	1.424	1.679	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Intracranial vascular abnormality : No	reference	reference	reference	reference	reference	reference
Intracranial vascular abnormality : Yes	0.286	0.12	1.331	1.053	1.683	0.017

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Intracranial bleeding : No	reference	reference	reference	reference	reference	reference
Intracranial bleeding : Yes	0.304	0.075	1.355	1.17	1.568	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
LMWH : No	reference	reference	reference	reference	reference	reference
LMWH : Yes	0.839	0.132	2.315	1.788	2.997	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Major bleedings : No	reference	reference	reference	reference	reference	reference
Major bleedings : Yes	0.389	0.035	1.476	1.378	1.581	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Oral antidiabetic : No	reference	reference	reference	reference	reference	reference
Oral antidiabetic : Yes	-0.448	0.043	0.639	0.587	0.695	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Other stroke (not sub-classified) : No	reference	reference	reference	reference	reference	reference
Other stroke (not sub-classified) : Yes	0.542	0.278	1.72	0.997	2.967	0.108

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Proton pump inhibitor : No	reference	reference	reference	reference	reference	reference
Proton pump inhibitor : Yes	0.257	0.025	1.293	1.232	1.358	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
SSRI : No	reference	reference	reference	reference	reference	reference
SSRI : Yes	0.246	0.044	1.279	1.174	1.393	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Stroke (Total) : No	reference	reference	reference	reference	reference	reference
Stroke (Total) : Yes	0.424	0.116	1.529	1.218	1.919	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Severe liver disease : No	reference	reference	reference	reference	reference	reference
Severe liver disease : Yes	0.885	0.142	2.422	1.834	3.199	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Severe renal failure requiring dialysis : No	reference	reference	reference	reference	reference	reference
Severe renal failure requiring dialysis : Yes	0.809	0.13	2.245	1.739	2.899	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Warfarin : No	reference	reference	reference	reference	reference	reference
Warfarin : Yes	0.211	0.032	1.235	1.16	1.314	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Invasive procedure related to index event : No invasive procedure	reference	reference	reference	reference	reference	reference
Invasive procedure related to index event : Coronary angiography only	-0.881	0.04	0.414	0.383	0.448	<0.001
Invasive procedure related to index event : PCI	-1.219	0.034	0.295	0.277	0.316	<0.001
Invasive procedure related to index event : CABG	-1.349	0.073	0.26	0.225	0.299	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Type of index MI : Non-ST elevation MI (and unspecified MI)	reference	reference	reference	reference	reference	reference
Type of index MI : ST elevation MI	-0.377	0.026	0.686	0.652	0.722	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Gastrointestinal bleeding : No	reference	reference	reference	reference	reference	reference
Gastrointestinal bleeding : Yes	0.536	0.077	1.709	1.47	1.988	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
PCI or CABG related to index event : No	reference	reference	reference	reference	reference	reference
PCI or CABG related to index event : Yes	-1.031	0.031	0.357	0.336	0.379	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Increased bleeding risk (Total) : No	reference	reference	reference	reference	reference	reference
Increased bleeding risk (Total) : Yes	0.423	0.05	1.526	1.385	1.682	<0.001

1.3.2 Explored risk factors for group 2

Myocardial infarction

Table 1.158: The effect of pre-defined and explored risk factors on the risk of Myocardial infarction estimated using the Cox proportional hazards model in Group 2 . Table shows the hazard ratios (HRs) for several factors with the corresponding 95% CI and p-value. Only those explored risk factors that indicated 20% effect on the hazard of the outcome with $p \leq 0.15$ are presented. Variables are evaluated at 1 year baseline check, medication use variables refer to ongoing use and comorbidities were searched in a 5 years history period.

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Age at 1 year baseline check (years) : 18-49	reference	reference	reference	reference	reference	reference
Age at 1 year baseline check (years) : 50-64	0.079	0.152	1.082	0.804	1.457	0.601
Age at 1 year baseline check (years) : 65-69	0.153	0.165	1.166	0.843	1.612	0.352
Age at 1 year baseline check (years) : 70-74	0.376	0.159	1.456	1.067	1.987	0.017
Age at 1 year baseline check (years) : 75-79	0.733	0.153	2.08	1.542	2.806	<0.001
Age at 1 year baseline check (years) : 80-84	1.107	0.15	3.024	2.254	4.056	<0.001
Age at 1 year baseline check (years) : 85 and over	1.592	0.148	4.913	3.679	6.561	<0.001
Sex : Male	reference	reference	reference	reference	reference	reference
Sex : Female	-0.037	0.051	0.964	0.873	1.065	0.47
Diabetes with ongoing medication : No	reference	reference	reference	reference	reference	reference
Diabetes with ongoing medication : Yes	0.497	0.052	1.644	1.484	1.82	<0.001
≥ 1 MI in addition to index MI : No	reference	reference	reference	reference	reference	reference
≥ 1 MI in addition to index MI : Yes	0.668	0.077	1.95	1.677	2.268	<0.001
Multivessel CAD : No	reference	reference	reference	reference	reference	reference
Multivessel CAD : Yes	0.186	0.051	1.204	1.089	1.331	<0.001
Chronic renal dysfunction : No	reference	reference	reference	reference	reference	reference
Chronic renal dysfunction : Yes	0.633	0.12	1.883	1.488	2.384	<0.001
Ischaemic stroke : No	reference	reference	reference	reference	reference	reference
Ischaemic stroke : Yes	0.337	0.09	1.4	1.174	1.671	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Invasive procedure related to index event : No invasive procedure	reference	reference	reference	reference	reference	reference
Invasive procedure related to index event : Coronary angiography only	-0.285	0.074	0.752	0.651	0.869	<0.001
Invasive procedure related to index event : PCI	-0.541	0.062	0.582	0.516	0.657	<0.001
Invasive procedure related to index event : CABG	-1.709	0.185	0.181	0.126	0.26	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Type of index MI : Non-ST elevation MI (and unspecified MI)	reference	reference	reference	reference	reference	reference
Type of index MI : ST elevation MI	-0.393	0.056	0.675	0.605	0.753	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
PCI or CABG related to index event : No	reference	reference	reference	reference	reference	reference
PCI or CABG related to index event : Yes	-0.571	0.057	0.565	0.506	0.631	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
CABG : No	reference	reference	reference	reference	reference	reference
CABG : Yes	-0.982	0.123	0.374	0.294	0.477	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
COPD : No	reference	reference	reference	reference	reference	reference
COPD : Yes	0.453	0.107	1.573	1.274	1.942	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Cancer : No	reference	reference	reference	reference	reference	reference
Cancer : Yes	0.189	0.086	1.208	1.02	1.429	0.029

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Diabetes mellitus : No	reference	reference	reference	reference	reference	reference
Diabetes mellitus : Yes	0.317	0.097	1.374	1.136	1.661	0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Heart failure : No	reference	reference	reference	reference	reference	reference
Heart failure : Yes	0.427	0.053	1.532	1.381	1.7	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Hypertension : No	reference	reference	reference	reference	reference	reference
Hypertension : Yes	0.603	0.244	1.828	1.132	2.951	0.014

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Insulin : No	reference	reference	reference	reference	reference	reference
Insulin : Yes	0.6	0.088	1.823	1.535	2.165	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
NSAID : No	reference	reference	reference	reference	reference	reference
NSAID : Yes	0.198	0.121	1.219	0.961	1.546	0.103

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Nitrate : No	reference	reference	reference	reference	reference	reference
Nitrate : Yes	0.643	0.052	1.903	1.72	2.105	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Oral antidiabetic : No	reference	reference	reference	reference	reference	reference
Oral antidiabetic : Yes	-0.487	0.09	0.615	0.516	0.733	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Severe renal failure requiring dialysis : No	reference	reference	reference	reference	reference	reference
Severe renal failure requiring dialysis : Yes	1.236	0.341	3.443	1.763	6.723	<0.001

Stroke (total)

Table 1.173: The effect of pre-defined and explored risk factors on the risk of Stroke (total) estimated using the Cox proportional hazards model in Group 2 . Table shows the hazard ratios (HRs) for several factors with the corresponding 95% CI and p-value. Only those explored risk factors that indicated 20% effect on the hazard of the outcome with $p \leq 0.15$ are presented. Variables are evaluated at 1 year baseline check, medication use variables refer to ongoing use and comorbidities were searched in a 5 years history period.

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Age at 1 year baseline check (years) : 18-49	reference	reference	reference	reference	reference	reference
Age at 1 year baseline check (years) : 50-64	0.795	0.349	2.214	1.117	4.386	0.023
Age at 1 year baseline check (years) : 65-69	1.289	0.355	3.629	1.808	7.282	<0.001
Age at 1 year baseline check (years) : 70-74	1.634	0.348	5.124	2.593	10.126	<0.001
Age at 1 year baseline check (years) : 75-79	1.801	0.345	6.053	3.078	11.902	<0.001
Age at 1 year baseline check (years) : 80-84	1.986	0.345	7.29	3.711	14.321	<0.001
Age at 1 year baseline check (years) : 85 and over	2.344	0.343	10.423	5.323	20.411	<0.001
Sex : Male	reference	reference	reference	reference	reference	reference
Sex : Female	-0.069	0.076	0.933	0.805	1.082	0.352
Diabetes with ongoing medication : No	reference	reference	reference	reference	reference	reference
Diabetes with ongoing medication : Yes	0.232	0.082	1.261	1.074	1.481	0.005
≥ 1 MI in addition to index MI : No	reference	reference	reference	reference	reference	reference
≥ 1 MI in addition to index MI : Yes	0.316	0.131	1.371	1.062	1.771	0.019
Multivessel CAD : No	reference	reference	reference	reference	reference	reference
Multivessel CAD : Yes	0.077	0.079	1.08	0.925	1.261	0.329
Chronic renal dysfunction : No	reference	reference	reference	reference	reference	reference
Chronic renal dysfunction : Yes	0.032	0.246	1.033	0.638	1.673	0.898
Ischaemic stroke : No	reference	reference	reference	reference	reference	reference
Ischaemic stroke : Yes	1.388	0.094	4.006	3.33	4.82	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Invasive procedure related to index event : No invasive procedure	reference	reference	reference	reference	reference	reference
Invasive procedure related to index event : Coronary angiography only	-0.22	0.111	0.803	0.646	0.997	0.048
Invasive procedure related to index event : PCI	-0.474	0.095	0.623	0.517	0.75	<0.001
Invasive procedure related to index event : CABG	-0.426	0.162	0.653	0.475	0.897	0.009

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
PCI or CABG related to index event : No	reference	reference	reference	reference	reference	reference

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
PCI or CABG related to index event : Yes	-0.393	0.083	0.675	0.574	0.795	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Atrial fibrillation : No	reference	reference	reference	reference	reference	reference
Atrial fibrillation : Yes	0.463	0.083	1.588	1.35	1.868	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Arrhythmia : No	reference	reference	reference	reference	reference	reference
Arrhythmia : Yes	0.396	0.078	1.486	1.275	1.732	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Cancer : No	reference	reference	reference	reference	reference	reference
Cancer : Yes	0.23	0.127	1.258	0.981	1.613	0.072

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Central nervous tumour : No	reference	reference	reference	reference	reference	reference
Central nervous tumour : Yes	1.763	0.711	5.832	1.449	23.481	0.038

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Diabetes mellitus : No	reference	reference	reference	reference	reference	reference
Diabetes mellitus : Yes	0.381	0.138	1.464	1.117	1.919	0.006

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Fibrate : No	reference	reference	reference	reference	reference	reference
Fibrate : Yes	0.978	0.579	2.66	0.854	8.279	0.092

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Haemorrhagic stroke : No	reference	reference	reference	reference	reference	reference
Haemorrhagic stroke : Yes	0.604	0.38	1.829	0.868	3.855	0.131

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Heart failure : No	reference	reference	reference	reference	reference	reference
Heart failure : Yes	0.237	0.082	1.267	1.079	1.488	0.005

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Increased bleeding risk (Total) : No	reference	reference	reference	reference	reference	reference
Increased bleeding risk (Total) : Yes	0.296	0.2	1.344	0.907	1.991	0.148

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Insulin : No	reference	reference	reference	reference	reference	reference
Insulin : Yes	0.42	0.141	1.522	1.154	2.006	0.003

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
LMWH : No	reference	reference	reference	reference	reference	reference
LMWH : Yes	0.997	0.449	2.71	1.123	6.535	0.029

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Major bleedings : No	reference	reference	reference	reference	reference	reference
Major bleedings : Yes	0.238	0.126	1.268	0.991	1.623	0.065

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
OAP use (Total) : No	reference	reference	reference	reference	reference	reference
OAP use (Total) : Yes	-0.23	0.083	0.795	0.676	0.934	0.006

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Oral antidiabetic : No	reference	reference	reference	reference	reference	reference
Oral antidiabetic : Yes	-0.236	0.151	0.789	0.588	1.061	0.125

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Proton pump inhibitor : No	reference	reference	reference	reference	reference	reference
Proton pump inhibitor : Yes	0.233	0.079	1.263	1.083	1.473	0.003

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Stroke (Total) : No	reference	reference	reference	reference	reference	reference
Stroke (Total) : Yes	0.836	0.411	2.306	1.031	5.158	0.044

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Severe liver disease : No	reference	reference	reference	reference	reference	reference
Severe liver disease : Yes	0.934	0.45	2.544	1.054	6.139	0.045

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Severe renal failure requiring dialysis : No	reference	reference	reference	reference	reference	reference
Severe renal failure requiring dialysis : Yes	1.818	0.571	6.16	2.011	18.862	0.002

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Transient ischemic attack : No	reference	reference	reference	reference	reference	reference
Transient ischemic attack : Yes	0.251	0.158	1.285	0.943	1.751	0.125

Cardiovascular mortality

Table 1.195: The effect of pre-defined and explored risk factors on the risk of Cardiovascular mortality estimated using the Cox proportional hazards model in Group 2 . Table shows the hazard ratios (HRs) for several factors with the corresponding 95% CI and p-value. Only those explored risk factors that indicated 20% effect on the hazard of the outcome with $p < 0.15$ are presented. Variables are evaluated at 1 year baseline check, medication use variables refer to ongoing use and comorbidities were searched in a 5 years history period.

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Age at 1 year baseline check (years) : 18-49	reference	reference	reference	reference	reference	reference
Age at 1 year baseline check (years) : 50-64	0.861	0.467	2.366	0.948	5.906	0.065
Age at 1 year baseline check (years) : 65-69	1.319	0.475	3.74	1.474	9.492	0.006
Age at 1 year baseline check (years) : 70-74	1.826	0.463	6.211	2.508	15.379	<0.001
Age at 1 year baseline check (years) : 75-79	2.281	0.457	9.784	3.998	23.946	<0.001
Age at 1 year baseline check (years) : 80-84	2.817	0.454	16.725	6.874	40.693	<0.001
Age at 1 year baseline check (years) : 85 and over	3.542	0.452	34.552	14.257	83.738	<0.001
Sex : Male	reference	reference	reference	reference	reference	reference
Sex : Female	0.032	0.07	1.033	0.9	1.185	0.648
Diabetes with ongoing medication : No	reference	reference	reference	reference	reference	reference
Diabetes with ongoing medication : Yes	0.533	0.073	1.703	1.477	1.964	<0.001
≥ 1 MI in addition to index MI : No	reference	reference	reference	reference	reference	reference
≥ 1 MI in addition to index MI : Yes	0.683	0.1	1.98	1.627	2.41	<0.001
Multivessel CAD : No	reference	reference	reference	reference	reference	reference
Multivessel CAD : Yes	0.196	0.072	1.216	1.056	1.4	0.007
Chronic renal dysfunction : No	reference	reference	reference	reference	reference	reference
Chronic renal dysfunction : Yes	1.013	0.138	2.755	2.103	3.609	<0.001
Ischaemic stroke : No	reference	reference	reference	reference	reference	reference
Ischaemic stroke : Yes	0.52	0.111	1.682	1.354	2.089	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Index year : 2009	reference	reference	reference	reference	reference	reference
Index year : 2010	0.06	0.081	1.062	0.906	1.244	0.462
Index year : 2011	-0.14	0.098	0.869	0.717	1.054	0.154
Index year : 2012	-0.373	0.158	0.688	0.505	0.939	0.019

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Invasive procedure related to index event : No invasive procedure	reference	reference	reference	reference	reference	reference
Invasive procedure related to index event : Coronary angiography only	-0.684	0.119	0.505	0.399	0.637	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Invasive procedure related to index event : PCI	-1.075	0.103	0.341	0.279	0.418	<0.001
Invasive procedure related to index event : CABG	-1.185	0.213	0.306	0.201	0.464	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Type of index MI : Non-ST elevation MI (and unspecified MI)	reference	reference	reference	reference	reference	reference
Type of index MI : ST elevation MI	-0.376	0.082	0.686	0.584	0.806	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
PCI or CABG related to index event : No	reference	reference	reference	reference	reference	reference
PCI or CABG related to index event : Yes	-0.922	0.094	0.398	0.331	0.478	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Atrial fibrillation : No	reference	reference	reference	reference	reference	reference
Atrial fibrillation : Yes	0.483	0.074	1.62	1.403	1.871	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Unstable angina pectoris : No	reference	reference	reference	reference	reference	reference
Unstable angina pectoris : Yes	0.268	0.101	1.307	1.073	1.592	0.007

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
ARB : No	reference	reference	reference	reference	reference	reference
ARB : Yes	-0.334	0.091	0.716	0.599	0.856	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Anticogulation medication : No	reference	reference	reference	reference	reference	reference
Anticogulation medication : Yes	0.213	0.087	1.237	1.044	1.466	0.015

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Arrhythmia : No	reference	reference	reference	reference	reference	reference
Arrhythmia : Yes	0.449	0.07	1.567	1.366	1.798	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
CABG : No	reference	reference	reference	reference	reference	reference
CABG : Yes	-0.648	0.169	0.523	0.376	0.728	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
COPD : No	reference	reference	reference	reference	reference	reference
COPD : Yes	0.527	0.147	1.694	1.269	2.26	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Diabetes mellitus : No	reference	reference	reference	reference	reference	reference
Diabetes mellitus : Yes	0.491	0.122	1.633	1.285	2.076	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Dementia/Alzheimer's disease : No	reference	reference	reference	reference	reference	reference
Dementia/Alzheimer's disease : Yes	0.246	0.111	1.279	1.029	1.59	0.03

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Heart failure : No	reference	reference	reference	reference	reference	reference
Heart failure : Yes	0.745	0.07	2.107	1.838	2.417	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Hyperlipidemia : No	reference	reference	reference	reference	reference	reference
Hyperlipidemia : Yes	-0.436	0.083	0.646	0.549	0.761	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Hypertension : No	reference	reference	reference	reference	reference	reference
Hypertension : Yes	0.522	0.336	1.686	0.873	3.256	0.122

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Insulin : No	reference	reference	reference	reference	reference	reference
Insulin : Yes	0.831	0.126	2.296	1.794	2.938	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Major bleedings : No	reference	reference	reference	reference	reference	reference
Major bleedings : Yes	0.387	0.106	1.472	1.197	1.811	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
NSAID : No	reference	reference	reference	reference	reference	reference
NSAID : Yes	-0.366	0.232	0.694	0.44	1.093	0.118

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Nitrate : No	reference	reference	reference	reference	reference	reference
Nitrate : Yes	0.546	0.073	1.727	1.497	1.992	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
OAP use (Total) : No	reference	reference	reference	reference	reference	reference
OAP use (Total) : Yes	-0.447	0.085	0.639	0.541	0.755	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Oral antidiabetic : No	reference	reference	reference	reference	reference	reference
Oral antidiabetic : Yes	-0.842	0.122	0.431	0.339	0.547	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Proton pump inhibitor : No	reference	reference	reference	reference	reference	reference
Proton pump inhibitor : Yes	0.243	0.071	1.275	1.109	1.466	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
SSRI : No	reference	reference	reference	reference	reference	reference
SSRI : Yes	0.239	0.127	1.27	0.991	1.628	0.062

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Statin : No	reference	reference	reference	reference	reference	reference
Statin : Yes	-0.299	0.071	0.741	0.645	0.851	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Severe renal failure requiring dialysis : No	reference	reference	reference	reference	reference	reference
Severe renal failure requiring dialysis : Yes	1.585	0.407	4.878	2.198	10.827	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Warfarin : No	reference	reference	reference	reference	reference	reference
Warfarin : Yes	0.198	0.088	1.219	1.027	1.448	0.025

Composite end-point

Table 1.223: The effect of pre-defined and explored risk factors on the risk of Composite end-point estimated using the Cox proportional hazards model in Group 2 . Table shows the hazard ratios (HRs) for several factors with the corresponding 95% CI and p-value. Only those explored risk factors that indicated 20% effect on the hazard of the outcome with $p \leq 0.15$ are presented. Variables are evaluated at 1 year baseline check, medication use variables refer to ongoing use and comorbidities were searched in a 5 years history period.

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Age at 1 year baseline check (years) : 18-49	reference	reference	reference	reference	reference	reference
Age at 1 year baseline check (years) : 50-64	0.236	0.136	1.267	0.97	1.654	0.083
Age at 1 year baseline check (years) : 65-69	0.474	0.144	1.607	1.212	2.131	<0.001
Age at 1 year baseline check (years) : 70-74	0.733	0.139	2.081	1.584	2.732	<0.001
Age at 1 year baseline check (years) : 75-79	1.031	0.136	2.804	2.15	3.658	<0.001
Age at 1 year baseline check (years) : 80-84	1.354	0.134	3.874	2.979	5.038	<0.001
Age at 1 year baseline check (years) : 85 and over	1.826	0.132	6.209	4.789	8.049	<0.001
Sex : Male	reference	reference	reference	reference	reference	reference
Sex : Female	-0.024	0.04	0.976	0.902	1.057	0.556
Diabetes with ongoing medication : No	reference	reference	reference	reference	reference	reference
Diabetes with ongoing medication : Yes	0.418	0.042	1.519	1.398	1.651	<0.001
≥ 1 MI in addition to index MI : No	reference	reference	reference	reference	reference	reference
≥ 1 MI in addition to index MI : Yes	0.603	0.063	1.827	1.613	2.069	<0.001
Multivessel CAD : No	reference	reference	reference	reference	reference	reference
Multivessel CAD : Yes	0.175	0.041	1.191	1.099	1.292	<0.001
Chronic renal dysfunction : No	reference	reference	reference	reference	reference	reference
Chronic renal dysfunction : Yes	0.567	0.1	1.764	1.451	2.144	<0.001
Ischaemic stroke : No	reference	reference	reference	reference	reference	reference
Ischaemic stroke : Yes	0.665	0.065	1.945	1.714	2.207	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Invasive procedure related to index event : No invasive procedure	reference	reference	reference	reference	reference	reference
Invasive procedure related to index event : Coronary angiography only	-0.309	0.06	0.734	0.653	0.826	<0.001
Invasive procedure related to index event : PCI	-0.563	0.05	0.569	0.516	0.628	<0.001
Invasive procedure related to index event : CABG	-1.115	0.113	0.328	0.263	0.409	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Type of index MI : Non-ST elevation MI (and unspecified MI)	reference	reference	reference	reference	reference	reference
Type of index MI : ST elevation MI	-0.28	0.044	0.756	0.694	0.824	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
PCI or CABG related to index event : No	reference	reference	reference	reference	reference	reference
PCI or CABG related to index event : Yes	-0.539	0.045	0.583	0.534	0.637	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Atrial fibrillation : No	reference	reference	reference	reference	reference	reference
Atrial fibrillation : Yes	0.252	0.046	1.287	1.175	1.409	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Arrhythmia : No	reference	reference	reference	reference	reference	reference
Arrhythmia : Yes	0.218	0.043	1.244	1.143	1.354	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Bleeding disorder : No	reference	reference	reference	reference	reference	reference
Bleeding disorder : Yes	0.485	0.303	1.623	0.896	2.94	0.095

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
CABG : No	reference	reference	reference	reference	reference	reference
CABG : Yes	-0.649	0.086	0.523	0.442	0.618	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
COPD : No	reference	reference	reference	reference	reference	reference
COPD : Yes	0.421	0.087	1.523	1.284	1.806	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Central nervous tumour : No	reference	reference	reference	reference	reference	reference
Central nervous tumour : Yes	1.383	0.501	3.986	1.492	10.646	0.004

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Diabetes mellitus : No	reference	reference	reference	reference	reference	reference
Diabetes mellitus : Yes	0.379	0.075	1.46	1.26	1.692	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Heart failure : No	reference	reference	reference	reference	reference	reference
Heart failure : Yes	0.432	0.042	1.54	1.418	1.674	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Hyperlipidemia : No	reference	reference	reference	reference	reference	reference
Hyperlipidemia : Yes	-0.225	0.054	0.799	0.719	0.887	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Hypertension : No	reference	reference	reference	reference	reference	reference
Hypertension : Yes	0.496	0.184	1.642	1.145	2.356	0.008

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Increased bleeding risk (Total) : No	reference	reference	reference	reference	reference	reference
Increased bleeding risk (Total) : Yes	0.212	0.115	1.236	0.986	1.549	0.067

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Insulin : No	reference	reference	reference	reference	reference	reference
Insulin : Yes	0.636	0.072	1.888	1.639	2.176	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Major bleedings : No	reference	reference	reference	reference	reference	reference
Major bleedings : Yes	0.226	0.068	1.253	1.098	1.431	0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Nitrate : No	reference	reference	reference	reference	reference	reference
Nitrate : Yes	0.478	0.041	1.612	1.488	1.746	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Oral antidiabetic : No	reference	reference	reference	reference	reference	reference
Oral antidiabetic : Yes	-0.497	0.073	0.608	0.526	0.702	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Proton pump inhibitor : No	reference	reference	reference	reference	reference	reference
Proton pump inhibitor : Yes	0.216	0.042	1.241	1.143	1.348	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Severe renal failure requiring dialysis : No	reference	reference	reference	reference	reference	reference
Severe renal failure requiring dialysis : Yes	1.244	0.288	3.468	1.974	6.093	<0.001

Overall mortality

Table 1.244: The effect of pre-defined and explored risk factors on the risk of Overall mortality estimated using the Cox proportional hazards model in Group 2 . Table shows the hazard ratios (HRs) for several factors with the corresponding 95% CI and p-value. Only those explored risk factors that indicated 20% effect on the hazard of the outcome with $p \leq 0.15$ are presented. Variables are evaluated at 1 year baseline check, medication use variables refer to ongoing use and comorbidities were searched in a 5 years history period.

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Age at 1 year baseline check (years) : 18-49	reference	reference	reference	reference	reference	reference
Age at 1 year baseline check (years) : 50-64	0.891	0.209	2.438	1.619	3.67	<0.001
Age at 1 year baseline check (years) : 65-69	1.442	0.212	4.228	2.791	6.405	<0.001
Age at 1 year baseline check (years) : 70-74	1.836	0.207	6.273	4.177	9.419	<0.001
Age at 1 year baseline check (years) : 75-79	2.305	0.205	10.029	6.716	14.977	<0.001
Age at 1 year baseline check (years) : 80-84	2.761	0.203	15.814	10.614	23.562	<0.001
Age at 1 year baseline check (years) : 85 and over	3.459	0.202	31.787	21.378	47.264	<0.001
Sex : Male	reference	reference	reference	reference	reference	reference
Sex : Female	-0.174	0.034	0.841	0.786	0.899	<0.001
Diabetes with ongoing medication : No	reference	reference	reference	reference	reference	reference
Diabetes with ongoing medication : Yes	0.258	0.038	1.295	1.203	1.394	<0.001
≥ 1 MI in addition to index MI : No	reference	reference	reference	reference	reference	reference
≥ 1 MI in addition to index MI : Yes	0.431	0.054	1.539	1.384	1.713	<0.001
Multivessel CAD : No	reference	reference	reference	reference	reference	reference
Multivessel CAD : Yes	0.162	0.035	1.176	1.098	1.261	<0.001
Chronic renal dysfunction : No	reference	reference	reference	reference	reference	reference
Chronic renal dysfunction : Yes	0.938	0.071	2.556	2.224	2.937	<0.001
Ischaemic stroke : No	reference	reference	reference	reference	reference	reference
Ischaemic stroke : Yes	0.269	0.061	1.308	1.161	1.473	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Invasive procedure related to index event : No invasive procedure	reference	reference	reference	reference	reference	reference
Invasive procedure related to index event : Coronary angiography only	-0.871	0.06	0.419	0.372	0.471	<0.001
Invasive procedure related to index event : PCI	-1.127	0.049	0.324	0.295	0.356	<0.001
Invasive procedure related to index event : CABG	-1.164	0.095	0.312	0.259	0.376	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Type of index MI : Non-ST elevation MI (and unspecified MI)	reference	reference	reference	reference	reference	reference
Type of index MI : ST elevation MI	-0.384	0.039	0.681	0.631	0.736	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Gastrointestinal bleeding : No	reference	reference	reference	reference	reference	reference
Gastrointestinal bleeding : Yes	0.693	0.158	1.999	1.468	2.722	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
PCI or CABG related to index event : No	reference	reference	reference	reference	reference	reference
PCI or CABG related to index event : Yes	-0.913	0.044	0.401	0.368	0.437	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Atrial fibrillation : No	reference	reference	reference	reference	reference	reference
Atrial fibrillation : Yes	0.431	0.037	1.539	1.432	1.653	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
ARB : No	reference	reference	reference	reference	reference	reference
ARB : Yes	-0.385	0.046	0.68	0.622	0.744	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
ACE inhibitor : No	reference	reference	reference	reference	reference	reference
ACE inhibitor : Yes	-0.231	0.034	0.794	0.742	0.849	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Antithrombotic medication : No	reference	reference	reference	reference	reference	reference
Antithrombotic medication : Yes	-0.38	0.034	0.684	0.64	0.731	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Arrhythmia : No	reference	reference	reference	reference	reference	reference
Arrhythmia : Yes	0.407	0.035	1.503	1.404	1.608	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Beta-blocker : No	reference	reference	reference	reference	reference	reference
Beta-blocker : Yes	-0.323	0.035	0.724	0.676	0.776	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Bleeding disorder : No	reference	reference	reference	reference	reference	reference
Bleeding disorder : Yes	0.742	0.215	2.1	1.379	3.197	0.003

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
CABG : No	reference	reference	reference	reference	reference	reference
CABG : Yes	-0.555	0.076	0.574	0.494	0.667	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
COPD : No	reference	reference	reference	reference	reference	reference
COPD : Yes	0.913	0.06	2.492	2.217	2.802	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Cancer : No	reference	reference	reference	reference	reference	reference
Cancer : Yes	0.676	0.047	1.967	1.794	2.155	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Central nervous tumour : No	reference	reference	reference	reference	reference	reference
Central nervous tumour : Yes	1.67	0.355	5.313	2.651	10.645	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Diabetes mellitus : No	reference	reference	reference	reference	reference	reference
Diabetes mellitus : Yes	0.653	0.055	1.921	1.725	2.14	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Dementia/Alzheimer's disease : No	reference	reference	reference	reference	reference	reference
Dementia/Alzheimer's disease : Yes	0.648	0.048	1.911	1.738	2.101	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Haemorrhagic stroke : No	reference	reference	reference	reference	reference	reference
Haemorrhagic stroke : Yes	0.419	0.19	1.52	1.047	2.206	0.039

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Heart failure : No	reference	reference	reference	reference	reference	reference
Heart failure : Yes	0.827	0.034	2.287	2.139	2.444	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Hyperlipidemia : No	reference	reference	reference	reference	reference	reference
Hyperlipidemia : Yes	-0.725	0.039	0.484	0.449	0.523	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Increased bleeding risk (Total) : No	reference	reference	reference	reference	reference	reference
Increased bleeding risk (Total) : Yes	0.581	0.082	1.788	1.523	2.1	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Insulin : No	reference	reference	reference	reference	reference	reference
Insulin : Yes	0.613	0.066	1.846	1.622	2.1	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Intracranial vascular abnormality : No	reference	reference	reference	reference	reference	reference
Intracranial vascular abnormality : Yes	0.584	0.19	1.794	1.236	2.603	0.003

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Intracranial bleeding : No	reference	reference	reference	reference	reference	reference
Intracranial bleeding : Yes	0.45	0.113	1.568	1.258	1.955	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
LMWH : No	reference	reference	reference	reference	reference	reference
LMWH : Yes	1.08	0.19	2.943	2.028	4.271	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Major bleedings : No	reference	reference	reference	reference	reference	reference
Major bleedings : Yes	0.485	0.05	1.624	1.472	1.793	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Nitrate : No	reference	reference	reference	reference	reference	reference
Nitrate : Yes	0.208	0.034	1.231	1.151	1.317	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
OAP use (Total) : No	reference	reference	reference	reference	reference	reference
OAP use (Total) : Yes	-0.638	0.043	0.528	0.486	0.575	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Oral antidiabetic : No	reference	reference	reference	reference	reference	reference
Oral antidiabetic : Yes	-0.647	0.066	0.524	0.46	0.596	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Proton pump inhibitor : No	reference	reference	reference	reference	reference	reference
Proton pump inhibitor : Yes	0.351	0.034	1.42	1.327	1.519	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
SSRI : No	reference	reference	reference	reference	reference	reference
SSRI : Yes	0.259	0.063	1.296	1.146	1.465	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Statin : No	reference	reference	reference	reference	reference	reference
Statin : Yes	-0.601	0.034	0.548	0.513	0.586	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Stroke (Total) : No	reference	reference	reference	reference	reference	reference
Stroke (Total) : Yes	0.474	0.197	1.607	1.092	2.364	0.025

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Severe liver disease : No	reference	reference	reference	reference	reference	reference
Severe liver disease : Yes	1.075	0.194	2.931	2.006	4.283	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Severe renal failure requiring dialysis : No	reference	reference	reference	reference	reference	reference
Severe renal failure requiring dialysis : Yes	1.256	0.222	3.51	2.272	5.422	<0.001

1.3.3 Explored risk factors for group 3

Myocardial infarction

Table 1.280: The effect of pre-defined and explored risk factors on the risk of Myocardial infarction estimated using the Cox proportional hazards model in Group 3 . Table shows the hazard ratios (HRs) for several factors with the corresponding 95% CI and p-value. Only those explored risk factors that indicated 20% effect on the hazard of the outcome with $p \leq 0.15$ are presented. Variables are evaluated at 1 year baseline check, medication use variables refer to ongoing use and comorbidities were searched in a 5 years history period.

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Age at 1 year baseline check (years) : 18-49	reference	reference	reference	reference	reference	reference
Age at 1 year baseline check (years) : 50-64	0.087	0.221	1.09	0.707	1.682	0.695
Age at 1 year baseline check (years) : 65-69	0.164	0.224	1.178	0.76	1.826	0.464
Age at 1 year baseline check (years) : 70-74	0.386	0.219	1.47	0.958	2.258	0.079
Age at 1 year baseline check (years) : 75-79	0.742	0.214	2.099	1.379	3.195	<0.001
Age at 1 year baseline check (years) : 80-84	1.114	0.213	3.047	2.009	4.621	<0.001
Age at 1 year baseline check (years) : 85 and over	1.598	0.211	4.943	3.267	7.479	<0.001
Sex : Male	reference	reference	reference	reference	reference	reference
Sex : Female	-0.027	0.052	0.973	0.879	1.078	0.608
Diabetes with ongoing medication : No	reference	reference	reference	reference	reference	reference
Diabetes with ongoing medication : Yes	0.498	0.053	1.645	1.481	1.826	<0.001
≥ 1 MI in addition to index MI : No	reference	reference	reference	reference	reference	reference
≥ 1 MI in addition to index MI : Yes	0.669	0.077	1.952	1.678	2.271	<0.001
Multivessel CAD : No	reference	reference	reference	reference	reference	reference
Multivessel CAD : Yes	0.187	0.053	1.206	1.087	1.338	<0.001
Chronic renal dysfunction : No	reference	reference	reference	reference	reference	reference
Chronic renal dysfunction : Yes	0.634	0.12	1.885	1.489	2.387	<0.001
Ischaemic stroke : No	reference	reference	reference	reference	reference	reference
Ischaemic stroke : Yes	0.337	0.09	1.401	1.174	1.672	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Invasive procedure related to index event : No invasive procedure	reference	reference	reference	reference	reference	reference
Invasive procedure related to index event : Coronary angiography only	-0.268	0.077	0.765	0.658	0.89	<0.001
Invasive procedure related to index event : PCI	-0.559	0.065	0.572	0.503	0.65	<0.001
Invasive procedure related to index event : CABG	-1.715	0.194	0.18	0.123	0.264	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Type of index MI : Non-ST elevation MI (and unspecified MI)	reference	reference	reference	reference	reference	reference
Type of index MI : ST elevation MI	-0.426	0.06	0.653	0.58	0.735	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
PCI or CABG related to index event : No	reference	reference	reference	reference	reference	reference
PCI or CABG related to index event : Yes	-0.61	0.061	0.544	0.483	0.612	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
CABG : No	reference	reference	reference	reference	reference	reference
CABG : Yes	-0.95	0.127	0.387	0.302	0.496	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Calcium channel blocker : No	reference	reference	reference	reference	reference	reference
Calcium channel blocker : Yes	0.201	0.057	1.223	1.093	1.368	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
COPD : No	reference	reference	reference	reference	reference	reference
COPD : Yes	0.429	0.111	1.535	1.235	1.909	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Cancer : No	reference	reference	reference	reference	reference	reference
Cancer : Yes	0.198	0.087	1.219	1.028	1.446	0.024

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Diabetes mellitus : No	reference	reference	reference	reference	reference	reference
Diabetes mellitus : Yes	0.263	0.103	1.3	1.064	1.59	0.011

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Heart failure : No	reference	reference	reference	reference	reference	reference
Heart failure : Yes	0.432	0.054	1.541	1.387	1.712	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Hypertension : No	reference	reference	reference	reference	reference	reference
Hypertension : Yes	0.676	0.279	1.966	1.138	3.398	0.015

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Insulin : No	reference	reference	reference	reference	reference	reference
Insulin : Yes	0.6	0.088	1.822	1.534	2.164	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Nitrate : No	reference	reference	reference	reference	reference	reference
Nitrate : Yes	0.642	0.054	1.9	1.71	2.11	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Oral antidiabetic : No	reference	reference	reference	reference	reference	reference
Oral antidiabetic : Yes	-0.486	0.09	0.615	0.516	0.733	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Proton pump inhibitor : No	reference	reference	reference	reference	reference	reference
Proton pump inhibitor : Yes	0.186	0.054	1.205	1.083	1.34	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Severe renal failure requiring dialysis : No	reference	reference	reference	reference	reference	reference
Severe renal failure requiring dialysis : Yes	1.244	0.342	3.468	1.773	6.783	<0.001

Stroke (total)

Table 1.296: The effect of pre-defined and explored risk factors on the risk of Stroke (total) estimated using the Cox proportional hazards model in Group 3 . Table shows the hazard ratios (HRs) for several factors with the corresponding 95% CI and p-value. Only those explored risk factors that indicated 20% effect on the hazard of the outcome with $p \leq 0.15$ are presented. Variables are evaluated at 1 year baseline check, medication use variables refer to ongoing use and comorbidities were searched in a 5 years history period.

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Age at 1 year baseline check (years) : 18-49	reference	reference	reference	reference	reference	reference
Age at 1 year baseline check (years) : 50-64	0.199	0.405	1.22	0.552	2.698	0.624
Age at 1 year baseline check (years) : 65-69	0.656	0.398	1.926	0.882	4.206	0.102
Age at 1 year baseline check (years) : 70-74	1.001	0.391	2.721	1.263	5.86	0.011
Age at 1 year baseline check (years) : 75-79	1.168	0.389	3.215	1.5	6.892	0.003
Age at 1 year baseline check (years) : 80-84	1.353	0.389	3.868	1.805	8.288	<0.001
Age at 1 year baseline check (years) : 85 and over	1.709	0.388	5.525	2.584	11.814	<0.001
Sex : Male	reference	reference	reference	reference	reference	reference
Sex : Female	-0.068	0.077	0.934	0.803	1.087	0.373
Diabetes with ongoing medication : No	reference	reference	reference	reference	reference	reference
Diabetes with ongoing medication : Yes	0.218	0.083	1.244	1.057	1.465	0.009
≥ 1 MI in addition to index MI : No	reference	reference	reference	reference	reference	reference
≥ 1 MI in addition to index MI : Yes	0.312	0.131	1.366	1.057	1.764	0.02
Multivessel CAD : No	reference	reference	reference	reference	reference	reference
Multivessel CAD : Yes	0.059	0.081	1.06	0.905	1.243	0.473
Chronic renal dysfunction : No	reference	reference	reference	reference	reference	reference
Chronic renal dysfunction : Yes	0.027	0.246	1.027	0.634	1.663	0.916
Ischaemic stroke : No	reference	reference	reference	reference	reference	reference
Ischaemic stroke : Yes	1.384	0.094	3.99	3.316	4.801	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Invasive procedure related to index event : No invasive procedure	reference	reference	reference	reference	reference	reference
Invasive procedure related to index event : Coronary angiography only	-0.264	0.116	0.768	0.611	0.965	0.024
Invasive procedure related to index event : PCI	-0.483	0.098	0.617	0.509	0.748	<0.001
Invasive procedure related to index event : CABG	-0.41	0.166	0.664	0.48	0.919	0.014

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
PCI or CABG related to index event : No	reference	reference	reference	reference	reference	reference

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
PCI or CABG related to index event : Yes	-0.388	0.086	0.678	0.573	0.804	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Atrial fibrillation : No	reference	reference	reference	reference	reference	reference
Atrial fibrillation : Yes	0.43	0.084	1.537	1.303	1.813	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Arrhythmia : No	reference	reference	reference	reference	reference	reference
Arrhythmia : Yes	0.381	0.08	1.464	1.253	1.711	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Cancer : No	reference	reference	reference	reference	reference	reference
Cancer : Yes	0.238	0.128	1.268	0.987	1.63	0.065

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Central nervous tumour : No	reference	reference	reference	reference	reference	reference
Central nervous tumour : Yes	1.781	0.711	5.935	1.474	23.9	0.037

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Diabetes mellitus : No	reference	reference	reference	reference	reference	reference
Diabetes mellitus : Yes	0.352	0.143	1.422	1.075	1.882	0.014

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Heart failure : No	reference	reference	reference	reference	reference	reference
Heart failure : Yes	0.241	0.083	1.273	1.083	1.497	0.004

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Insulin : No	reference	reference	reference	reference	reference	reference
Insulin : Yes	0.419	0.141	1.521	1.153	2.004	0.003

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
LMWH : No	reference	reference	reference	reference	reference	reference
LMWH : Yes	0.767	0.502	2.154	0.805	5.758	0.125

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Major bleedings : No	reference	reference	reference	reference	reference	reference
Major bleedings : Yes	0.232	0.128	1.261	0.981	1.619	0.076

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Oral antidiabetic : No	reference	reference	reference	reference	reference	reference
Oral antidiabetic : Yes	-0.237	0.151	0.789	0.587	1.06	0.124

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Proton pump inhibitor : No	reference	reference	reference	reference	reference	reference
Proton pump inhibitor : Yes	0.236	0.08	1.266	1.082	1.482	0.004

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Stroke (Total) : No	reference	reference	reference	reference	reference	reference
Stroke (Total) : Yes	0.708	0.45	2.031	0.841	4.902	0.117

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Severe liver disease : No	reference	reference	reference	reference	reference	reference
Severe liver disease : Yes	0.761	0.502	2.141	0.8	5.73	0.141

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Severe renal failure requiring dialysis : No	reference	reference	reference	reference	reference	reference
Severe renal failure requiring dialysis : Yes	1.771	0.572	5.875	1.915	18.022	0.002

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Transient ischemic attack : No	reference	reference	reference	reference	reference	reference
Transient ischemic attack : Yes	0.24	0.16	1.271	0.929	1.739	0.146

Cardiovascular mortality

Table 1.314: The effect of pre-defined and explored risk factors on the risk of Cardiovascular mortality estimated using the Cox proportional hazards model in Group 3 . Table shows the hazard ratios (HRs) for several factors with the corresponding 95% CI and p-value. Only those explored risk factors that indicated 20% effect on the hazard of the outcome with $p < 0.15$ are presented. Variables are evaluated at 1 year baseline check, medication use variables refer to ongoing use and comorbidities were searched in a 5 years history period.

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Age at 1 year baseline check (years) : 18-49	reference	reference	reference	reference	reference	reference
Age at 1 year baseline check (years) : 50-64	0.95	0.598	2.587	0.801	8.354	0.113
Age at 1 year baseline check (years) : 65-69	1.103	0.6	3.013	0.93	9.759	0.067
Age at 1 year baseline check (years) : 70-74	1.611	0.59	5.008	1.576	15.91	0.006
Age at 1 year baseline check (years) : 75-79	2.068	0.585	7.913	2.514	24.902	<0.001
Age at 1 year baseline check (years) : 80-84	2.605	0.583	13.532	4.318	42.404	<0.001
Age at 1 year baseline check (years) : 85 and over	3.331	0.581	27.96	8.947	87.379	<0.001
Sex : Male	reference	reference	reference	reference	reference	reference
Sex : Female	0.013	0.071	1.014	0.883	1.164	0.849
Diabetes with ongoing medication : No	reference	reference	reference	reference	reference	reference
Diabetes with ongoing medication : Yes	0.503	0.073	1.654	1.432	1.91	<0.001
≥ 1 MI in addition to index MI : No	reference	reference	reference	reference	reference	reference
≥ 1 MI in addition to index MI : Yes	0.676	0.1	1.966	1.615	2.392	<0.001
Multivessel CAD : No	reference	reference	reference	reference	reference	reference
Multivessel CAD : Yes	0.163	0.073	1.178	1.021	1.358	0.026
Chronic renal dysfunction : No	reference	reference	reference	reference	reference	reference
Chronic renal dysfunction : Yes	1.006	0.138	2.733	2.087	3.58	<0.001
Ischaemic stroke : No	reference	reference	reference	reference	reference	reference
Ischaemic stroke : Yes	0.511	0.111	1.667	1.343	2.071	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Index year : 2009	reference	reference	reference	reference	reference	reference
Index year : 2010	0.075	0.082	1.078	0.918	1.265	0.362
Index year : 2011	-0.126	0.099	0.882	0.726	1.072	0.205
Index year : 2012	-0.336	0.159	0.714	0.523	0.975	0.034

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Invasive procedure related to index event : No invasive procedure	reference	reference	reference	reference	reference	reference
Invasive procedure related to index event : Coronary angiography only	-0.666	0.121	0.514	0.405	0.651	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Invasive procedure related to index event : PCI	-1.083	0.106	0.339	0.275	0.417	<0.001
Invasive procedure related to index event : CABG	-1.162	0.213	0.313	0.206	0.475	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Type of index MI : Non-ST elevation MI (and unspecified MI)	reference	reference	reference	reference	reference	reference
Type of index MI : ST elevation MI	-0.367	0.083	0.693	0.589	0.815	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
PCI or CABG related to index event : No	reference	reference	reference	reference	reference	reference
PCI or CABG related to index event : Yes	-0.937	0.096	0.392	0.325	0.473	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Atrial fibrillation : No	reference	reference	reference	reference	reference	reference
Atrial fibrillation : Yes	0.479	0.074	1.615	1.397	1.866	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Unstable angina pectoris : No	reference	reference	reference	reference	reference	reference
Unstable angina pectoris : Yes	0.262	0.101	1.299	1.065	1.585	0.009

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
ARB : No	reference	reference	reference	reference	reference	reference
ARB : Yes	-0.354	0.092	0.702	0.586	0.841	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Anticogulation medication : No	reference	reference	reference	reference	reference	reference
Anticogulation medication : Yes	0.21	0.087	1.234	1.041	1.463	0.016

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Arrhythmia : No	reference	reference	reference	reference	reference	reference
Arrhythmia : Yes	0.452	0.07	1.572	1.369	1.805	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
CABG : No	reference	reference	reference	reference	reference	reference
CABG : Yes	-0.639	0.169	0.528	0.379	0.736	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
COPD : No	reference	reference	reference	reference	reference	reference
COPD : Yes	0.509	0.149	1.663	1.243	2.225	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Diabetes mellitus : No	reference	reference	reference	reference	reference	reference
Diabetes mellitus : Yes	0.456	0.125	1.579	1.237	2.015	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Dementia/Alzheimer's disease : No	reference	reference	reference	reference	reference	reference
Dementia/Alzheimer's disease : Yes	0.247	0.111	1.28	1.03	1.592	0.029

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Heart failure : No	reference	reference	reference	reference	reference	reference
Heart failure : Yes	0.75	0.07	2.118	1.846	2.429	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Hyperlipidemia : No	reference	reference	reference	reference	reference	reference
Hyperlipidemia : Yes	-0.431	0.084	0.65	0.552	0.766	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Insulin : No	reference	reference	reference	reference	reference	reference
Insulin : Yes	0.834	0.126	2.302	1.799	2.946	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Major bleedings : No	reference	reference	reference	reference	reference	reference
Major bleedings : Yes	0.393	0.106	1.481	1.204	1.822	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
NSAID : No	reference	reference	reference	reference	reference	reference
NSAID : Yes	-0.399	0.238	0.671	0.421	1.071	0.097

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Nitrate : No	reference	reference	reference	reference	reference	reference
Nitrate : Yes	0.529	0.073	1.698	1.471	1.959	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
OAP use (Total) : No	reference	reference	reference	reference	reference	reference
OAP use (Total) : Yes	-0.403	0.086	0.668	0.565	0.79	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Oral antidiabetic : No	reference	reference	reference	reference	reference	reference
Oral antidiabetic : Yes	-0.852	0.122	0.427	0.336	0.542	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Proton pump inhibitor : No	reference	reference	reference	reference	reference	reference
Proton pump inhibitor : Yes	0.243	0.072	1.275	1.108	1.467	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
SSRI : No	reference	reference	reference	reference	reference	reference
SSRI : Yes	0.254	0.127	1.289	1.006	1.653	0.048

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Statin : No	reference	reference	reference	reference	reference	reference
Statin : Yes	-0.286	0.071	0.751	0.653	0.864	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Severe renal failure requiring dialysis : No	reference	reference	reference	reference	reference	reference
Severe renal failure requiring dialysis : Yes	1.521	0.408	4.577	2.058	10.182	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Warfarin : No	reference	reference	reference	reference	reference	reference
Warfarin : Yes	0.195	0.088	1.216	1.023	1.444	0.027

Composite end-point

Table 1.341: The effect of pre-defined and explored risk factors on the risk of Composite end-point estimated using the Cox proportional hazards model in Group 3 . Table shows the hazard ratios (HRs) for several factors with the corresponding 95% CI and p-value. Only those explored risk factors that indicated 20% effect on the hazard of the outcome with $p \leq 0.15$ are presented. Variables are evaluated at 1 year baseline check, medication use variables refer to ongoing use and comorbidities were searched in a 5 years history period.

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Age at 1 year baseline check (years) : 18-49	reference	reference	reference	reference	reference	reference
Age at 1 year baseline check (years) : 50-64	0.155	0.19	1.167	0.804	1.695	0.418
Age at 1 year baseline check (years) : 65-69	0.356	0.191	1.427	0.982	2.073	0.064
Age at 1 year baseline check (years) : 70-74	0.614	0.187	1.848	1.281	2.664	0.001
Age at 1 year baseline check (years) : 75-79	0.913	0.184	2.491	1.737	3.574	<0.001
Age at 1 year baseline check (years) : 80-84	1.235	0.183	3.439	2.402	4.924	<0.001
Age at 1 year baseline check (years) : 85 and over	1.706	0.182	5.506	3.852	7.869	<0.001
Sex : Male	reference	reference	reference	reference	reference	reference
Sex : Female	-0.024	0.042	0.976	0.9	1.059	0.563
Diabetes with ongoing medication : No	reference	reference	reference	reference	reference	reference
Diabetes with ongoing medication : Yes	0.409	0.043	1.505	1.383	1.639	<0.001
≥ 1 MI in addition to index MI : No	reference	reference	reference	reference	reference	reference
≥ 1 MI in addition to index MI : Yes	0.601	0.063	1.823	1.61	2.065	<0.001
Multivessel CAD : No	reference	reference	reference	reference	reference	reference
Multivessel CAD : Yes	0.164	0.042	1.179	1.085	1.281	<0.001
Chronic renal dysfunction : No	reference	reference	reference	reference	reference	reference
Chronic renal dysfunction : Yes	0.565	0.1	1.759	1.447	2.139	<0.001
Ischaemic stroke : No	reference	reference	reference	reference	reference	reference
Ischaemic stroke : Yes	0.663	0.065	1.94	1.709	2.202	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Invasive procedure related to index event : No invasive procedure	reference	reference	reference	reference	reference	reference
Invasive procedure related to index event : Coronary angiography only	-0.318	0.063	0.728	0.644	0.823	<0.001
Invasive procedure related to index event : PCI	-0.584	0.053	0.558	0.503	0.619	<0.001
Invasive procedure related to index event : CABG	-1.098	0.116	0.334	0.266	0.419	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Type of index MI : Non-ST elevation MI (and unspecified MI)	reference	reference	reference	reference	reference	reference
Type of index MI : ST elevation MI	-0.3	0.046	0.741	0.676	0.811	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
PCI or CABG related to index event : No	reference	reference	reference	reference	reference	reference
PCI or CABG related to index event : Yes	-0.564	0.048	0.569	0.518	0.625	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Atrial fibrillation : No	reference	reference	reference	reference	reference	reference
Atrial fibrillation : Yes	0.244	0.047	1.277	1.164	1.4	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Arrhythmia : No	reference	reference	reference	reference	reference	reference
Arrhythmia : Yes	0.216	0.044	1.241	1.138	1.352	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Bleeding disorder : No	reference	reference	reference	reference	reference	reference
Bleeding disorder : Yes	0.499	0.303	1.648	0.91	2.985	0.086

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
CABG : No	reference	reference	reference	reference	reference	reference
CABG : Yes	-0.624	0.088	0.536	0.451	0.636	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
COPD : No	reference	reference	reference	reference	reference	reference
COPD : Yes	0.389	0.09	1.475	1.237	1.759	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Central nervous tumour : No	reference	reference	reference	reference	reference	reference
Central nervous tumour : Yes	1.406	0.501	4.079	1.527	10.894	0.003

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Diabetes mellitus : No	reference	reference	reference	reference	reference	reference
Diabetes mellitus : Yes	0.34	0.078	1.406	1.205	1.639	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Heart failure : No	reference	reference	reference	reference	reference	reference
Heart failure : Yes	0.439	0.043	1.551	1.426	1.687	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Hyperlipidemia : No	reference	reference	reference	reference	reference	reference
Hyperlipidemia : Yes	-0.232	0.055	0.793	0.712	0.883	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Hypertension : No	reference	reference	reference	reference	reference	reference
Hypertension : Yes	0.52	0.202	1.683	1.134	2.498	0.011

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Increased bleeding risk (Total) : No	reference	reference	reference	reference	reference	reference
Increased bleeding risk (Total) : Yes	0.191	0.118	1.211	0.96	1.527	0.107

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Insulin : No	reference	reference	reference	reference	reference	reference
Insulin : Yes	0.636	0.072	1.888	1.639	2.176	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Major bleedings : No	reference	reference	reference	reference	reference	reference
Major bleedings : Yes	0.213	0.069	1.238	1.081	1.417	0.003

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Nitrate : No	reference	reference	reference	reference	reference	reference
Nitrate : Yes	0.467	0.042	1.595	1.469	1.731	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Oral antidiabetic : No	reference	reference	reference	reference	reference	reference
Oral antidiabetic : Yes	-0.499	0.074	0.607	0.525	0.701	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Proton pump inhibitor : No	reference	reference	reference	reference	reference	reference
Proton pump inhibitor : Yes	0.218	0.043	1.243	1.143	1.353	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Severe renal failure requiring dialysis : No	reference	reference	reference	reference	reference	reference
Severe renal failure requiring dialysis : Yes	1.227	0.288	3.412	1.939	6.001	<0.001

Overall mortality

Table 1.362: The effect of pre-defined and explored risk factors on the risk of Overall mortality estimated using the Cox proportional hazards model in Group 3 . Table shows the hazard ratios (HRs) for several factors with the corresponding 95% CI and p-value. Only those explored risk factors that indicated 20% effect on the hazard of the outcome with $p \leq 0.15$ are presented. Variables are evaluated at 1 year baseline check, medication use variables refer to ongoing use and comorbidities were searched in a 5 years history period.

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Age at 1 year baseline check (years) : 18-49	reference	reference	reference	reference	reference	reference
Age at 1 year baseline check (years) : 50-64	1.226	0.343	3.409	1.742	6.671	<0.001
Age at 1 year baseline check (years) : 65-69	1.632	0.341	5.114	2.622	9.974	<0.001
Age at 1 year baseline check (years) : 70-74	2.027	0.338	7.588	3.912	14.72	<0.001
Age at 1 year baseline check (years) : 75-79	2.497	0.336	12.144	6.282	23.476	<0.001
Age at 1 year baseline check (years) : 80-84	2.952	0.336	19.15	9.919	36.972	<0.001
Age at 1 year baseline check (years) : 85 and over	3.65	0.335	38.478	19.952	74.208	<0.001
Sex : Male	reference	reference	reference	reference	reference	reference
Sex : Female	-0.179	0.034	0.836	0.782	0.895	<0.001
Diabetes with ongoing medication : No	reference	reference	reference	reference	reference	reference
Diabetes with ongoing medication : Yes	0.246	0.038	1.279	1.187	1.378	<0.001
≥ 1 MI in addition to index MI : No	reference	reference	reference	reference	reference	reference
≥ 1 MI in addition to index MI : Yes	0.428	0.054	1.535	1.379	1.707	<0.001
Multivessel CAD : No	reference	reference	reference	reference	reference	reference
Multivessel CAD : Yes	0.148	0.036	1.16	1.081	1.244	<0.001
Chronic renal dysfunction : No	reference	reference	reference	reference	reference	reference
Chronic renal dysfunction : Yes	0.935	0.071	2.548	2.217	2.928	<0.001
Ischaemic stroke : No	reference	reference	reference	reference	reference	reference
Ischaemic stroke : Yes	0.265	0.061	1.303	1.157	1.468	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Invasive procedure related to index event : No invasive procedure	reference	reference	reference	reference	reference	reference
Invasive procedure related to index event : Coronary angiography only	-0.856	0.062	0.425	0.376	0.479	<0.001
Invasive procedure related to index event : PCI	-1.1	0.05	0.333	0.302	0.367	<0.001
Invasive procedure related to index event : CABG	-1.142	0.097	0.319	0.264	0.387	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Type of index MI : Non-ST elevation MI (and unspecified MI)	reference	reference	reference	reference	reference	reference
Type of index MI : ST elevation MI	-0.381	0.04	0.683	0.632	0.74	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Gastrointestinal bleeding : No	reference	reference	reference	reference	reference	reference
Gastrointestinal bleeding : Yes	0.682	0.159	1.978	1.447	2.704	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
PCI or CABG related to index event : No	reference	reference	reference	reference	reference	reference
PCI or CABG related to index event : Yes	-0.905	0.045	0.404	0.37	0.442	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Atrial fibrillation : No	reference	reference	reference	reference	reference	reference
Atrial fibrillation : Yes	0.427	0.037	1.532	1.425	1.647	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
ARB : No	reference	reference	reference	reference	reference	reference
ARB : Yes	-0.397	0.047	0.672	0.614	0.737	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Antithrombotic medication : No	reference	reference	reference	reference	reference	reference
Antithrombotic medication : Yes	-0.356	0.035	0.701	0.655	0.75	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Arrhythmia : No	reference	reference	reference	reference	reference	reference
Arrhythmia : Yes	0.403	0.035	1.497	1.398	1.603	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Beta-blocker : No	reference	reference	reference	reference	reference	reference
Beta-blocker : Yes	-0.313	0.036	0.731	0.682	0.784	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Bleeding disorder : No	reference	reference	reference	reference	reference	reference
Bleeding disorder : Yes	0.693	0.22	2	1.301	3.076	0.006

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
CABG : No	reference	reference	reference	reference	reference	reference
CABG : Yes	-0.56	0.078	0.571	0.49	0.666	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
COPD : No	reference	reference	reference	reference	reference	reference
COPD : Yes	0.892	0.061	2.439	2.165	2.747	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Cancer : No	reference	reference	reference	reference	reference	reference
Cancer : Yes	0.638	0.048	1.892	1.723	2.078	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Central nervous tumour : No	reference	reference	reference	reference	reference	reference
Central nervous tumour : Yes	1.391	0.409	4.018	1.802	8.959	0.005

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Diabetes mellitus : No	reference	reference	reference	reference	reference	reference
Diabetes mellitus : Yes	0.628	0.056	1.874	1.678	2.092	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Dementia/Alzheimer's disease : No	reference	reference	reference	reference	reference	reference
Dementia/Alzheimer's disease : Yes	0.646	0.049	1.908	1.735	2.099	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Haemorrhagic stroke : No	reference	reference	reference	reference	reference	reference
Haemorrhagic stroke : Yes	0.438	0.19	1.55	1.068	2.249	0.032

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Heart failure : No	reference	reference	reference	reference	reference	reference
Heart failure : Yes	0.827	0.034	2.287	2.138	2.446	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Hyperlipidemia : No	reference	reference	reference	reference	reference	reference
Hyperlipidemia : Yes	-0.7	0.04	0.497	0.459	0.537	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Increased bleeding risk (Total) : No	reference	reference	reference	reference	reference	reference
Increased bleeding risk (Total) : Yes	0.57	0.083	1.768	1.502	2.08	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Insulin : No	reference	reference	reference	reference	reference	reference
Insulin : Yes	0.614	0.066	1.849	1.625	2.103	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Intracranial vascular abnormality : No	reference	reference	reference	reference	reference	reference
Intracranial vascular abnormality : Yes	0.598	0.19	1.819	1.253	2.641	0.002

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Intracranial bleeding : No	reference	reference	reference	reference	reference	reference
Intracranial bleeding : Yes	0.452	0.113	1.572	1.259	1.963	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
LMWH : No	reference	reference	reference	reference	reference	reference
LMWH : Yes	1.002	0.197	2.724	1.851	4.008	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Major bleedings : No	reference	reference	reference	reference	reference	reference
Major bleedings : Yes	0.458	0.051	1.581	1.431	1.748	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Nitrate : No	reference	reference	reference	reference	reference	reference
Nitrate : Yes	0.202	0.035	1.224	1.143	1.309	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
OAP use (Total) : No	reference	reference	reference	reference	reference	reference
OAP use (Total) : Yes	-0.604	0.044	0.547	0.502	0.596	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Oral antidiabetic : No	reference	reference	reference	reference	reference	reference
Oral antidiabetic : Yes	-0.652	0.066	0.521	0.458	0.593	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Proton pump inhibitor : No	reference	reference	reference	reference	reference	reference
Proton pump inhibitor : Yes	0.337	0.035	1.401	1.308	1.501	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
SSRI : No	reference	reference	reference	reference	reference	reference
SSRI : Yes	0.274	0.063	1.315	1.162	1.488	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Statin : No	reference	reference	reference	reference	reference	reference
Statin : Yes	-0.58	0.034	0.56	0.523	0.599	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Stroke (Total) : No	reference	reference	reference	reference	reference	reference
Stroke (Total) : Yes	0.496	0.197	1.642	1.116	2.417	0.02

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Severe liver disease : No	reference	reference	reference	reference	reference	reference
Severe liver disease : Yes	1.025	0.201	2.786	1.878	4.132	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Severe renal failure requiring dialysis : No	reference	reference	reference	reference	reference	reference
Severe renal failure requiring dialysis : Yes	1.241	0.222	3.461	2.238	5.35	<0.001

1.3.4 Explored risk factors for group 4

Myocardial infarction

Table 1.397: The effect of pre-defined and explored risk factors on the risk of Myocardial infarction estimated using the Cox proportional hazards model in Group 4 . Table shows the hazard ratios (HRs) for several factors with the corresponding 95% CI and p-value. Only those explored risk factors that indicated 20% effect on the hazard of the outcome with $p \leq 0.15$ are presented. Variables are evaluated at 1 year baseline check, medication use variables refer to ongoing use and comorbidities were searched in a 5 years history period.

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Age at 1 year baseline check (years) : 18-49	reference	reference	reference	reference	reference	reference
Age at 1 year baseline check (years) : 50-64	0.129	0.231	1.138	0.724	1.789	0.575
Age at 1 year baseline check (years) : 65-69	0.23	0.234	1.259	0.796	1.991	0.326
Age at 1 year baseline check (years) : 70-74	0.407	0.23	1.502	0.958	2.357	0.078
Age at 1 year baseline check (years) : 75-79	0.782	0.225	2.186	1.407	3.396	<0.001
Age at 1 year baseline check (years) : 80-84	1.184	0.223	3.267	2.112	5.055	<0.001
Age at 1 year baseline check (years) : 85 and over	1.664	0.221	5.282	3.423	8.151	<0.001
Sex : Male	reference	reference	reference	reference	reference	reference
Sex : Female	-0.005	0.056	0.995	0.891	1.111	0.925
Diabetes with ongoing medication : No	reference	reference	reference	reference	reference	reference
Diabetes with ongoing medication : Yes	0.492	0.058	1.636	1.46	1.833	<0.001
≥ 1 MI in addition to index MI : No	reference	reference	reference	reference	reference	reference
≥ 1 MI in addition to index MI : Yes	0.719	0.082	2.052	1.746	2.412	<0.001
Multivessel CAD : No	reference	reference	reference	reference	reference	reference
Multivessel CAD : Yes	0.191	0.057	1.211	1.083	1.353	<0.001
Chronic renal dysfunction : No	reference	reference	reference	reference	reference	reference
Chronic renal dysfunction : Yes	0.651	0.129	1.918	1.491	2.468	<0.001
Ischaemic stroke : No	reference	reference	reference	reference	reference	reference
Ischaemic stroke : Yes	0.301	0.103	1.352	1.104	1.655	0.004

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Invasive procedure related to index event : No invasive procedure	reference	reference	reference	reference	reference	reference
Invasive procedure related to index event : Coronary angiography only	-0.266	0.083	0.766	0.651	0.902	0.001
Invasive procedure related to index event : PCI	-0.597	0.07	0.55	0.48	0.632	<0.001
Invasive procedure related to index event : CABG	-1.789	0.219	0.167	0.109	0.257	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Type of index MI : Non-ST elevation MI (and unspecified MI)	reference	reference	reference	reference	reference	reference
Type of index MI : ST elevation MI	-0.434	0.064	0.648	0.571	0.735	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
PCI or CABG related to index event : No	reference	reference	reference	reference	reference	reference
PCI or CABG related to index event : Yes	-0.638	0.065	0.528	0.465	0.6	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Bleeding disorder : No	reference	reference	reference	reference	reference	reference
Bleeding disorder : Yes	0.596	0.38	1.814	0.861	3.821	0.091

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
CABG : No	reference	reference	reference	reference	reference	reference
CABG : Yes	-0.909	0.136	0.403	0.309	0.526	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Calcium channel blocker : No	reference	reference	reference	reference	reference	reference
Calcium channel blocker : Yes	0.196	0.062	1.216	1.077	1.373	0.002

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
COPD : No	reference	reference	reference	reference	reference	reference
COPD : Yes	0.347	0.122	1.415	1.114	1.797	0.005

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Cancer : No	reference	reference	reference	reference	reference	reference
Cancer : Yes	0.222	0.093	1.249	1.042	1.498	0.017

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Diabetes mellitus : No	reference	reference	reference	reference	reference	reference
Diabetes mellitus : Yes	0.336	0.107	1.4	1.135	1.726	0.002

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Heart failure : No	reference	reference	reference	reference	reference	reference
Heart failure : Yes	0.495	0.059	1.64	1.462	1.84	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Hypertension : No	reference	reference	reference	reference	reference	reference
Hypertension : Yes	0.667	0.279	1.949	1.127	3.369	0.017

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Insulin : No	reference	reference	reference	reference	reference	reference
Insulin : Yes	0.572	0.096	1.771	1.467	2.138	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Nitrate : No	reference	reference	reference	reference	reference	reference
Nitrate : Yes	0.691	0.057	1.995	1.783	2.233	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Oral antidiabetic : No	reference	reference	reference	reference	reference	reference
Oral antidiabetic : Yes	-0.486	0.098	0.615	0.507	0.745	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Proton pump inhibitor : No	reference	reference	reference	reference	reference	reference
Proton pump inhibitor : Yes	0.231	0.058	1.26	1.124	1.412	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Severe renal failure requiring dialysis : No	reference	reference	reference	reference	reference	reference
Severe renal failure requiring dialysis : Yes	1.34	0.346	3.817	1.936	7.526	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Transient ischemic attack : No	reference	reference	reference	reference	reference	reference
Transient ischemic attack : Yes	0.206	0.129	1.229	0.955	1.581	0.113

Stroke (total)

Table 1.415: The effect of pre-defined and explored risk factors on the risk of Stroke (total) estimated using the Cox proportional hazards model in Group 4 . Table shows the hazard ratios (HRs) for several factors with the corresponding 95% CI and p-value. Only those explored risk factors that indicated 20% effect on the hazard of the outcome with $p \leq 0.15$ are presented. Variables are evaluated at 1 year baseline check, medication use variables refer to ongoing use and comorbidities were searched in a 5 years history period.

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Age at 1 year baseline check (years) : 18-49	reference	reference	reference	reference	reference	reference
Age at 1 year baseline check (years) : 50-64	0.333	0.435	1.395	0.595	3.271	0.446
Age at 1 year baseline check (years) : 65-69	0.79	0.429	2.204	0.95	5.112	0.067
Age at 1 year baseline check (years) : 70-74	1.052	0.424	2.862	1.248	6.565	0.013
Age at 1 year baseline check (years) : 75-79	1.268	0.421	3.554	1.558	8.106	0.003
Age at 1 year baseline check (years) : 80-84	1.428	0.421	4.17	1.828	9.514	<0.001
Age at 1 year baseline check (years) : 85 and over	1.849	0.419	6.352	2.794	14.438	<0.001
Sex : Male	reference	reference	reference	reference	reference	reference
Sex : Female	-0.024	0.084	0.976	0.828	1.151	0.77
Diabetes with ongoing medication : No	reference	reference	reference	reference	reference	reference
Diabetes with ongoing medication : Yes	0.28	0.09	1.323	1.108	1.579	0.002
≥ 1 MI in addition to index MI : No	reference	reference	reference	reference	reference	reference
≥ 1 MI in addition to index MI : Yes	0.418	0.137	1.518	1.16	1.987	0.003
Multivessel CAD : No	reference	reference	reference	reference	reference	reference
Multivessel CAD : Yes	0.074	0.088	1.077	0.907	1.279	0.403
Chronic renal dysfunction : No	reference	reference	reference	reference	reference	reference
Chronic renal dysfunction : Yes	-0.028	0.271	0.972	0.572	1.654	0.92
Ischaemic stroke : No	reference	reference	reference	reference	reference	reference
Ischaemic stroke : Yes	1.407	0.106	4.082	3.316	5.026	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Invasive procedure related to index event : No invasive procedure	reference	reference	reference	reference	reference	reference
Invasive procedure related to index event : Coronary angiography only	-0.4	0.132	0.67	0.518	0.867	0.002
Invasive procedure related to index event : PCI	-0.514	0.106	0.598	0.486	0.736	<0.001
Invasive procedure related to index event : CABG	-0.432	0.183	0.649	0.453	0.929	0.019

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
PCI or CABG related to index event : No	reference	reference	reference	reference	reference	reference

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
PCI or CABG related to index event : Yes	-0.38	0.094	0.684	0.569	0.822	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Atrial fibrillation : No	reference	reference	reference	reference	reference	reference
Atrial fibrillation : Yes	0.546	0.104	1.726	1.408	2.115	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Arrhythmia : No	reference	reference	reference	reference	reference	reference
Arrhythmia : Yes	0.451	0.094	1.571	1.308	1.887	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Central nervous tumour : No	reference	reference	reference	reference	reference	reference
Central nervous tumour : Yes	1.842	0.713	6.31	1.56	25.527	0.041

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Diabetes mellitus : No	reference	reference	reference	reference	reference	reference
Diabetes mellitus : Yes	0.341	0.156	1.407	1.036	1.911	0.029

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Heart failure : No	reference	reference	reference	reference	reference	reference
Heart failure : Yes	0.276	0.092	1.317	1.1	1.578	0.004

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Insulin : No	reference	reference	reference	reference	reference	reference
Insulin : Yes	0.455	0.153	1.576	1.169	2.125	0.003

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
LMWH : No	reference	reference	reference	reference	reference	reference
LMWH : Yes	2.343	0.71	10.415	2.591	41.869	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Major bleedings : No	reference	reference	reference	reference	reference	reference
Major bleedings : Yes	0.215	0.143	1.24	0.938	1.64	0.141

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
OAP use (Total) : No	reference	reference	reference	reference	reference	reference
OAP use (Total) : Yes	-0.224	0.09	0.799	0.67	0.954	0.014

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Oral antidiabetic : No	reference	reference	reference	reference	reference	reference
Oral antidiabetic : Yes	-0.283	0.162	0.753	0.549	1.034	0.089

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Proton pump inhibitor : No	reference	reference	reference	reference	reference	reference
Proton pump inhibitor : Yes	0.248	0.088	1.281	1.079	1.522	0.005

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Stroke (Total) : No	reference	reference	reference	reference	reference	reference
Stroke (Total) : Yes	0.801	0.45	2.227	0.922	5.38	0.077

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Severe renal failure requiring dialysis : No	reference	reference	reference	reference	reference	reference
Severe renal failure requiring dialysis : Yes	2.007	0.591	7.442	2.339	23.681	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Transient ischemic attack : No	reference	reference	reference	reference	reference	reference
Transient ischemic attack : Yes	0.378	0.171	1.459	1.045	2.038	0.032

Cardiovascular mortality

Table 1.432: The effect of pre-defined and explored risk factors on the risk of Cardiovascular mortality estimated using the Cox proportional hazards model in Group 4 . Table shows the hazard ratios (HRs) for several factors with the corresponding 95% CI and p-value. Only those explored risk factors that indicated 20% effect on the hazard of the outcome with $p < 0.15$ are presented. Variables are evaluated at 1 year baseline check, medication use variables refer to ongoing use and comorbidities were searched in a 5 years history period.

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Age at 1 year baseline check (years) : 18-49	reference	reference	reference	reference	reference	reference
Age at 1 year baseline check (years) : 50-64	0.889	0.6	2.433	0.75	7.893	0.139
Age at 1 year baseline check (years) : 65-69	1.061	0.602	2.89	0.888	9.408	0.079
Age at 1 year baseline check (years) : 70-74	1.508	0.592	4.516	1.414	14.424	0.011
Age at 1 year baseline check (years) : 75-79	1.979	0.587	7.232	2.29	22.843	<0.001
Age at 1 year baseline check (years) : 80-84	2.539	0.584	12.672	4.034	39.806	<0.001
Age at 1 year baseline check (years) : 85 and over	3.245	0.582	25.662	8.196	80.348	<0.001
Sex : Male	reference	reference	reference	reference	reference	reference
Sex : Female	0.068	0.078	1.071	0.919	1.247	0.381
Diabetes with ongoing medication : No	reference	reference	reference	reference	reference	reference
Diabetes with ongoing medication : Yes	0.532	0.081	1.702	1.452	1.994	<0.001
≥ 1 MI in addition to index MI : No	reference	reference	reference	reference	reference	reference
≥ 1 MI in addition to index MI : Yes	0.712	0.11	2.039	1.644	2.528	<0.001
Multivessel CAD : No	reference	reference	reference	reference	reference	reference
Multivessel CAD : Yes	0.171	0.08	1.186	1.015	1.387	0.035
Chronic renal dysfunction : No	reference	reference	reference	reference	reference	reference
Chronic renal dysfunction : Yes	0.974	0.153	2.649	1.962	3.577	<0.001
Ischaemic stroke : No	reference	reference	reference	reference	reference	reference
Ischaemic stroke : Yes	0.497	0.127	1.644	1.282	2.109	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Index year : 2009	reference	reference	reference	reference	reference	reference
Index year : 2010	0.092	0.09	1.096	0.919	1.306	0.309
Index year : 2011	-0.113	0.109	0.894	0.721	1.107	0.302
Index year : 2012	-0.291	0.173	0.748	0.532	1.05	0.092

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Invasive procedure related to index event : No invasive procedure	reference	reference	reference	reference	reference	reference
Invasive procedure related to index event : Coronary angiography only	-0.699	0.135	0.497	0.381	0.648	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Invasive procedure related to index event : PCI	-1.07	0.113	0.343	0.275	0.428	<0.001
Invasive procedure related to index event : CABG	-1.078	0.229	0.34	0.217	0.533	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Type of index MI : Non-ST elevation MI (and unspecified MI)	reference	reference	reference	reference	reference	reference
Type of index MI : ST elevation MI	-0.445	0.092	0.641	0.535	0.768	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
PCI or CABG related to index event : No	reference	reference	reference	reference	reference	reference
PCI or CABG related to index event : Yes	-0.904	0.103	0.405	0.331	0.496	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Atrial fibrillation : No	reference	reference	reference	reference	reference	reference
Atrial fibrillation : Yes	0.573	0.09	1.773	1.487	2.115	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Unstable angina pectoris : No	reference	reference	reference	reference	reference	reference
Unstable angina pectoris : Yes	0.189	0.115	1.208	0.965	1.512	0.095

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
ARB : No	reference	reference	reference	reference	reference	reference
ARB : Yes	-0.412	0.104	0.662	0.54	0.812	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Anticogulation medication : No	reference	reference	reference	reference	reference	reference
Anticogulation medication : Yes	0.91	0.292	2.485	1.403	4.401	0.002

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Antithrombotic medication : No	reference	reference	reference	reference	reference	reference
Antithrombotic medication : Yes	-0.307	0.083	0.736	0.625	0.866	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Arrhythmia : No	reference	reference	reference	reference	reference	reference
Arrhythmia : Yes	0.523	0.082	1.687	1.436	1.982	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
CABG : No	reference	reference	reference	reference	reference	reference
CABG : Yes	-0.584	0.184	0.557	0.388	0.8	0.002

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
COPD : No	reference	reference	reference	reference	reference	reference
COPD : Yes	0.51	0.161	1.665	1.215	2.282	0.002

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Diabetes mellitus : No	reference	reference	reference	reference	reference	reference
Diabetes mellitus : Yes	0.595	0.13	1.814	1.405	2.341	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Dementia/Alzheimer's disease : No	reference	reference	reference	reference	reference	reference
Dementia/Alzheimer's disease : Yes	0.335	0.116	1.398	1.114	1.756	0.005

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Heart failure : No	reference	reference	reference	reference	reference	reference
Heart failure : Yes	0.849	0.077	2.337	2.008	2.719	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Hyperlipidemia : No	reference	reference	reference	reference	reference	reference
Hyperlipidemia : Yes	-0.462	0.092	0.63	0.527	0.754	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Insulin : No	reference	reference	reference	reference	reference	reference
Insulin : Yes	0.848	0.14	2.335	1.776	3.07	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Major bleedings : No	reference	reference	reference	reference	reference	reference
Major bleedings : Yes	0.448	0.115	1.565	1.249	1.961	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
NSAID : No	reference	reference	reference	reference	reference	reference
NSAID : Yes	-0.354	0.239	0.702	0.44	1.122	0.142

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Nitrate : No	reference	reference	reference	reference	reference	reference
Nitrate : Yes	0.541	0.08	1.718	1.47	2.008	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
OAP use (Total) : No	reference	reference	reference	reference	reference	reference
OAP use (Total) : Yes	-0.439	0.091	0.645	0.54	0.77	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Oral antidiabetic : No	reference	reference	reference	reference	reference	reference
Oral antidiabetic : Yes	-0.804	0.135	0.448	0.343	0.583	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Proton pump inhibitor : No	reference	reference	reference	reference	reference	reference
Proton pump inhibitor : Yes	0.321	0.078	1.379	1.183	1.608	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
SSRI : No	reference	reference	reference	reference	reference	reference
SSRI : Yes	0.312	0.136	1.366	1.046	1.784	0.023

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Statin : No	reference	reference	reference	reference	reference	reference
Statin : Yes	-0.326	0.078	0.722	0.619	0.841	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Severe renal failure requiring dialysis : No	reference	reference	reference	reference	reference	reference
Severe renal failure requiring dialysis : Yes	1.7	0.415	5.476	2.426	12.361	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Warfarin : No	reference	reference	reference	reference	reference	reference
Warfarin : Yes	0.939	0.305	2.557	1.408	4.645	0.002

Composite end-point

Table 1.460: The effect of pre-defined and explored risk factors on the risk of Composite end-point estimated using the Cox proportional hazards model in Group 4 . Table shows the hazard ratios (HRs) for several factors with the corresponding 95% CI and p-value. Only those explored risk factors that indicated 20% effect on the hazard of the outcome with $p \leq 0.15$ are presented. Variables are evaluated at 1 year baseline check, medication use variables refer to ongoing use and comorbidities were searched in a 5 years history period.

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Age at 1 year baseline check (years) : 18-49	reference	reference	reference	reference	reference	reference
Age at 1 year baseline check (years) : 50-64	0.212	0.2	1.236	0.836	1.829	0.29
Age at 1 year baseline check (years) : 65-69	0.425	0.2	1.53	1.033	2.266	0.035
Age at 1 year baseline check (years) : 70-74	0.633	0.197	1.884	1.28	2.772	0.001
Age at 1 year baseline check (years) : 75-79	0.959	0.194	2.61	1.784	3.819	<0.001
Age at 1 year baseline check (years) : 80-84	1.307	0.193	3.694	2.531	5.392	<0.001
Age at 1 year baseline check (years) : 85 and over	1.787	0.192	5.974	4.102	8.7	<0.001
Sex : Male	reference	reference	reference	reference	reference	reference
Sex : Female	-0.001	0.045	0.999	0.915	1.091	0.983
Diabetes with ongoing medication : No	reference	reference	reference	reference	reference	reference
Diabetes with ongoing medication : Yes	0.432	0.047	1.54	1.405	1.689	<0.001
≥ 1 MI in addition to index MI : No	reference	reference	reference	reference	reference	reference
≥ 1 MI in addition to index MI : Yes	0.651	0.068	1.918	1.679	2.191	<0.001
Multivessel CAD : No	reference	reference	reference	reference	reference	reference
Multivessel CAD : Yes	0.165	0.046	1.179	1.078	1.29	<0.001
Chronic renal dysfunction : No	reference	reference	reference	reference	reference	reference
Chronic renal dysfunction : Yes	0.583	0.107	1.791	1.453	2.206	<0.001
Ischaemic stroke : No	reference	reference	reference	reference	reference	reference
Ischaemic stroke : Yes	0.65	0.074	1.916	1.659	2.213	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Invasive procedure related to index event : No invasive procedure	reference	reference	reference	reference	reference	reference
Invasive procedure related to index event : Coronary angiography only	-0.354	0.069	0.702	0.614	0.803	<0.001
Invasive procedure related to index event : PCI	-0.609	0.056	0.544	0.487	0.607	<0.001
Invasive procedure related to index event : CABG	-1.123	0.129	0.325	0.253	0.418	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Type of index MI : Non-ST elevation MI (and unspecified MI)	reference	reference	reference	reference	reference	reference
Type of index MI : ST elevation MI	-0.324	0.05	0.723	0.656	0.797	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
PCI or CABG related to index event : No	reference	reference	reference	reference	reference	reference
PCI or CABG related to index event : Yes	-0.573	0.051	0.564	0.51	0.624	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Atrial fibrillation : No	reference	reference	reference	reference	reference	reference
Atrial fibrillation : Yes	0.339	0.058	1.403	1.252	1.573	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Anticogulation medication : No	reference	reference	reference	reference	reference	reference
Anticogulation medication : Yes	0.42	0.22	1.522	0.99	2.341	0.053

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Arrhythmia : No	reference	reference	reference	reference	reference	reference
Arrhythmia : Yes	0.292	0.052	1.338	1.21	1.481	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Bleeding disorder : No	reference	reference	reference	reference	reference	reference
Bleeding disorder : Yes	0.565	0.318	1.76	0.944	3.283	0.064

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
CABG : No	reference	reference	reference	reference	reference	reference
CABG : Yes	-0.615	0.096	0.541	0.448	0.653	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
COPD : No	reference	reference	reference	reference	reference	reference
COPD : Yes	0.364	0.097	1.439	1.19	1.739	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Cancer : No	reference	reference	reference	reference	reference	reference
Cancer : Yes	0.209	0.075	1.232	1.064	1.427	0.005

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Central nervous tumour : No	reference	reference	reference	reference	reference	reference
Central nervous tumour : Yes	1.518	0.502	4.564	1.706	12.208	0.002

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Diabetes mellitus : No	reference	reference	reference	reference	reference	reference
Diabetes mellitus : Yes	0.399	0.083	1.49	1.267	1.753	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Heart failure : No	reference	reference	reference	reference	reference	reference
Heart failure : Yes	0.502	0.047	1.653	1.507	1.812	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Hyperlipidemia : No	reference	reference	reference	reference	reference	reference
Hyperlipidemia : Yes	-0.234	0.059	0.791	0.704	0.889	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Hypertension : No	reference	reference	reference	reference	reference	reference
Hypertension : Yes	0.541	0.206	1.718	1.148	2.573	0.009

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Increased bleeding risk (Total) : No	reference	reference	reference	reference	reference	reference
Increased bleeding risk (Total) : Yes	0.262	0.123	1.3	1.022	1.654	0.034

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Insulin : No	reference	reference	reference	reference	reference	reference
Insulin : Yes	0.618	0.079	1.855	1.589	2.164	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
LMWH : No	reference	reference	reference	reference	reference	reference
LMWH : Yes	1.497	0.578	4.467	1.438	13.876	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Major bleedings : No	reference	reference	reference	reference	reference	reference
Major bleedings : Yes	0.248	0.075	1.282	1.107	1.484	0.002

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Nitrate : No	reference	reference	reference	reference	reference	reference
Nitrate : Yes	0.501	0.045	1.651	1.511	1.804	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Oral antidiabetic : No	reference	reference	reference	reference	reference	reference
Oral antidiabetic : Yes	-0.493	0.08	0.611	0.522	0.715	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Proton pump inhibitor : No	reference	reference	reference	reference	reference	reference
Proton pump inhibitor : Yes	0.256	0.047	1.292	1.179	1.415	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Severe renal failure requiring dialysis : No	reference	reference	reference	reference	reference	reference
Severe renal failure requiring dialysis : Yes	1.336	0.291	3.805	2.149	6.736	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Transient ischemic attack : No	reference	reference	reference	reference	reference	reference
Transient ischemic attack : Yes	0.265	0.1	1.304	1.072	1.586	0.009

Overall mortality

Table 1.485: The effect of pre-defined and explored risk factors on the risk of Overall mortality estimated using the Cox proportional hazards model in Group 4 . Table shows the hazard ratios (HRs) for several factors with the corresponding 95% CI and p-value. Only those explored risk factors that indicated 20% effect on the hazard of the outcome with $p \leq 0.15$ are presented. Variables are evaluated at 1 year baseline check, medication use variables refer to ongoing use and comorbidities were searched in a 5 years history period.

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Age at 1 year baseline check (years) : 18-49	reference	reference	reference	reference	reference	reference
Age at 1 year baseline check (years) : 50-64	1.169	0.344	3.218	1.641	6.31	<0.001
Age at 1 year baseline check (years) : 65-69	1.524	0.342	4.59	2.347	8.977	<0.001
Age at 1 year baseline check (years) : 70-74	1.903	0.339	6.703	3.448	13.031	<0.001
Age at 1 year baseline check (years) : 75-79	2.449	0.337	11.571	5.979	22.394	<0.001
Age at 1 year baseline check (years) : 80-84	2.891	0.336	18.01	9.319	34.805	<0.001
Age at 1 year baseline check (years) : 85 and over	3.609	0.335	36.94	19.141	71.29	<0.001
Sex : Male	reference	reference	reference	reference	reference	reference
Sex : Female	-0.16	0.037	0.852	0.792	0.917	<0.001
Diabetes with ongoing medication : No	reference	reference	reference	reference	reference	reference
Diabetes with ongoing medication : Yes	0.234	0.042	1.264	1.164	1.372	<0.001
≥ 1 MI in addition to index MI : No	reference	reference	reference	reference	reference	reference
≥ 1 MI in addition to index MI : Yes	0.484	0.058	1.623	1.447	1.82	<0.001
Multivessel CAD : No	reference	reference	reference	reference	reference	reference
Multivessel CAD : Yes	0.152	0.039	1.164	1.078	1.256	<0.001
Chronic renal dysfunction : No	reference	reference	reference	reference	reference	reference
Chronic renal dysfunction : Yes	0.979	0.075	2.663	2.296	3.087	<0.001
Ischaemic stroke : No	reference	reference	reference	reference	reference	reference
Ischaemic stroke : Yes	0.27	0.069	1.31	1.145	1.499	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Invasive procedure related to index event : No invasive procedure	reference	reference	reference	reference	reference	reference
Invasive procedure related to index event : Coronary angiography only	-0.898	0.068	0.407	0.356	0.466	<0.001
Invasive procedure related to index event : PCI	-1.165	0.054	0.312	0.28	0.347	<0.001
Invasive procedure related to index event : CABG	-1.142	0.107	0.319	0.259	0.394	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Type of index MI : Non-ST elevation MI (and unspecified MI)	reference	reference	reference	reference	reference	reference
Type of index MI : ST elevation MI	-0.411	0.044	0.663	0.608	0.722	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Gastrointestinal bleeding : No	reference	reference	reference	reference	reference	reference
Gastrointestinal bleeding : Yes	0.789	0.166	2.201	1.589	3.047	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
PCI or CABG related to index event : No	reference	reference	reference	reference	reference	reference
PCI or CABG related to index event : Yes	-0.949	0.049	0.387	0.351	0.426	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Atrial fibrillation : No	reference	reference	reference	reference	reference	reference
Atrial fibrillation : Yes	0.574	0.044	1.775	1.628	1.935	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
ARB : No	reference	reference	reference	reference	reference	reference
ARB : Yes	-0.456	0.052	0.634	0.572	0.702	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
ACE inhibitor : No	reference	reference	reference	reference	reference	reference
ACE inhibitor : Yes	-0.23	0.039	0.794	0.737	0.857	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Anticogulation medication : No	reference	reference	reference	reference	reference	reference
Anticogulation medication : Yes	0.599	0.168	1.821	1.31	2.531	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Antithrombotic medication : No	reference	reference	reference	reference	reference	reference
Antithrombotic medication : Yes	-0.519	0.042	0.595	0.548	0.646	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Arrhythmia : No	reference	reference	reference	reference	reference	reference
Arrhythmia : Yes	0.495	0.04	1.641	1.516	1.776	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Beta-blocker : No	reference	reference	reference	reference	reference	reference
Beta-blocker : Yes	-0.337	0.038	0.714	0.662	0.77	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Bleeding disorder : No	reference	reference	reference	reference	reference	reference
Bleeding disorder : Yes	0.755	0.225	2.127	1.368	3.307	0.005

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
CABG : No	reference	reference	reference	reference	reference	reference
CABG : Yes	-0.502	0.085	0.606	0.513	0.715	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Calcium channel blocker : No	reference	reference	reference	reference	reference	reference
Calcium channel blocker : Yes	-0.233	0.047	0.792	0.722	0.868	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
COPD : No	reference	reference	reference	reference	reference	reference
COPD : Yes	0.878	0.065	2.406	2.116	2.735	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Cancer : No	reference	reference	reference	reference	reference	reference
Cancer : Yes	0.674	0.051	1.963	1.776	2.17	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Central nervous tumour : No	reference	reference	reference	reference	reference	reference
Central nervous tumour : Yes	1.503	0.41	4.494	2.014	10.031	0.004

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Diabetes mellitus : No	reference	reference	reference	reference	reference	reference
Diabetes mellitus : Yes	0.622	0.061	1.862	1.652	2.099	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Dementia/Alzheimer's disease : No	reference	reference	reference	reference	reference	reference
Dementia/Alzheimer's disease : Yes	0.675	0.051	1.963	1.775	2.172	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Haemorrhagic stroke : No	reference	reference	reference	reference	reference	reference
Haemorrhagic stroke : Yes	0.417	0.197	1.517	1.03	2.233	0.05

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Heart failure : No	reference	reference	reference	reference	reference	reference
Heart failure : Yes	0.862	0.038	2.369	2.2	2.55	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Hyperlipidemia : No	reference	reference	reference	reference	reference	reference
Hyperlipidemia : Yes	-0.714	0.043	0.49	0.45	0.533	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Increased bleeding risk (Total) : No	reference	reference	reference	reference	reference	reference
Increased bleeding risk (Total) : Yes	0.597	0.087	1.817	1.53	2.156	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Insulin : No	reference	reference	reference	reference	reference	reference
Insulin : Yes	0.656	0.074	1.927	1.668	2.227	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Intracranial vascular abnormality : No	reference	reference	reference	reference	reference	reference
Intracranial vascular abnormality : Yes	0.403	0.225	1.496	0.963	2.325	0.081

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Intracranial bleeding : No	reference	reference	reference	reference	reference	reference
Intracranial bleeding : Yes	0.493	0.117	1.638	1.302	2.061	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
LMWH : No	reference	reference	reference	reference	reference	reference
LMWH : Yes	1.152	0.501	3.165	1.185	8.454	0.076

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Major bleedings : No	reference	reference	reference	reference	reference	reference
Major bleedings : Yes	0.488	0.055	1.628	1.461	1.815	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
OAP use (Total) : No	reference	reference	reference	reference	reference	reference
OAP use (Total) : Yes	-0.631	0.046	0.532	0.486	0.582	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Oral antidiabetic : No	reference	reference	reference	reference	reference	reference
Oral antidiabetic : Yes	-0.681	0.073	0.506	0.438	0.584	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Proton pump inhibitor : No	reference	reference	reference	reference	reference	reference
Proton pump inhibitor : Yes	0.358	0.038	1.43	1.327	1.541	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
SSRI : No	reference	reference	reference	reference	reference	reference
SSRI : Yes	0.227	0.07	1.255	1.094	1.439	0.002

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Statin : No	reference	reference	reference	reference	reference	reference
Statin : Yes	-0.616	0.038	0.54	0.502	0.581	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Stroke (Total) : No	reference	reference	reference	reference	reference	reference
Stroke (Total) : Yes	0.51	0.205	1.665	1.113	2.49	0.022

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Severe liver disease : No	reference	reference	reference	reference	reference	reference
Severe liver disease : Yes	0.994	0.22	2.703	1.757	4.156	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Severe renal failure requiring dialysis : No	reference	reference	reference	reference	reference	reference
Severe renal failure requiring dialysis : Yes	1.345	0.224	3.838	2.473	5.956	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Warfarin : No	reference	reference	reference	reference	reference	reference
Warfarin : Yes	0.526	0.184	1.693	1.181	2.427	0.003

1.3.5 Explored risk factors for group 5

Myocardial infarction

Table 1.523: The effect of pre-defined and explored risk factors on the risk of Myocardial infarction estimated using the Cox proportional hazards model in Group 5 . Table shows the hazard ratios (HRs) for several factors with the corresponding 95% CI and p-value. Only those explored risk factors that indicated 20% effect on the hazard of the outcome with $p \leq 0.15$ are presented. Variables are evaluated at 1 year baseline check, medication use variables refer to ongoing use and comorbidities were searched in a 5 years history period.

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Age at 1 year baseline check (years) : 50-64	reference	reference	reference	reference	reference	reference
Age at 1 year baseline check (years) : 65-69	0.252	0.213	1.287	0.848	1.953	0.235
Age at 1 year baseline check (years) : 70-74	0.295	0.206	1.343	0.897	2.01	0.155
Age at 1 year baseline check (years) : 75-79	0.889	0.185	2.432	1.692	3.494	<0.001
Age at 1 year baseline check (years) : 80-84	1.162	0.177	3.196	2.258	4.524	<0.001
Age at 1 year baseline check (years) : 85 and over	1.57	0.173	4.807	3.426	6.744	<0.001
Sex : Male	reference	reference	reference	reference	reference	reference
Sex : Female	-0.096	0.075	0.909	0.784	1.053	0.202
Diabetes with ongoing medication : No	reference	reference	reference	reference	reference	reference
Diabetes with ongoing medication : Yes	0.589	0.08	1.802	1.54	2.108	<0.001
≥ 1 MI in addition to index MI : No	reference	reference	reference	reference	reference	reference
≥ 1 MI in addition to index MI : Yes	0.664	0.115	1.942	1.551	2.433	<0.001
Multivessel CAD : No	reference	reference	reference	reference	reference	reference
Multivessel CAD : Yes	0.22	0.08	1.246	1.066	1.457	0.006
Chronic renal dysfunction : No	reference	reference	reference	reference	reference	reference
Chronic renal dysfunction : Yes	0.35	0.187	1.419	0.983	2.048	0.063

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Index year : 2009	reference	reference	reference	reference	reference	reference
Index year : 2010	0.059	0.087	1.061	0.894	1.258	0.494
Index year : 2011	-0.142	0.104	0.867	0.707	1.064	0.171
Index year : 2012	-0.391	0.158	0.676	0.496	0.922	0.013

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Type of index MI : Non-ST elevation MI (and unspecified MI)	reference	reference	reference	reference	reference	reference
Type of index MI : ST elevation MI	-0.331	0.09	0.718	0.602	0.856	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
PCI or CABG related to index event : No	reference	reference	reference	reference	reference	reference
PCI or CABG related to index event : Yes	-0.529	0.104	0.589	0.48	0.723	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Unstable angina pectoris : No	reference	reference	reference	reference	reference	reference
Unstable angina pectoris : Yes	0.25	0.131	1.284	0.993	1.661	0.059

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
COPD : No	reference	reference	reference	reference	reference	reference
COPD : Yes	0.35	0.152	1.42	1.054	1.913	0.026

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Cancer : No	reference	reference	reference	reference	reference	reference
Cancer : Yes	0.248	0.116	1.281	1.02	1.609	0.033

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Diabetes mellitus : No	reference	reference	reference	reference	reference	reference
Diabetes mellitus : Yes	0.37	0.137	1.448	1.107	1.895	0.007

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Dementia/Alzheimer's disease : No	reference	reference	reference	reference	reference	reference
Dementia/Alzheimer's disease : Yes	-0.337	0.132	0.714	0.551	0.925	0.011

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Heart failure : No	reference	reference	reference	reference	reference	reference
Heart failure : Yes	0.585	0.076	1.796	1.548	2.083	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Hypertension : No	reference	reference	reference	reference	reference	reference
Hypertension : Yes	0.986	0.356	2.681	1.333	5.389	0.005

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Insulin : No	reference	reference	reference	reference	reference	reference
Insulin : Yes	0.541	0.137	1.718	1.315	2.246	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
LMWH : No	reference	reference	reference	reference	reference	reference
LMWH : Yes	1.095	1.002	2.988	0.419	21.294	0.053

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Nitrate : No	reference	reference	reference	reference	reference	reference
Nitrate : Yes	0.528	0.077	1.696	1.46	1.971	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Oral antidiabetic : No	reference	reference	reference	reference	reference	reference
Oral antidiabetic : Yes	-0.358	0.139	0.699	0.532	0.919	0.011

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Proton pump inhibitor : No	reference	reference	reference	reference	reference	reference
Proton pump inhibitor : Yes	0.233	0.078	1.262	1.084	1.47	0.003

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Transient ischemic attack : No	reference	reference	reference	reference	reference	reference
Transient ischemic attack : Yes	0.298	0.176	1.347	0.954	1.904	0.092

Stroke (total)

Table 1.540: The effect of pre-defined and explored risk factors on the risk of Stroke (total) estimated using the Cox proportional hazards model in Group 5 . Table shows the hazard ratios (HRs) for several factors with the corresponding 95% CI and p-value. Only those explored risk factors that indicated 20% effect on the hazard of the outcome with $p \leq 0.15$ are presented. Variables are evaluated at 1 year baseline check, medication use variables refer to ongoing use and comorbidities were searched in a 5 years history period.

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Age at 1 year baseline check (years) : 50-64	reference	reference	reference	reference	reference	reference
Age at 1 year baseline check (years) : 65-69	0.792	0.357	2.207	1.097	4.443	0.027
Age at 1 year baseline check (years) : 70-74	0.973	0.341	2.646	1.356	5.162	0.004
Age at 1 year baseline check (years) : 75-79	1.257	0.328	3.516	1.849	6.684	<0.001
Age at 1 year baseline check (years) : 80-84	1.386	0.321	3.999	2.13	7.507	<0.001
Age at 1 year baseline check (years) : 85 and over	1.881	0.313	6.562	3.554	12.114	<0.001
Sex : Male	reference	reference	reference	reference	reference	reference
Sex : Female	-0.184	0.12	0.832	0.657	1.052	0.114
Diabetes with ongoing medication : No	reference	reference	reference	reference	reference	reference
Diabetes with ongoing medication : Yes	0.474	0.132	1.606	1.24	2.08	<0.001
≥ 1 MI in addition to index MI : No	reference	reference	reference	reference	reference	reference
≥ 1 MI in addition to index MI : Yes	0.471	0.194	1.602	1.095	2.343	0.014
Multivessel CAD : No	reference	reference	reference	reference	reference	reference
Multivessel CAD : Yes	0.358	0.126	1.43	1.118	1.829	0.004
Chronic renal dysfunction : No	reference	reference	reference	reference	reference	reference
Chronic renal dysfunction : Yes	0.145	0.34	1.156	0.594	2.249	0.674

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Index year : 2009	reference	reference	reference	reference	reference	reference
Index year : 2010	-0.198	0.144	0.82	0.618	1.088	0.17
Index year : 2011	-0.372	0.178	0.69	0.487	0.978	0.035
Index year : 2012	0.106	0.228	1.112	0.712	1.737	0.633

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
PCI or CABG related to index event : No	reference	reference	reference	reference	reference	reference
PCI or CABG related to index event : Yes	-0.494	0.162	0.61	0.444	0.839	0.003

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Atrial fibrillation : No	reference	reference	reference	reference	reference	reference
Atrial fibrillation : Yes	0.497	0.14	1.644	1.249	2.163	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Antithrombotic medication : No	reference	reference	reference	reference	reference	reference
Antithrombotic medication : Yes	0.509	0.228	1.663	1.064	2.599	0.028

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Arrhythmia : No	reference	reference	reference	reference	reference	reference
Arrhythmia : Yes	0.421	0.13	1.524	1.181	1.965	0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Diabetes mellitus : No	reference	reference	reference	reference	reference	reference
Diabetes mellitus : Yes	0.356	0.221	1.428	0.926	2.203	0.104

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Fibrate : No	reference	reference	reference	reference	reference	reference
Fibrate : Yes	1.634	0.712	5.125	1.269	20.696	0.015

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Heart failure : No	reference	reference	reference	reference	reference	reference
Heart failure : Yes	0.194	0.129	1.215	0.944	1.564	0.136

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Insulin : No	reference	reference	reference	reference	reference	reference
Insulin : Yes	0.441	0.227	1.554	0.995	2.426	0.054

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
LMWH : No	reference	reference	reference	reference	reference	reference
LMWH : Yes	2.177	1.006	8.817	1.228	63.319	0.062

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
NSAID : No	reference	reference	reference	reference	reference	reference
NSAID : Yes	-0.87	0.451	0.419	0.173	1.015	0.055

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Nitrate : No	reference	reference	reference	reference	reference	reference
Nitrate : Yes	0.203	0.12	1.225	0.968	1.552	0.09

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Proton pump inhibitor : No	reference	reference	reference	reference	reference	reference
Proton pump inhibitor : Yes	0.3	0.124	1.35	1.058	1.722	0.016

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
SSRI : No	reference	reference	reference	reference	reference	reference
SSRI : Yes	0.313	0.214	1.367	0.899	2.078	0.142

Cardiovascular mortality

Table 1.555: The effect of pre-defined and explored risk factors on the risk of Cardiovascular mortality estimated using the Cox proportional hazards model in Group 5 . Table shows the hazard ratios (HRs) for several factors with the corresponding 95% CI and p-value. Only those explored risk factors that indicated 20% effect on the hazard of the outcome with $p < 0.15$ are presented. Variables are evaluated at 1 year baseline check, medication use variables refer to ongoing use and comorbidities were searched in a 5 years history period.

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Age at 1 year baseline check (years) : 50-64	reference	reference	reference	reference	reference	reference
Age at 1 year baseline check (years) : 65-69	0.471	0.35	1.602	0.807	3.183	0.175
Age at 1 year baseline check (years) : 70-74	0.655	0.33	1.924	1.009	3.672	0.045
Age at 1 year baseline check (years) : 75-79	1.17	0.304	3.221	1.774	5.85	<0.001
Age at 1 year baseline check (years) : 80-84	1.717	0.288	5.565	3.162	9.795	<0.001
Age at 1 year baseline check (years) : 85 and over	2.348	0.282	10.464	6.021	18.186	<0.001
Sex : Male	reference	reference	reference	reference	reference	reference
Sex : Female	-0.005	0.098	0.995	0.821	1.206	0.961
Diabetes with ongoing medication : No	reference	reference	reference	reference	reference	reference
Diabetes with ongoing medication : Yes	0.693	0.102	1.999	1.636	2.442	<0.001
≥ 1 MI in addition to index MI : No	reference	reference	reference	reference	reference	reference
≥ 1 MI in addition to index MI : Yes	0.807	0.134	2.242	1.723	2.918	<0.001
Multivessel CAD : No	reference	reference	reference	reference	reference	reference
Multivessel CAD : Yes	0.325	0.101	1.384	1.134	1.688	0.001
Chronic renal dysfunction : No	reference	reference	reference	reference	reference	reference
Chronic renal dysfunction : Yes	0.636	0.211	1.889	1.249	2.856	0.004

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Index year : 2009	reference	reference	reference	reference	reference	reference
Index year : 2010	0.077	0.112	1.08	0.867	1.345	0.492
Index year : 2011	-0.219	0.139	0.803	0.612	1.054	0.112
Index year : 2012	-0.545	0.231	0.58	0.369	0.913	0.018

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Type of index MI : Non-ST elevation MI (and unspecified MI)	reference	reference	reference	reference	reference	reference
Type of index MI : ST elevation MI	-0.339	0.119	0.713	0.565	0.9	0.004

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
PCI or CABG related to index event : No	reference	reference	reference	reference	reference	reference

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
PCI or CABG related to index event : Yes	-0.833	0.161	0.435	0.317	0.596	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Atrial fibrillation : No	reference	reference	reference	reference	reference	reference
Atrial fibrillation : Yes	0.503	0.108	1.653	1.337	2.043	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Unstable angina pectoris : No	reference	reference	reference	reference	reference	reference
Unstable angina pectoris : Yes	0.438	0.155	1.55	1.144	2.1	0.004

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
ARB : No	reference	reference	reference	reference	reference	reference
ARB : Yes	-0.383	0.134	0.682	0.525	0.886	0.004

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Anticogulation medication : No	reference	reference	reference	reference	reference	reference
Anticogulation medication : Yes	1.024	0.306	2.786	1.529	5.077	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Antithrombotic medication : No	reference	reference	reference	reference	reference	reference
Antithrombotic medication : Yes	0.407	0.182	1.502	1.052	2.144	0.03

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Arrhythmia : No	reference	reference	reference	reference	reference	reference
Arrhythmia : Yes	0.486	0.101	1.626	1.335	1.98	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Diabetes mellitus : No	reference	reference	reference	reference	reference	reference
Diabetes mellitus : Yes	0.319	0.18	1.375	0.967	1.956	0.081

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Heart failure : No	reference	reference	reference	reference	reference	reference
Heart failure : Yes	0.824	0.096	2.28	1.888	2.754	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Hyperlipidemia : No	reference	reference	reference	reference	reference	reference
Hyperlipidemia : Yes	-0.32	0.105	0.726	0.591	0.893	0.003

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Insulin : No	reference	reference	reference	reference	reference	reference
Insulin : Yes	0.767	0.178	2.154	1.519	3.055	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Major bleedings : No	reference	reference	reference	reference	reference	reference
Major bleedings : Yes	0.352	0.158	1.421	1.042	1.939	0.03

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
NSAID : No	reference	reference	reference	reference	reference	reference
NSAID : Yes	-0.641	0.337	0.527	0.272	1.02	0.059

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Nitrate : No	reference	reference	reference	reference	reference	reference
Nitrate : Yes	0.409	0.099	1.505	1.238	1.828	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Oral antidiabetic : No	reference	reference	reference	reference	reference	reference
Oral antidiabetic : Yes	-0.659	0.173	0.517	0.369	0.725	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Proton pump inhibitor : No	reference	reference	reference	reference	reference	reference
Proton pump inhibitor : Yes	0.361	0.097	1.435	1.185	1.736	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
SSRI : No	reference	reference	reference	reference	reference	reference
SSRI : Yes	0.286	0.168	1.331	0.958	1.849	0.09

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Warfarin : No	reference	reference	reference	reference	reference	reference
Warfarin : Yes	1.032	0.321	2.808	1.497	5.266	<0.001

Composite end-point

Table 1.576: The effect of pre-defined and explored risk factors on the risk of Composite end-point estimated using the Cox proportional hazards model in Group 5 . Table shows the hazard ratios (HRs) for several factors with the corresponding 95% CI and p-value. Only those explored risk factors that indicated 20% effect on the hazard of the outcome with $p \leq 0.15$ are presented. Variables are evaluated at 1 year baseline check, medication use variables refer to ongoing use and comorbidities were searched in a 5 years history period.

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Age at 1 year baseline check (years) : 50-64	reference	reference	reference	reference	reference	reference
Age at 1 year baseline check (years) : 65-69	0.337	0.17	1.4	1.003	1.956	0.047
Age at 1 year baseline check (years) : 70-74	0.439	0.163	1.551	1.126	2.135	0.007
Age at 1 year baseline check (years) : 75-79	0.896	0.151	2.45	1.824	3.292	<0.001
Age at 1 year baseline check (years) : 80-84	1.186	0.144	3.274	2.468	4.341	<0.001
Age at 1 year baseline check (years) : 85 and over	1.607	0.14	4.989	3.79	6.567	<0.001
Sex : Male	reference	reference	reference	reference	reference	reference
Sex : Female	-0.089	0.06	0.915	0.813	1.029	0.137
Diabetes with ongoing medication : No	reference	reference	reference	reference	reference	reference
Diabetes with ongoing medication : Yes	0.555	0.065	1.743	1.535	1.979	<0.001
≥ 1 MI in addition to index MI : No	reference	reference	reference	reference	reference	reference
≥ 1 MI in addition to index MI : Yes	0.672	0.092	1.958	1.636	2.343	<0.001
Multivessel CAD : No	reference	reference	reference	reference	reference	reference
Multivessel CAD : Yes	0.255	0.064	1.29	1.139	1.462	<0.001
Chronic renal dysfunction : No	reference	reference	reference	reference	reference	reference
Chronic renal dysfunction : Yes	0.384	0.148	1.468	1.098	1.962	0.011

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Index year : 2009	reference	reference	reference	reference	reference	reference
Index year : 2010	-0.047	0.071	0.954	0.831	1.096	0.504
Index year : 2011	-0.207	0.084	0.813	0.69	0.958	0.013
Index year : 2012	-0.316	0.123	0.729	0.573	0.928	0.01

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Type of index MI : Non-ST elevation MI (and unspecified MI)	reference	reference	reference	reference	reference	reference
Type of index MI : ST elevation MI	-0.236	0.07	0.789	0.688	0.906	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
PCI or CABG related to index event : No	reference	reference	reference	reference	reference	reference

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
PCI or CABG related to index event : Yes	-0.538	0.084	0.584	0.495	0.688	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Atrial fibrillation : No	reference	reference	reference	reference	reference	reference
Atrial fibrillation : Yes	0.319	0.073	1.376	1.193	1.587	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Unstable angina pectoris : No	reference	reference	reference	reference	reference	reference
Unstable angina pectoris : Yes	0.314	0.103	1.369	1.12	1.674	0.002

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Antithrombotic medication : No	reference	reference	reference	reference	reference	reference
Antithrombotic medication : Yes	0.311	0.123	1.365	1.073	1.737	0.011

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Arrhythmia : No	reference	reference	reference	reference	reference	reference
Arrhythmia : Yes	0.303	0.066	1.354	1.189	1.541	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
COPD : No	reference	reference	reference	reference	reference	reference
COPD : Yes	0.338	0.123	1.402	1.102	1.784	0.007

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Diabetes mellitus : No	reference	reference	reference	reference	reference	reference
Diabetes mellitus : Yes	0.368	0.11	1.445	1.165	1.793	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Heart failure : No	reference	reference	reference	reference	reference	reference
Heart failure : Yes	0.548	0.061	1.73	1.534	1.95	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Hypertension : No	reference	reference	reference	reference	reference	reference
Hypertension : Yes	0.681	0.245	1.975	1.222	3.193	0.006

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Insulin : No	reference	reference	reference	reference	reference	reference
Insulin : Yes	0.614	0.112	1.847	1.483	2.301	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
LMWH : No	reference	reference	reference	reference	reference	reference
LMWH : Yes	1.392	0.709	4.024	1.003	16.15	0.014

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Major bleedings : No	reference	reference	reference	reference	reference	reference
Major bleedings : Yes	0.293	0.104	1.341	1.093	1.645	0.007

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Nitrate : No	reference	reference	reference	reference	reference	reference
Nitrate : Yes	0.396	0.061	1.486	1.319	1.674	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Oral antidiabetic : No	reference	reference	reference	reference	reference	reference
Oral antidiabetic : Yes	-0.427	0.113	0.652	0.523	0.813	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Proton pump inhibitor : No	reference	reference	reference	reference	reference	reference
Proton pump inhibitor : Yes	0.283	0.062	1.327	1.176	1.498	<0.001

Overall mortality

Table 1.594: The effect of pre-defined and explored risk factors on the risk of Overall mortality estimated using the Cox proportional hazards model in Group 5 . Table shows the hazard ratios (HRs) for several factors with the corresponding 95% CI and p-value. Only those explored risk factors that indicated 20% effect on the hazard of the outcome with $p \leq 0.15$ are presented. Variables are evaluated at 1 year baseline check, medication use variables refer to ongoing use and comorbidities were searched in a 5 years history period.

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Age at 1 year baseline check (years) : 50-64	reference	reference	reference	reference	reference	reference
Age at 1 year baseline check (years) : 65-69	0.614	0.182	1.849	1.293	2.643	<0.001
Age at 1 year baseline check (years) : 70-74	0.943	0.171	2.567	1.837	3.587	<0.001
Age at 1 year baseline check (years) : 75-79	1.537	0.16	4.651	3.401	6.362	<0.001
Age at 1 year baseline check (years) : 80-84	1.897	0.155	6.665	4.915	9.039	<0.001
Age at 1 year baseline check (years) : 85 and over	2.565	0.152	12.999	9.642	17.525	<0.001
Sex : Male	reference	reference	reference	reference	reference	reference
Sex : Female	-0.199	0.046	0.82	0.749	0.897	<0.001
Diabetes with ongoing medication : No	reference	reference	reference	reference	reference	reference
Diabetes with ongoing medication : Yes	0.24	0.055	1.272	1.143	1.415	<0.001
≥ 1 MI in addition to index MI : No	reference	reference	reference	reference	reference	reference
≥ 1 MI in addition to index MI : Yes	0.364	0.076	1.439	1.239	1.672	<0.001
Multivessel CAD : No	reference	reference	reference	reference	reference	reference
Multivessel CAD : Yes	0.244	0.05	1.277	1.158	1.407	<0.001
Chronic renal dysfunction : No	reference	reference	reference	reference	reference	reference
Chronic renal dysfunction : Yes	0.704	0.101	2.022	1.658	2.466	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Type of index MI : Non-ST elevation MI (and unspecified MI)	reference	reference	reference	reference	reference	reference
Type of index MI : ST elevation MI	-0.335	0.056	0.715	0.64	0.799	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
PCI or CABG related to index event : No	reference	reference	reference	reference	reference	reference
PCI or CABG related to index event : Yes	-0.921	0.077	0.398	0.342	0.464	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Atrial fibrillation : No	reference	reference	reference	reference	reference	reference
Atrial fibrillation : Yes	0.464	0.053	1.59	1.435	1.763	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
ARB : No	reference	reference	reference	reference	reference	reference
ARB : Yes	-0.43	0.066	0.65	0.571	0.74	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
ACE inhibitor : No	reference	reference	reference	reference	reference	reference
ACE inhibitor : Yes	-0.229	0.049	0.796	0.723	0.876	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Anticogulation medication : No	reference	reference	reference	reference	reference	reference
Anticogulation medication : Yes	0.524	0.187	1.689	1.17	2.437	0.005

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Arrhythmia : No	reference	reference	reference	reference	reference	reference
Arrhythmia : Yes	0.414	0.049	1.512	1.374	1.664	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Beta-blocker : No	reference	reference	reference	reference	reference	reference
Beta-blocker : Yes	-0.303	0.046	0.738	0.675	0.808	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Calcium channel blocker : No	reference	reference	reference	reference	reference	reference
Calcium channel blocker : Yes	-0.283	0.06	0.754	0.67	0.848	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
COPD : No	reference	reference	reference	reference	reference	reference
COPD : Yes	0.685	0.082	1.983	1.687	2.331	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Cancer : No	reference	reference	reference	reference	reference	reference
Cancer : Yes	0.551	0.063	1.734	1.532	1.964	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Diabetes mellitus : No	reference	reference	reference	reference	reference	reference
Diabetes mellitus : Yes	0.513	0.076	1.671	1.44	1.939	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Dementia/Alzheimer's disease : No	reference	reference	reference	reference	reference	reference
Dementia/Alzheimer's disease : Yes	0.571	0.058	1.771	1.58	1.984	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Heart failure : No	reference	reference	reference	reference	reference	reference
Heart failure : Yes	0.766	0.046	2.151	1.965	2.354	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Hyperlipidemia : No	reference	reference	reference	reference	reference	reference
Hyperlipidemia : Yes	-0.494	0.049	0.61	0.554	0.671	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Insulin : No	reference	reference	reference	reference	reference	reference
Insulin : Yes	0.549	0.098	1.732	1.429	2.099	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
LMWH : No	reference	reference	reference	reference	reference	reference
LMWH : Yes	1.423	0.579	4.152	1.336	12.905	0.04

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Major bleedings : No	reference	reference	reference	reference	reference	reference
Major bleedings : Yes	0.411	0.075	1.508	1.303	1.746	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
NSAID : No	reference	reference	reference	reference	reference	reference
NSAID : Yes	-0.261	0.134	0.77	0.592	1.002	0.051

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Oral antidiabetic : No	reference	reference	reference	reference	reference	reference
Oral antidiabetic : Yes	-0.561	0.098	0.57	0.471	0.691	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Other stroke (not sub-classified) : No	reference	reference	reference	reference	reference	reference
Other stroke (not sub-classified) : Yes	2.629	1.002	13.857	1.945	98.716	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Proton pump inhibitor : No	reference	reference	reference	reference	reference	reference
Proton pump inhibitor : Yes	0.243	0.048	1.275	1.162	1.4	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Statin : No	reference	reference	reference	reference	reference	reference
Statin : Yes	-0.488	0.046	0.614	0.561	0.672	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Stroke (Total) : No	reference	reference	reference	reference	reference	reference
Stroke (Total) : Yes	2.629	1.002	13.857	1.945	98.716	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Warfarin : No	reference	reference	reference	reference	reference	reference
Warfarin : Yes	0.477	0.202	1.611	1.085	2.391	0.015

1.3.6 Explored risk factors for group 1 (first year only)

Myocardial infarction

Table 1.620: The effect of pre-defined and explored risk factors on the risk of Myocardial infarction estimated using the Cox proportional hazards model in Group 1 . Table shows the hazard ratios (HRs) for several factors with the corresponding 95% CI and p-value. Only those explored risk factors that indicated 20% effect on the hazard of the outcome with $p < 0.15$ are presented. Variables are evaluated at index date, medication use variables refer to ongoing use and comorbidities were searched in a 5 years history period.

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Age at index (years) : 18-49	reference	reference	reference	reference	reference	reference
Age at index (years) : 50-64	0.071	0.096	1.074	0.889	1.297	0.461
Age at index (years) : 65-69	0.394	0.102	1.482	1.214	1.809	<0.001
Age at index (years) : 70-74	0.407	0.1	1.502	1.235	1.826	<0.001
Age at index (years) : 75-79	0.706	0.096	2.026	1.678	2.445	<0.001
Age at index (years) : 80-84	0.935	0.094	2.547	2.116	3.065	<0.001
Age at index (years) : 85 and over	1.199	0.093	3.317	2.763	3.983	<0.001
Sex : Male	reference	reference	reference	reference	reference	reference
Sex : Female	-0.071	0.032	0.932	0.875	0.992	0.028
Diabetes with ongoing medication : No	reference	reference	reference	reference	reference	reference
Diabetes with ongoing medication : Yes	0.399	0.034	1.49	1.394	1.593	<0.001
≥ 1 MI in addition to index MI : No	reference	reference	reference	reference	reference	reference
≥ 1 MI in addition to index MI : Yes	0.591	0.046	1.806	1.651	1.976	<0.001
Multivessel CAD : No	reference	reference	reference	reference	reference	reference
Multivessel CAD : Yes	0.061	0.035	1.063	0.993	1.139	0.076
Chronic renal dysfunction : No	reference	reference	reference	reference	reference	reference
Chronic renal dysfunction : Yes	0.651	0.071	1.917	1.669	2.203	<0.001
Ischaemic stroke : No	reference	reference	reference	reference	reference	reference
Ischaemic stroke : Yes	0.085	0.056	1.089	0.975	1.215	0.13

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Antithrombotic medication : No	reference	reference	reference	reference	reference	reference
Antithrombotic medication : Yes	0.227	0.035	1.254	1.171	1.343	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Beta-blocker : No	reference	reference	reference	reference	reference	reference
Beta-blocker : Yes	0.241	0.032	1.273	1.196	1.354	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
CABG : No	reference	reference	reference	reference	reference	reference
CABG : Yes	-0.626	0.078	0.535	0.459	0.623	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Calcium channel blocker : No	reference	reference	reference	reference	reference	reference
Calcium channel blocker : Yes	0.226	0.035	1.253	1.169	1.343	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Diabetes mellitus : No	reference	reference	reference	reference	reference	reference
Diabetes mellitus : Yes	0.211	0.058	1.235	1.103	1.384	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Heart failure : No	reference	reference	reference	reference	reference	reference
Heart failure : Yes	0.347	0.034	1.415	1.323	1.514	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Insulin : No	reference	reference	reference	reference	reference	reference
Insulin : Yes	0.428	0.058	1.535	1.369	1.72	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Major bleedings : No	reference	reference	reference	reference	reference	reference
Major bleedings : Yes	0.226	0.056	1.254	1.124	1.399	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Nitrate : No	reference	reference	reference	reference	reference	reference
Nitrate : Yes	0.41	0.033	1.506	1.412	1.607	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
OAP use (Total) : No	reference	reference	reference	reference	reference	reference
OAP use (Total) : Yes	0.284	0.062	1.329	1.177	1.499	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Oral antidiabetic : No	reference	reference	reference	reference	reference	reference
Oral antidiabetic : Yes	-0.354	0.059	0.702	0.625	0.788	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Proton pump inhibitor : No	reference	reference	reference	reference	reference	reference
Proton pump inhibitor : Yes	0.269	0.036	1.309	1.219	1.406	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Severe renal failure requiring dialysis : No	reference	reference	reference	reference	reference	reference
Severe renal failure requiring dialysis : Yes	0.395	0.195	1.485	1.013	2.175	0.034

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Transient ischemic attack : No	reference	reference	reference	reference	reference	reference
Transient ischemic attack : Yes	0.189	0.074	1.208	1.045	1.396	0.011

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Invasive procedure related to index event : No invasive procedure	reference	reference	reference	reference	reference	reference
Invasive procedure related to index event : Coronary angiography only	-0.247	0.05	0.781	0.709	0.862	<0.001
Invasive procedure related to index event : PCI	-0.501	0.041	0.606	0.559	0.657	<0.001
Invasive procedure related to index event : CABG	-0.939	0.093	0.391	0.326	0.47	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Gastrointestinal bleeding : No	reference	reference	reference	reference	reference	reference
Gastrointestinal bleeding : Yes	0.435	0.118	1.545	1.226	1.948	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
PCI or CABG related to index event : No	reference	reference	reference	reference	reference	reference
PCI or CABG related to index event : Yes	-0.485	0.037	0.615	0.572	0.662	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Increased bleeding risk (Total) : No	reference	reference	reference	reference	reference	reference
Increased bleeding risk (Total) : Yes	0.192	0.081	1.212	1.034	1.42	0.018

Stroke (total)

Table 1.639: The effect of pre-defined and explored risk factors on the risk of Stroke (total) estimated using the Cox proportional hazards model in Group 1 . Table shows the hazard ratios (HRs) for several factors with the corresponding 95% CI and p-value. Only those explored risk factors that indicated 20% effect on the hazard of the outcome with $p < 0.15$ are presented. Variables are evaluated at index date, medication use variables refer to ongoing use and comorbidities were searched in a 5 years history period.

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Age at index (years) : 18-49	reference	reference	reference	reference	reference	reference
Age at index (years) : 50-64	0.535	0.266	1.708	1.015	2.874	0.043
Age at index (years) : 65-69	1.099	0.269	3.002	1.772	5.089	<0.001
Age at index (years) : 70-74	0.926	0.269	2.523	1.491	4.272	<0.001
Age at index (years) : 75-79	1.269	0.262	3.559	2.129	5.95	<0.001
Age at index (years) : 80-84	1.474	0.26	4.366	2.621	7.271	<0.001
Age at index (years) : 85 and over	1.545	0.26	4.69	2.819	7.803	<0.001
Sex : Male	reference	reference	reference	reference	reference	reference
Sex : Female	-0.041	0.065	0.959	0.845	1.09	0.522
Diabetes with ongoing medication : No	reference	reference	reference	reference	reference	reference
Diabetes with ongoing medication : Yes	0.181	0.072	1.198	1.04	1.38	0.013
≥ 1 MI in addition to index MI : No	reference	reference	reference	reference	reference	reference
≥ 1 MI in addition to index MI : Yes	0.251	0.103	1.286	1.05	1.575	0.016
Multivessel CAD : No	reference	reference	reference	reference	reference	reference
Multivessel CAD : Yes	-0.143	0.075	0.866	0.748	1.004	0.058
Chronic renal dysfunction : No	reference	reference	reference	reference	reference	reference
Chronic renal dysfunction : Yes	0.468	0.156	1.596	1.175	2.169	0.004
Ischaemic stroke : No	reference	reference	reference	reference	reference	reference
Ischaemic stroke : Yes	1.893	0.067	6.639	5.822	7.571	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Atrial fibrillation : No	reference	reference	reference	reference	reference	reference
Atrial fibrillation : Yes	0.346	0.072	1.414	1.228	1.627	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Arrhythmia : No	reference	reference	reference	reference	reference	reference
Arrhythmia : Yes	0.325	0.068	1.384	1.212	1.58	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Dementia/Alzheimer's disease : No	reference	reference	reference	reference	reference	reference
Dementia/Alzheimer's disease : Yes	0.199	0.114	1.22	0.975	1.526	0.087

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Haemorrhagic stroke : No	reference	reference	reference	reference	reference	reference
Haemorrhagic stroke : Yes	1.043	0.2	2.838	1.918	4.199	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Insulin : No	reference	reference	reference	reference	reference	reference
Insulin : Yes	0.239	0.125	1.27	0.993	1.624	0.057

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Intracranial bleeding : No	reference	reference	reference	reference	reference	reference
Intracranial bleeding : Yes	0.606	0.171	1.834	1.312	2.563	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
LMWH : No	reference	reference	reference	reference	reference	reference
LMWH : Yes	0.996	0.304	2.707	1.492	4.912	0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
NOAC : No	reference	reference	reference	reference	reference	reference
NOAC : Yes	1.368	1.001	3.928	0.552	27.94	0.143

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Proton pump inhibitor : No	reference	reference	reference	reference	reference	reference
Proton pump inhibitor : Yes	0.21	0.074	1.234	1.068	1.427	0.005

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
SSRI : No	reference	reference	reference	reference	reference	reference
SSRI : Yes	0.318	0.119	1.374	1.088	1.735	0.009

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Stroke (Total) : No	reference	reference	reference	reference	reference	reference
Stroke (Total) : Yes	1.636	0.227	5.135	3.29	8.014	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Severe liver disease : No	reference	reference	reference	reference	reference	reference
Severe liver disease : Yes	0.745	0.41	2.107	0.943	4.708	0.066

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Transient ischemic attack : No	reference	reference	reference	reference	reference	reference
Transient ischemic attack : Yes	0.245	0.124	1.277	1.001	1.63	0.058

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Index year : 2009	reference	reference	reference	reference	reference	reference
Index year : 2010	-0.23	0.085	0.795	0.673	0.939	0.007
Index year : 2011	-0.259	0.086	0.772	0.652	0.914	0.003
Index year : 2012	-0.14	0.085	0.869	0.736	1.027	0.1

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Invasive procedure related to index event : No invasive procedure	reference	reference	reference	reference	reference	reference
Invasive procedure related to index event : Coronary angiography only	-0.248	0.102	0.781	0.639	0.953	0.015
Invasive procedure related to index event : PCI	-0.704	0.091	0.495	0.414	0.591	<0.001
Invasive procedure related to index event : CABG	-0.401	0.152	0.669	0.497	0.902	0.009

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
PCI or CABG related to index event : No	reference	reference	reference	reference	reference	reference
PCI or CABG related to index event : Yes	-0.579	0.08	0.56	0.479	0.656	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Increased bleeding risk (Total) : No	reference	reference	reference	reference	reference	reference
Increased bleeding risk (Total) : Yes	0.384	0.133	1.468	1.131	1.906	0.006

Cardiovascular mortality

Table 1.657: The effect of pre-defined and explored risk factors on the risk of Cardiovascular mortality estimated using the Cox proportional hazards model in Group 1 . Table shows the hazard ratios (HRs) for several factors with the corresponding 95% CI and p-value. Only those explored risk factors that indicated 20% effect on the hazard of the outcome with $p < 0.15$ are presented. Variables are evaluated at index date, medication use variables refer to ongoing use and comorbidities were searched in a 5 years history period.

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Age at index (years) : 18-49	reference	reference	reference	reference	reference	reference
Age at index (years) : 50-64	0.944	0.426	2.571	1.116	5.924	0.027
Age at index (years) : 65-69	1.651	0.428	5.21	2.252	12.055	<0.001
Age at index (years) : 70-74	1.953	0.421	7.047	3.088	16.081	<0.001
Age at index (years) : 75-79	2.531	0.415	12.566	5.572	28.339	<0.001
Age at index (years) : 80-84	2.983	0.413	19.755	8.797	44.36	<0.001
Age at index (years) : 85 and over	3.624	0.411	37.49	16.746	83.929	<0.001
Sex : Male	reference	reference	reference	reference	reference	reference
Sex : Female	-0.158	0.056	0.854	0.766	0.952	0.004
Diabetes with ongoing medication : No	reference	reference	reference	reference	reference	reference
Diabetes with ongoing medication : Yes	0.422	0.06	1.525	1.356	1.715	<0.001
≥ 1 MI in addition to index MI : No	reference	reference	reference	reference	reference	reference
≥ 1 MI in addition to index MI : Yes	0.487	0.078	1.628	1.396	1.897	<0.001
Multivessel CAD : No	reference	reference	reference	reference	reference	reference
Multivessel CAD : Yes	0.074	0.062	1.077	0.954	1.216	0.232
Chronic renal dysfunction : No	reference	reference	reference	reference	reference	reference
Chronic renal dysfunction : Yes	0.667	0.12	1.948	1.54	2.466	<0.001
Ischaemic stroke : No	reference	reference	reference	reference	reference	reference
Ischaemic stroke : Yes	0.406	0.084	1.5	1.274	1.767	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Atrial fibrillation : No	reference	reference	reference	reference	reference	reference
Atrial fibrillation : Yes	0.24	0.062	1.272	1.127	1.435	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Arrhythmia : No	reference	reference	reference	reference	reference	reference
Arrhythmia : Yes	0.229	0.058	1.257	1.121	1.409	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Beta-blocker : No	reference	reference	reference	reference	reference	reference
Beta-blocker : Yes	0.226	0.056	1.253	1.124	1.398	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
CABG : No	reference	reference	reference	reference	reference	reference
CABG : Yes	-1.134	0.204	0.322	0.216	0.479	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
COPD : No	reference	reference	reference	reference	reference	reference
COPD : Yes	0.466	0.114	1.594	1.274	1.995	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Diabetes mellitus : No	reference	reference	reference	reference	reference	reference
Diabetes mellitus : Yes	0.44	0.093	1.552	1.294	1.862	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Dementia/Alzheimer's disease : No	reference	reference	reference	reference	reference	reference
Dementia/Alzheimer's disease : Yes	0.452	0.082	1.572	1.338	1.847	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Heart failure : No	reference	reference	reference	reference	reference	reference
Heart failure : Yes	0.727	0.056	2.069	1.853	2.311	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Hyperlipidemia : No	reference	reference	reference	reference	reference	reference
Hyperlipidemia : Yes	-0.351	0.058	0.704	0.628	0.789	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Hypertension : No	reference	reference	reference	reference	reference	reference
Hypertension : Yes	0.278	0.131	1.321	1.022	1.708	0.034

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Insulin : No	reference	reference	reference	reference	reference	reference
Insulin : Yes	0.624	0.103	1.866	1.525	2.285	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Nitrate : No	reference	reference	reference	reference	reference	reference
Nitrate : Yes	0.231	0.057	1.259	1.126	1.409	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
OAP use (Total) : No	reference	reference	reference	reference	reference	reference
OAP use (Total) : Yes	0.197	0.11	1.217	0.981	1.511	0.084

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Oral antidiabetic : No	reference	reference	reference	reference	reference	reference
Oral antidiabetic : Yes	-0.55	0.102	0.577	0.473	0.704	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Other acute ischaemic heart diseases : No	reference	reference	reference	reference	reference	reference
Other acute ischaemic heart diseases : Yes	0.713	0.252	2.04	1.245	3.342	0.004

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
SSRI : No	reference	reference	reference	reference	reference	reference
SSRI : Yes	0.261	0.108	1.298	1.05	1.605	0.016

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Invasive procedure related to index event : No invasive procedure	reference	reference	reference	reference	reference	reference
Invasive procedure related to index event : Coronary angiography only	-0.6	0.103	0.549	0.449	0.671	<0.001
Invasive procedure related to index event : PCI	-1.235	0.096	0.291	0.241	0.351	<0.001
Invasive procedure related to index event : CABG	-1.795	0.263	0.166	0.099	0.278	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Type of index MI : Non-ST elevation MI (and unspecified MI)	reference	reference	reference	reference	reference	reference
Type of index MI : ST elevation MI	-0.433	0.071	0.649	0.564	0.746	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Gastrointestinal bleeding : No	reference	reference	reference	reference	reference	reference
Gastrointestinal bleeding : Yes	0.609	0.182	1.839	1.288	2.627	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
PCI or CABG related to index event : No	reference	reference	reference	reference	reference	reference
PCI or CABG related to index event : Yes	-1.172	0.09	0.31	0.26	0.369	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Increased bleeding risk (Total) : No	reference	reference	reference	reference	reference	reference
Increased bleeding risk (Total) : Yes	0.282	0.13	1.325	1.028	1.708	0.031

Composite end-point

Table 1.679: The effect of pre-defined and explored risk factors on the risk of Composite end-point estimated using the Cox proportional hazards model in Group 1 . Table shows the hazard ratios (HRs) for several factors with the corresponding 95% CI and p-value. Only those explored risk factors that indicated 20% effect on the hazard of the outcome with $p < 0.15$ are presented. Variables are evaluated at index date, medication use variables refer to ongoing use and comorbidities were searched in a 5 years history period.

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Age at index (years) : 18-49	reference	reference	reference	reference	reference	reference
Age at index (years) : 50-64	0.134	0.09	1.144	0.959	1.363	0.137
Age at index (years) : 65-69	0.505	0.094	1.658	1.379	1.993	<0.001
Age at index (years) : 70-74	0.513	0.092	1.67	1.394	2.001	<0.001
Age at index (years) : 75-79	0.825	0.089	2.282	1.916	2.718	<0.001
Age at index (years) : 80-84	1.082	0.088	2.95	2.484	3.504	<0.001
Age at index (years) : 85 and over	1.36	0.087	3.897	3.288	4.619	<0.001
Sex : Male	reference	reference	reference	reference	reference	reference
Sex : Female	-0.092	0.028	0.912	0.863	0.964	0.001
Diabetes with ongoing medication : No	reference	reference	reference	reference	reference	reference
Diabetes with ongoing medication : Yes	0.358	0.03	1.431	1.349	1.518	<0.001
≥ 1 MI in addition to index MI : No	reference	reference	reference	reference	reference	reference
≥ 1 MI in addition to index MI : Yes	0.534	0.041	1.706	1.574	1.849	<0.001
Multivessel CAD : No	reference	reference	reference	reference	reference	reference
Multivessel CAD : Yes	0.048	0.031	1.049	0.988	1.115	0.115
Chronic renal dysfunction : No	reference	reference	reference	reference	reference	reference
Chronic renal dysfunction : Yes	0.55	0.065	1.734	1.525	1.97	<0.001
Ischaemic stroke : No	reference	reference	reference	reference	reference	reference
Ischaemic stroke : Yes	0.542	0.042	1.719	1.584	1.866	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Antithrombotic medication : No	reference	reference	reference	reference	reference	reference
Antithrombotic medication : Yes	0.2	0.031	1.221	1.15	1.297	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Beta-blocker : No	reference	reference	reference	reference	reference	reference
Beta-blocker : Yes	0.211	0.028	1.235	1.17	1.304	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
CABG : No	reference	reference	reference	reference	reference	reference
CABG : Yes	-0.539	0.067	0.583	0.512	0.665	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Diabetes mellitus : No	reference	reference	reference	reference	reference	reference
Diabetes mellitus : Yes	0.228	0.05	1.256	1.139	1.386	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Haemorrhagic stroke : No	reference	reference	reference	reference	reference	reference
Haemorrhagic stroke : Yes	0.343	0.136	1.41	1.08	1.84	0.011

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Heart failure : No	reference	reference	reference	reference	reference	reference
Heart failure : Yes	0.358	0.03	1.43	1.349	1.517	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Insulin : No	reference	reference	reference	reference	reference	reference
Insulin : Yes	0.417	0.052	1.517	1.371	1.68	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Major bleedings : No	reference	reference	reference	reference	reference	reference
Major bleedings : Yes	0.197	0.049	1.218	1.106	1.342	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Nitrate : No	reference	reference	reference	reference	reference	reference
Nitrate : Yes	0.3	0.029	1.35	1.275	1.429	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
OAP use (Total) : No	reference	reference	reference	reference	reference	reference
OAP use (Total) : Yes	0.226	0.055	1.254	1.125	1.397	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Oral antidiabetic : No	reference	reference	reference	reference	reference	reference
Oral antidiabetic : Yes	-0.344	0.053	0.709	0.639	0.786	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Other acute ischaemic heart diseases : No	reference	reference	reference	reference	reference	reference
Other acute ischaemic heart diseases : Yes	0.245	0.165	1.277	0.924	1.765	0.109

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Proton pump inhibitor : No	reference	reference	reference	reference	reference	reference
Proton pump inhibitor : Yes	0.236	0.032	1.266	1.189	1.348	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Stroke (Total) : No	reference	reference	reference	reference	reference	reference
Stroke (Total) : Yes	0.449	0.15	1.566	1.168	2.101	0.003

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Severe liver disease : No	reference	reference	reference	reference	reference	reference
Severe liver disease : Yes	0.379	0.209	1.461	0.97	2.202	0.068

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Severe renal failure requiring dialysis : No	reference	reference	reference	reference	reference	reference
Severe renal failure requiring dialysis : Yes	0.516	0.177	1.676	1.185	2.369	0.003

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Transient ischemic attack : No	reference	reference	reference	reference	reference	reference
Transient ischemic attack : Yes	0.199	0.063	1.22	1.079	1.38	0.002

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Invasive procedure related to index event : No invasive procedure	reference	reference	reference	reference	reference	reference
Invasive procedure related to index event : Coronary angiography only	-0.279	0.044	0.756	0.694	0.825	<0.001
Invasive procedure related to index event : PCI	-0.589	0.037	0.555	0.516	0.596	<0.001
Invasive procedure related to index event : CABG	-0.877	0.079	0.416	0.356	0.486	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Gastrointestinal bleeding : No	reference	reference	reference	reference	reference	reference
Gastrointestinal bleeding : Yes	0.4	0.105	1.492	1.215	1.832	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
PCI or CABG related to index event : No	reference	reference	reference	reference	reference	reference
PCI or CABG related to index event : Yes	-0.549	0.033	0.578	0.541	0.617	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Increased bleeding risk (Total) : No	reference	reference	reference	reference	reference	reference
Increased bleeding risk (Total) : Yes	0.233	0.068	1.262	1.104	1.443	<0.001

Overall mortality

Table 1.701: The effect of pre-defined and explored risk factors on the risk of Overall mortality estimated using the Cox proportional hazards model in Group 1 . Table shows the hazard ratios (HRs) for several factors with the corresponding 95% CI and p-value. Only those explored risk factors that indicated 20% effect on the hazard of the outcome with $p \leq 0.15$ are presented. Variables are evaluated at index date, medication use variables refer to ongoing use and comorbidities were searched in a 5 years history period.

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Age at index (years) : 18-49	reference	reference	reference	reference	reference	reference
Age at index (years) : 50-64	1.031	0.208	2.803	1.865	4.215	<0.001
Age at index (years) : 65-69	1.527	0.211	4.606	3.044	6.968	<0.001
Age at index (years) : 70-74	1.818	0.207	6.157	4.101	9.245	<0.001
Age at index (years) : 75-79	2.315	0.204	10.129	6.787	15.115	<0.001
Age at index (years) : 80-84	2.731	0.203	15.347	10.311	22.844	<0.001
Age at index (years) : 85 and over	3.265	0.202	26.179	17.618	38.9	<0.001
Sex : Male	reference	reference	reference	reference	reference	reference
Sex : Female	-0.143	0.032	0.867	0.815	0.923	<0.001
Diabetes with ongoing medication : No	reference	reference	reference	reference	reference	reference
Diabetes with ongoing medication : Yes	0.187	0.036	1.206	1.124	1.294	<0.001
≥ 1 MI in addition to index MI : No	reference	reference	reference	reference	reference	reference
≥ 1 MI in addition to index MI : Yes	0.426	0.046	1.532	1.398	1.677	<0.001
Multivessel CAD : No	reference	reference	reference	reference	reference	reference
Multivessel CAD : Yes	0.049	0.035	1.05	0.98	1.126	0.168
Chronic renal dysfunction : No	reference	reference	reference	reference	reference	reference
Chronic renal dysfunction : Yes	0.846	0.065	2.33	2.052	2.645	<0.001
Ischaemic stroke : No	reference	reference	reference	reference	reference	reference
Ischaemic stroke : Yes	0.364	0.049	1.44	1.308	1.584	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Atrial fibrillation : No	reference	reference	reference	reference	reference	reference
Atrial fibrillation : Yes	0.304	0.035	1.356	1.266	1.452	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Unstable angina pectoris : No	reference	reference	reference	reference	reference	reference
Unstable angina pectoris : Yes	-0.239	0.06	0.788	0.701	0.885	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
ARB : No	reference	reference	reference	reference	reference	reference
ARB : Yes	-0.226	0.043	0.798	0.734	0.867	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Anticoagulation medication : No	reference	reference	reference	reference	reference	reference
Anticoagulation medication : Yes	0.208	0.045	1.232	1.127	1.346	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Arrhythmia : No	reference	reference	reference	reference	reference	reference
Arrhythmia : Yes	0.297	0.033	1.346	1.262	1.437	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
CABG : No	reference	reference	reference	reference	reference	reference
CABG : Yes	-0.848	0.098	0.428	0.353	0.519	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
COPD : No	reference	reference	reference	reference	reference	reference
COPD : Yes	0.796	0.057	2.217	1.984	2.477	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Cancer : No	reference	reference	reference	reference	reference	reference
Cancer : Yes	0.731	0.042	2.077	1.913	2.256	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Chronic use of anticoagulation medication : No	reference	reference	reference	reference	reference	reference
Chronic use of anticoagulation medication : Yes	0.214	0.047	1.239	1.131	1.357	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Central nervous tumour : No	reference	reference	reference	reference	reference	reference
Central nervous tumour : Yes	1.173	0.354	3.231	1.613	6.472	0.002

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Diabetes mellitus : No	reference	reference	reference	reference	reference	reference
Diabetes mellitus : Yes	0.498	0.05	1.646	1.491	1.817	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Dementia/Alzheimer's disease : No	reference	reference	reference	reference	reference	reference

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Dementia/Alzheimer's disease : Yes	0.543	0.046	1.721	1.571	1.885	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Heart failure : No	reference	reference	reference	reference	reference	reference
Heart failure : Yes	0.77	0.032	2.159	2.027	2.3	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Hyperlipidemia : No	reference	reference	reference	reference	reference	reference
Hyperlipidemia : Yes	-0.484	0.033	0.616	0.578	0.657	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Insulin : No	reference	reference	reference	reference	reference	reference
Insulin : Yes	0.49	0.063	1.632	1.442	1.848	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Intracranial bleeding : No	reference	reference	reference	reference	reference	reference
Intracranial bleeding : Yes	0.208	0.11	1.231	0.991	1.529	0.065

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
LMWH : No	reference	reference	reference	reference	reference	reference
LMWH : Yes	0.776	0.183	2.172	1.517	3.112	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Major bleedings : No	reference	reference	reference	reference	reference	reference
Major bleedings : Yes	0.324	0.051	1.382	1.25	1.528	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Oral antidiabetic : No	reference	reference	reference	reference	reference	reference
Oral antidiabetic : Yes	-0.476	0.063	0.621	0.549	0.703	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Other stroke (not sub-classified) : No	reference	reference	reference	reference	reference	reference
Other stroke (not sub-classified) : Yes	0.774	0.355	2.169	1.082	4.346	0.056

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Proton pump inhibitor : No	reference	reference	reference	reference	reference	reference
Proton pump inhibitor : Yes	0.226	0.036	1.253	1.167	1.345	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
SSRI : No	reference	reference	reference	reference	reference	reference
SSRI : Yes	0.194	0.064	1.214	1.071	1.377	0.003

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Stroke (Total) : No	reference	reference	reference	reference	reference	reference
Stroke (Total) : Yes	0.341	0.172	1.406	1.003	1.971	0.056

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Severe liver disease : No	reference	reference	reference	reference	reference	reference
Severe liver disease : Yes	1.017	0.183	2.766	1.931	3.962	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Severe renal failure requiring dialysis : No	reference	reference	reference	reference	reference	reference
Severe renal failure requiring dialysis : Yes	0.478	0.195	1.613	1.101	2.364	0.024

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Invasive procedure related to index event : No invasive procedure	reference	reference	reference	reference	reference	reference
Invasive procedure related to index event : Coronary angiography only	-0.905	0.062	0.404	0.358	0.457	<0.001
Invasive procedure related to index event : PCI	-1.448	0.055	0.235	0.211	0.262	<0.001
Invasive procedure related to index event : CABG	-1.599	0.124	0.202	0.159	0.257	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Type of index MI : Non-ST elevation MI (and unspecified MI)	reference	reference	reference	reference	reference	reference
Type of index MI : ST elevation MI	-0.375	0.039	0.688	0.637	0.742	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Gastrointestinal bleeding : No	reference	reference	reference	reference	reference	reference
Gastrointestinal bleeding : Yes	0.563	0.107	1.755	1.424	2.163	<0.001

Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
PCI or CABG related to index event : No	reference	reference	reference	reference	reference	reference
PCI or CABG related to index event : Yes	-1.274	0.05	0.28	0.254	0.309	<0.001


Variable	Parameter est	std	Hazard ratio	lower	upper	P-val
Increased bleeding risk (Total) : No	reference	reference	reference	reference	reference	reference
Increased bleeding risk (Total) : Yes	0.38	0.071	1.462	1.271	1.681	<0.001

1.4 Cumulative incidence rates for the primary outcomes

1.4.1 cumulative incidence of primary outcomes for group 1

Myocardial infarction


Cumulative incidence of Myocardial infarction , stratified by Age at index (years)
in Group 1 .The follow-up time is from index date to 1 year after index date.




85 and over	6354	5123	4549	4139	3801
80-84	5396	4648	4309	4023	3816
75-79	4930	4392	4156	3974	3823
70-74	4350	3974	3837	3735	3642
65-69	3704	3409	3304	3235	3173
50-64	8531	8051	7881	7768	7674
18-49	1973	1873	1853	1832	1821

Number of patients at risk, stratified by Age at index (years)


Cumulative incidence of Myocardial infarction , stratified by Sex
in Group 1 .The follow-up time is from index date to 1 year after index date.



Cumulative incidence of Myocardial infarction , stratified by OAP use (Total)
in Group 1 .The follow-up time is from index date to 1 year after index date.




Cumulative incidence of Myocardial infarction , stratified by Number of additional risk factors in Group 1 .The follow-up time is from index date to 1 year after index date.



5	59	44	34	28	25
4	549	428	371	328	295
3	2821	2371	2137	1977	1849
2	9021	7870	7341	6921	6586
1	15969	14267	13611	13111	12697
0	6819	6490	6395	6341	6298

Number of patients at risk, stratified by Number of additional risk factors

Cumulative incidence of Myocardial infarction , stratified by Chronic use of anticoagulation medication in Group 1 .The follow-up time is from index date to 1 year after index date.




Yes	2655	2246	2079	1930	1807
No	32583	29224	27810	26776	25943

Number of patients at risk, stratified by Chronic use of anticoagulation medication

Stroke (total)


Cumulative incidence of Stroke (total) , stratified by Age at index (years)
in Group 1 .The follow-up time is from index date to 1 year after index date.



85 and over	6354	5557	5081	4710	4395
80-84	5396	4975	4694	4443	4241
75-79	4930	4670	4467	4312	4168
70-74	4350	4196	4100	4010	3930
65-69	3704	3591	3516	3459	3408
50-64	8531	8368	8284	8191	8114
18-49	1973	1961	1953	1942	1933

Number of patients at risk, stratified by Age at index (years)


Cumulative incidence of Stroke (total) , stratified by Sex
in Group 1 .The follow-up time is from index date to 1 year after index date.




Female	13977	13033	12458	11988	11570
Male	21261	20285	19637	19079	18619

Number of patients at risk, stratified by Sex


Cumulative incidence of Stroke (total) , stratified by OAP use (Total)
in Group 1 .The follow-up time is from index date to 1 year after index date.



Cumulative incidence of Stroke (total) , stratified by Number of additional risk factors
in Group 1 .The follow-up time is from index date to 1 year after index date.




Cumulative incidence of Stroke (total) , stratified by Chronic use of anticoagulation medication in Group 1 .The follow-up time is from index date to 1 year after index date.



Number of patients at risk, stratified by Chronic use of anticoagulation medication


Cardiovascular mortality

Cumulative incidence of Cardiovascular mortality , stratified by Age at index (years) in Group 1 .The follow-up time is from index date to 1 year after index date.




Number of patients at risk, stratified by Age at index (years)

Cumulative incidence of Cardiovascular mortality , stratified by Sex
in Group 1 .The follow-up time is from index date to 1 year after index date.




Number of patients at risk, stratified by Sex

Cumulative incidence of Cardiovascular mortality , stratified by OAP use (Total)
in Group 1 .The follow-up time is from index date to 1 year after index date.



Number of patients at risk, stratified by OAP use (Total)


Cumulative incidence of Cardiovascular mortality , stratified by Number of additional risk factors in Group 1 .The follow-up time is from index date to 1 year after index date.



5	59	54	45	39	36
4	549	496	458	430	407
3	2821	2629	2457	2324	2206
2	9021	8498	8145	7825	7543
1	15969	15254	14771	14373	14036
0	6819	6766	6735	6700	6672

Number of patients at risk, stratified by Number of additional risk factors

Cumulative incidence of Cardiovascular mortality , stratified by Chronic use of anticoagulation medication in Group 1 .The follow-up time is from index date to 1 year after index date.




Yes	2655	2464	2335	2221	2121
No	32583	31233	30276	29470	28779

Number of patients at risk, stratified by Chronic use of anticoagulation medication

Composite end-point


Cumulative incidence of Composite end-point , stratified by Age at index (years)
in Group 1 .The follow-up time is from index date to 1 year after index date.



85 and over	6354	5057	4468	4047	3706
80-84	5396	4587	4214	3913	3690
75-79	4930	4336	4077	3883	3718
70-74	4350	3950	3800	3688	3583
65-69	3704	3378	3263	3181	3113
50-64	8531	8004	7817	7687	7582
18-49	1973	1867	1845	1822	1808

Number of patients at risk, stratified by Age at index (years)


Cumulative incidence of Composite end-point , stratified by Sex
in Group 1 .The follow-up time is from index date to 1 year after index date.



Female	13977	12141	11370	10777	10293
Male	21261	19038	18114	17444	16907

Number of patients at risk, stratified by Sex


Cumulative incidence of Composite end-point , stratified by OAP use (Total)
in Group 1 .The follow-up time is from index date to 1 year after index date.



Yes	1458	1232	1115	1047	986
No	33780	29947	28369	27174	26214

Number of patients at risk, stratified by OAP use (Total)


Cumulative incidence of Composite end-point , stratified by Number of additional risk factors
in Group 1 .The follow-up time is from index date to 1 year after index date.



5	59	41	29	23	21
4	549	416	350	307	274
3	2821	2324	2082	1912	1771
2	9021	7755	7180	6731	6376
1	15969	14170	13475	12940	12498
0	6819	6473	6368	6308	6260

Number of patients at risk, stratified by Number of additional risk factors


Cumulative incidence of Composite end-point , stratified by Chronic use of anticoagulation medication in Group 1 .The follow-up time is from index date to 1 year after index date.



Number of patients at risk, stratified by Chronic use of anticoagulation medication


Overall mortality

Cumulative incidence of Overall mortality , stratified by Age at index (years) in Group 1 .The follow-up time is from index date to 1 year after index date.



Number of patients at risk, stratified by Age at index (years)


Cumulative incidence of Overall mortality , stratified by Sex
in Group 1 .The follow-up time is from index date to 1 year after index date.



Female	13977	13202	12673	12234	11853
Male	21261	20495	19938	19457	19047

Number of patients at risk, stratified by Sex


Cumulative incidence of Overall mortality , stratified by OAP use (Total)
in Group 1 .The follow-up time is from index date to 1 year after index date.



Yes	1458	1384	1319	1272	1230
No	33780	32313	31292	30419	29670

Number of patients at risk, stratified by OAP use (Total)


Cumulative incidence of Overall mortality , stratified by Number of additional risk factors in Group 1 .The follow-up time is from index date to 1 year after index date.



5	59	54	45	39	36
4	549	496	458	430	407
3	2821	2629	2457	2324	2206
2	9021	8498	8145	7825	7543
1	15969	15254	14771	14373	14036
0	6819	6766	6735	6700	6672

Number of patients at risk, stratified by Number of additional risk factors

Cumulative incidence of Overall mortality , stratified by Chronic use of anticoagulation medication in Group 1 .The follow-up time is from index date to 1 year after index date.



Yes	2655	2464	2335	2221	2121
No	32583	31233	30276	29470	28779

Number of patients at risk, stratified by Chronic use of anticoagulation medication

EPID Research Oy	Confidential	200
------------------	--------------	-----


1.4.2 Cumulative incidence of primary outcomes for group 2

Myocardial infarction

Cumulative incidence of Myocardial infarction, stratified by Age at 1 year baseline check (years) in Group 2.


The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,

C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




85 and over	4339	3782	3243	2811	2385	2019	1729	1448	1186	962	782	612	484	344	239	121	19
80-84	3788	3425	3108	2760	2439	2148	1866	1601	1350	1128	936	748	588	442	289	148	20
75-79	3684	3395	3100	2796	2486	2199	1973	1724	1495	1300	1114	932	741	549	389	207	38
70-74	3450	3172	2912	2681	2429	2195	1957	1746	1517	1286	1099	907	750	587	406	209	49
65-69	3202	2924	2664	2425	2184	1961	1764	1564	1350	1169	990	821	669	494	335	171	29
50-64	7171	6638	6204	5702	5184	4734	4308	3874	3410	2947	2562	2122	1670	1283	885	480	88
18-49	1554	1439	1336	1245	1148	1039	927	839	732	638	557	457	362	272	199	119	17

Number of patients at risk, stratified by Age at 1 year baseline check (years)




85 and over	2383		2019		1729		1448		1186
80-84	2433		2148		1866		1601		1350
75-79	2484		2199		1973		1724		1495
70-74	2426		2195		1957		1746		1517
65-69	2177		1961		1764		1564		1350
50-64	5182		4734		4308		3874		3410
18-49	1147		1039		927		839		732

Number of patients at risk, stratified by Age at 1 year baseline check (years)



85 and over	4339		3782		3243		2811		2385
80-84	3788		3425		3108		2760		2439
75-79	3684		3395		3100		2796		2486
70-74	3450		3172		2912		2681		2429
65-69	3202		2924		2664		2425		2184
50-64	7171		6638		6204		5702		5184
18-49	1554		1439		1336		1245		1148

Number of patients at risk, stratified by Age at 1 year baseline check (years)




85 and over	1186	962	782	612	484	344	239	121	19
80-84	1350	1128	936	748	588	442	289	148	20
75-79	1495	1300	1114	932	741	549	389	207	38
70-74	1517	1286	1099	907	750	587	406	209	49
65-69	1348	1169	990	821	669	494	335	171	29
50-64	3409	2947	2562	2122	1670	1283	885	480	88
18-49	732	638	557	457	362	272	199	119	17

Number of patients at risk, stratified by Age at 1 year baseline check (years)


Cumulative incidence of Myocardial infarction , stratified by Sex in Group 2 .

The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Female	10284	9317	8404	7553	6675	5944	5252	4581	3930	3347	2826	2297	1851	1383	948	490	88
Male	16904	15458	14163	12867	11580	10351	9272	8215	7110	6083	5214	4302	3413	2588	1794	965	172

Number of patients at risk, stratified by Sex




Female	6666		5944		5252		4581		3930
Male	11566		10351		9272		8215		7110

Number of patients at risk, stratified by Sex



Female	10284		9317		8404		7553		6675
Male	16904		15458		14163		12867		11580


Number of patients at risk, stratified by Sex



Female	3930	3347	2826	2297	1851	1383	948	490	88
Male	7107	6083	5214	4302	3413	2588	1794	965	172


Number of patients at risk, stratified by Sex

Cumulative incidence of Myocardial infarction , stratified by OAP use (Total) in Group 2 .
 The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,
 C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Yes	10287	9463	8717	7923	7097	6367	5693	5003	4342	3676	3162	2578	2049	1543	1042	570	110
No	16901	15312	13850	12497	11158	9928	8831	7793	6698	5754	4878	4021	3215	2428	1700	885	150

Number of patients at risk, stratified by OAP use (Total)




Yes	7087		6367		5693		5003		4342
No	11145		9928		8831		7793		6698

Number of patients at risk, stratified by OAP use (Total)



Yes	10287		9463		8717		7923		7097
No	16901		15312		13850		12497		11158


Number of patients at risk, stratified by OAP use (Total)



Yes	4341	3676	3162	2578	2049	1543	1042	570	110
No	6696	5754	4878	4021	3215	2428	1700	885	150


Number of patients at risk, stratified by OAP use (Total)

Cumulative incidence of Myocardial infarction, stratified by Number of additional risk factors in Group 2.
The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




5	25	25	19	15	12	11	10	9	9	9	8	7	6	5	3	3	1
4	292	256	222	197	172	152	137	118	96	82	71	60	49	40	31	18	4
3	2045	1827	1611	1452	1271	1121	998	855	720	600	504	406	327	244	178	95	13
2	7395	6668	6024	5378	4761	4188	3718	3250	2788	2357	2003	1612	1267	957	650	342	72
1	12284	11203	10211	9231	8242	7358	6534	5749	4972	4236	3595	2968	2395	1787	1226	649	108
0	5147	4796	4480	4147	3797	3465	3127	2815	2455	2146	1859	1546	1220	938	654	348	62

Number of patients at risk, stratified by Number of additional risk factors




5	12	11	10	9	9
4	172	152	137	118	96
3	1270	1121	998	855	720
2	4754	4188	3718	3250	2788
1	8229	7358	6534	5749	4972
0	3795	3465	3127	2815	2455

Number of patients at risk, stratified by Number of additional risk factors



5	25	25	19	15	12
4	292	256	222	197	172
3	2045	1827	1611	1452	1271
2	7395	6668	6024	5378	4761
1	12284	11203	10211	9231	8242
0	5147	4796	4480	4147	3797


Number of patients at risk, stratified by Number of additional risk factors



5	9	9	8	7	6	5	3	3	1
4	96	82	71	60	49	40	31	18	4
3	720	600	504	406	327	244	178	95	13
2	2787	2357	2003	1612	1267	957	650	342	72
1	4971	4236	3595	2968	2395	1787	1226	649	108
0	2454	2146	1859	1546	1220	938	654	348	62


Number of patients at risk, stratified by Number of additional risk factors

Cumulative incidence of Myocardial infarction , stratified by Chronic use of anticoagulation medication in Group 2 .
The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,
C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Yes	3035	2731	2435	2172	1924	1684	1477	1302	1077	915	761	634	500	375	257	123	21
No	24153	22044	20132	18248	16331	14611	13047	11494	9963	8515	7279	5965	4764	3596	2485	1332	239

Number of patients at risk, stratified by Chronic use of anticoagulation medication




Yes	1922	1684	1477	1302	1077
No	16310	14611	13047	11494	9963

Number of patients at risk, stratified by Chronic use of anticoagulation medication



Yes	3035	2731	2435	2172	1924
No	24153	22044	20132	18248	16331

Number of patients at risk, stratified by Chronic use of anticoagulation medication







Yes	1077	915	761	634	500	375	257	123	21
No	9960	8515	7279	5965	4764	3596	2485	1332	239

Number of patients at risk, stratified by Chronic use of anticoagulation medication

Stroke (total)


Cumulative incidence of Stroke (total) , stratified by Age at 1 year baseline check (years) in Group 2 .

The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Cumulative incidence of Stroke (total) , stratified by Sex in Group 2 .

The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Female	10284	9397	8521	7726	6870	6116	5424	4751	4084	3483	2945	2391	1920	1432	982	510	93
Male	16904	15552	14323	13037	11768	10558	9487	8401	7282	6256	5364	4420	3515	2665	1865	1015	177

Number of patients at risk, stratified by Sex




Female	6861	6116	5424	4751	4084
Male	11755	10558	9487	8401	7282

Number of patients at risk, stratified by Sex



Female	10284	9397	8521	7726	6870
Male	16904	15552	14323	13037	11768


Number of patients at risk, stratified by Sex



Female	4082	3483	2945	2391	1920	1432	982	510	93
Male	7279	6256	5364	4420	3515	2665	1865	1015	177


Number of patients at risk, stratified by Sex

Cumulative incidence of Stroke (total) , stratified by OAP use (Total) in Group 2 .
 The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,
 C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Yes	10287	9534	8825	8038	7227	6499	5823	5133	4463	3792	3271	2662	2127	1596	1091	592	108
No	16901	15415	14019	12725	11411	10175	9088	8019	6903	5947	5038	4149	3308	2501	1756	933	162

Number of patients at risk, stratified by OAP use (Total)




Yes	7217	6499	5823	5133	4463
No	11399	10175	9088	8019	6903

Number of patients at risk, stratified by OAP use (Total)



Yes	10287	9534	8825	8038	7227
No	16901	15415	14019	12725	11411





Number of patients at risk, stratified by OAP use (Total)




Yes	4462	3792	3271	2662	2127	1596	1091	592	108
No	6899	5947	5038	4149	3308	2501	1756	933	162

Number of patients at risk, stratified by OAP use (Total)


Cumulative incidence of Stroke (total) , stratified by Number of additional risk factors in Group 2 .
The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,
C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Cumulative incidence of Stroke (total) , stratified by Chronic use of anticoagulation medication in Group 2 .
The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,
C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Number of patients at risk, stratified by Chronic use of anticoagulation medication



Number of patients at risk, stratified by Chronic use of anticoagulation medication



Number of patients at risk, stratified by Chronic use of anticoagulation medication




Number of patients at risk, stratified by Chronic use of anticoagulation medication


Cardiovascular mortality

Cumulative incidence of Cardiovascular mortality, stratified by Age at 1 year baseline check (years) in Group 2.


The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Number of patients at risk, stratified by Age at 1 year baseline check (years)



Number of patients at risk, stratified by Age at 1 year baseline check (years)







Number of patients at risk, stratified by Age at 1 year baseline check (years)




Number of patients at risk, stratified by Age at 1 year baseline check (years)

Cumulative incidence of Cardiovascular mortality , stratified by Sex in Group 2 .

The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Cumulative incidence of Cardiovascular mortality , stratified by OAP use (Total) in Group 2 .
 The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,
 C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Yes	10287	9552	8868	8099	7296	6573	5902	5214	4539	3861	3338	2725	2179	1648	1129	617	113
No	16901	15476	14130	12858	11564	10339	9261	8203	7083	6125	5200	4299	3442	2608	1833	970	165

Number of patients at risk, stratified by OAP use (Total)




Yes	7286	6573	5902	5214	4539
No	11552	10339	9261	8203	7083

Number of patients at risk, stratified by OAP use (Total)



Yes	10287	9552	8868	8099	7296
No	16901	15476	14130	12858	11564


Number of patients at risk, stratified by OAP use (Total)




Yes	4538	3861	3338	2725	2179	1648	1129	617	113
No	7080	6125	5200	4299	3442	2608	1833	970	165

Number of patients at risk, stratified by OAP use (Total)


Cumulative incidence of Cardiovascular mortality , stratified by Number of additional risk factors in Group 2 .
The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,
C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Number of patients at risk, stratified by Number of additional risk factors



Number of patients at risk, stratified by Number of additional risk factors




Number of patients at risk, stratified by Number of additional risk factors




Number of patients at risk, stratified by Number of additional risk factors

Cumulative incidence of Cardiovascular mortality , stratified by Chronic use of anticoagulation medication in Group 2 .
The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,
C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Yes	3035	2758	2486	2236	1989	1752	1552	1373	1145	980	809	671	530	397	274	137	24
No	24153	22270	20512	18721	16871	15160	13611	12044	10477	9006	7729	6353	5091	3859	2688	1450	254

Number of patients at risk, stratified by Chronic use of anticoagulation medication




Yes	1988	1752	1552	1373	1145
No	16850	15160	13611	12044	10477

Number of patients at risk, stratified by Chronic use of anticoagulation medication



Yes	3035	2758	2486	2236	1989
No	24153	22270	20512	18721	16871

Number of patients at risk, stratified by Chronic use of anticoagulation medication







Yes	1145	980	809	671	530	397	274	137	24
No	10473	9006	7729	6353	5091	3859	2688	1450	254

Number of patients at risk, stratified by Chronic use of anticoagulation medication

Composite end-point


Cumulative incidence of Composite end-point , stratified by Age at 1 year baseline check (years) in Group 2 .

The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Cumulative incidence of Composite end-point , stratified by Sex in Group 2 .

The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.



Female	10284	9287	8340	7474	6589	5847	5151	4479	3831	3258	2740	2216	1782	1325	905	465	86
Male	16904	15415	14087	12769	11466	10235	9150	8078	6980	5958	5101	4193	3318	2505	1736	940	166

Number of patients at risk, stratified by Sex




Female	6580		5847		5151		4479		3831
Male	11452		10235		9150		8078		6980

Number of patients at risk, stratified by Sex


B

D



Female	10284		9287		8340		7474		6589
Male	16904		15415		14087		12769		11466


Number of patients at risk, stratified by Sex



Female	3830	3258	2740	2216	1782	1325	905	465	86
Male	6977	5958	5101	4193	3318	2505	1736	940	166


Number of patients at risk, stratified by Sex

Cumulative incidence of Composite end-point , stratified by OAP use (Total) in Group 2 .
The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,
C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Yes	10287	9447	8678	7868	7035	6302	5625	4933	4276	3616	3104	2521	2002	1496	1008	548	105
No	16901	15255	13749	12375	11020	9780	8676	7624	6535	5600	4737	3888	3098	2334	1633	857	147

Number of patients at risk, stratified by OAP use (Total)




Yes	7025	6302	5625	4933	4276
No	11007	9780	8676	7624	6535

Number of patients at risk, stratified by OAP use (Total)



Yes	10287	9447	8678	7868	7035
No	16901	15255	13749	12375	11020


Number of patients at risk, stratified by OAP use (Total)



Yes	4275	3616	3104	2521	2002	1496	1008	548	105
No	6532	5600	4737	3888	3098	2334	1633	857	147


Number of patients at risk, stratified by OAP use (Total)

Cumulative incidence of Composite end-point , stratified by Number of additional risk factors in Group 2 .
The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,
C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




5	25	23	18	14	11	10	9	8	8	8	7	6	5	4	2	2	1
4	292	254	218	195	169	149	133	115	95	81	69	58	48	39	30	18	4
3	2045	1814	1586	1418	1235	1088	964	820	689	569	481	382	305	225	163	86	12
2	7395	6641	5971	5305	4684	4106	3642	3165	2707	2287	1936	1552	1214	919	619	328	70
1	12284	11178	10164	9176	8177	7281	6445	5655	4878	4146	3505	2879	2319	1717	1182	628	105
0	5147	4792	4470	4135	3779	3448	3108	2794	2434	2125	1843	1532	1209	926	645	343	60

Number of patients at risk, stratified by Number of additional risk factors




5	11	10	9	8	8
4	169	149	133	115	95
3	1234	1088	964	820	689
2	4677	4106	3642	3165	2707
1	8164	7281	6445	5655	4878
0	3777	3448	3108	2794	2434

Number of patients at risk, stratified by Number of additional risk factors



5	25	23	18	14	11
4	292	254	218	195	169
3	2045	1814	1586	1418	1235
2	7395	6641	5971	5305	4684
1	12284	11178	10164	9176	8177
0	5147	4792	4470	4135	3779


Number of patients at risk, stratified by Number of additional risk factors



5	8	8	7	6	5	4	2	2	1
4	95	81	69	58	48	39	30	18	4
3	689	569	481	382	305	225	163	86	12
2	2705	2287	1936	1552	1214	919	619	328	70
1	4877	4146	3505	2879	2319	1717	1182	628	105
0	2433	2125	1843	1532	1209	926	645	343	60


Number of patients at risk, stratified by Number of additional risk factors

Cumulative incidence of Composite end-point , stratified by Chronic use of anticoagulation medication in Group 2 .
The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,
C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Yes	3035	2721	2415	2148	1896	1651	1442	1261	1042	882	728	600	473	354	245	120	21
No	24153	21981	20012	18095	16159	14431	12859	11296	9769	8334	7113	5809	4627	3476	2396	1285	231

Number of patients at risk, stratified by Chronic use of anticoagulation medication




Yes	1894	1651	1442	1261	1042
No	16138	14431	12859	11296	9769

Number of patients at risk, stratified by Chronic use of anticoagulation medication



Yes	3035	2721	2415	2148	1896
No	24153	21981	20012	18095	16159

Number of patients at risk, stratified by Chronic use of anticoagulation medication




Yes	1042	882	728	600	473	354	245	120	21
No	9765	8334	7113	5809	4627	3476	2396	1285	231

Number of patients at risk, stratified by Chronic use of anticoagulation medication

Overall mortality


Cumulative incidence of Overall mortality, stratified by Age at 1 year baseline check (years) in Group 2.

The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




85 and over	4339	3854	3370	2959	2546	2174	1883	1587	1311	1077	874	695	545	389	268	139	20
80-84	3788	3466	3184	2867	2559	2265	1989	1713	1453	1220	1021	820	647	489	323	170	25
75-79	3684	3426	3152	2866	2568	2294	2074	1830	1590	1396	1205	1010	810	602	429	231	42
70-74	3450	3201	2962	2741	2495	2264	2032	1818	1585	1349	1156	955	791	621	438	224	51
65-69	3202	2948	2706	2474	2235	2007	1810	1614	1392	1210	1027	851	696	517	356	183	30
50-64	7171	6687	6276	5790	5288	4846	4423	3992	3533	3070	2673	2215	1750	1350	939	513	90
18-49	1554	1446	1348	1260	1169	1062	952	863	758	664	582	478	382	288	209	127	20

Number of patients at risk, stratified by Age at 1 year baseline check (years)




85 and over	2544	2174	1883	1587	1311
80-84	2554	2265	1989	1713	1453
75-79	2566	2294	2074	1830	1590
70-74	2492	2264	2032	1818	1585
65-69	2228	2007	1810	1614	1392
50-64	5286	4846	4423	3992	3533
18-49	1168	1062	952	863	758

Number of patients at risk, stratified by Age at 1 year baseline check (years)



85 and over	4339	3854	3370	2959	2546
80-84	3788	3466	3184	2867	2559
75-79	3684	3426	3152	2866	2568
70-74	3450	3201	2962	2741	2495
65-69	3202	2948	2706	2474	2235
50-64	7171	6687	6276	5790	5288
18-49	1554	1446	1348	1260	1169

Number of patients at risk, stratified by Age at 1 year baseline check (years)




85 and over	1310	1077	874	695	545	389	268	139	20
80-84	1453	1220	1021	820	647	489	323	170	25
75-79	1590	1396	1205	1010	810	602	429	231	42
70-74	1585	1349	1156	955	791	621	438	224	51
65-69	1390	1210	1027	851	696	517	356	183	30
50-64	3532	3070	2673	2215	1750	1350	939	513	90
18-49	758	664	582	478	382	288	209	127	20

Number of patients at risk, stratified by Age at 1 year baseline check (years)


Cumulative incidence of Overall mortality , stratified by Sex in Group 2 .

The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Female	10284	9430	8592	7812	6968	6224	5540	4865	4194	3588	3045	2484	1998	1497	1031	542	95
Male	16904	15598	14406	13145	11892	10688	9623	8552	7428	6398	5493	4540	3623	2759	1931	1045	183

Number of patients at risk, stratified by Sex




Female	6959		6224		5540		4865		4194
Male	11879		10688		9623		8552		7428

Number of patients at risk, stratified by Sex



Female	10284		9430		8592		7812		6968
Male	16904		15598		14406		13145		11892


Number of patients at risk, stratified by Sex



Female	4193	3588	3045	2484	1998	1497	1031	542	95
Male	7425	6398	5493	4540	3623	2759	1931	1045	183


Number of patients at risk, stratified by Sex

Cumulative incidence of Overall mortality , stratified by OAP use (Total) in Group 2 .
 The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,
 C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Yes	10287	9552	8868	8099	7296	6573	5902	5214	4539	3861	3338	2725	2179	1648	1129	617	113
No	16901	15476	14130	12858	11564	10339	9261	8203	7083	6125	5200	4299	3442	2608	1833	970	165

Number of patients at risk, stratified by OAP use (Total)




Yes	7286	6573	5902	5214	4539
No	11552	10339	9261	8203	7083

Number of patients at risk, stratified by OAP use (Total)



Yes	10287	9552	8868	8099	7296
No	16901	15476	14130	12858	11564

Number of patients at risk, stratified by OAP use (Total)




Yes	4538	3861	3338	2725	2179	1648	1129	617	113
No	7080	6125	5200	4299	3442	2608	1833	970	165

Number of patients at risk, stratified by OAP use (Total)


Cumulative incidence of Overall mortality , stratified by Number of additional risk factors in Group 2 .

The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




5	25	25	20	16	12	11	11	10	10	10	9	9	7	6	4	3	1
4	292	265	234	209	189	168	153	134	115	100	87	74	64	50	39	22	5
3	2045	1855	1672	1525	1350	1202	1087	939	792	664	560	447	358	268	198	109	14
2	7395	6744	6158	5568	4964	4387	3921	3444	2971	2535	2159	1748	1374	1042	720	384	76
1	12284	11319	10390	9443	8491	7617	6798	6006	5204	4459	3794	3140	2542	1906	1312	701	119
0	5147	4820	4524	4196	3854	3527	3193	2884	2530	2218	1929	1606	1276	984	689	368	63

Number of patients at risk, stratified by Number of additional risk factors




5	12	11	11	10	10
4	189	168	153	134	115
3	1349	1202	1087	939	792
2	4958	4387	3921	3444	2971
1	8478	7617	6798	6006	5204
0	3852	3527	3193	2884	2530

Number of patients at risk, stratified by Number of additional risk factors



5	25	25	20	16	12
4	292	265	234	209	189
3	2045	1855	1672	1525	1350
2	7395	6744	6158	5568	4964
1	12284	11319	10390	9443	8491
0	5147	4820	4524	4196	3854


Number of patients at risk, stratified by Number of additional risk factors



5	10	10	9	9	7	6	4	3	1
4	115	100	87	74	64	50	39	22	5
3	792	664	560	447	358	268	198	109	14
2	2969	2535	2159	1748	1374	1042	720	384	76
1	5203	4459	3794	3140	2542	1906	1312	701	119
0	2529	2218	1929	1606	1276	984	689	368	63


Number of patients at risk, stratified by Number of additional risk factors

Cumulative incidence of Overall mortality , stratified by Chronic use of anticoagulation medication in Group 2 .
The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,
C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Yes	3035	2758	2486	2236	1989	1752	1552	1373	1145	980	809	671	530	397	274	137	24
No	24153	22270	20512	18721	16871	15160	13611	12044	10477	9006	7729	6353	5091	3859	2688	1450	254

Number of patients at risk, stratified by Chronic use of anticoagulation medication




Yes	1988	1752	1552	1373	1145
No	16850	15160	13611	12044	10477

Number of patients at risk, stratified by Chronic use of anticoagulation medication



Yes	3035	2758	2486	2236	1989
No	24153	22270	20512	18721	16871

Number of patients at risk, stratified by Chronic use of anticoagulation medication



Yes	1145	980	809	671	530	397	274	137	24
No	10473	9006	7729	6353	5091	3859	2688	1450	254

Number of patients at risk, stratified by Chronic use of anticoagulation medication

EPID Research Oy	Confidential	226
------------------	--------------	-----


1.4.3 Cumulative incidence of primary outcomes for group 3

Myocardial infarction

Cumulative incidence of Myocardial infarction, stratified by Age at 1 year baseline check (years) in Group 3.


The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,

C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




85 and over	4339	3782	3243	2811	2385	2019	1729	1448	1186	962	782	612	484	344	239	121	19
80-84	3788	3425	3108	2760	2439	2148	1866	1601	1350	1128	936	748	588	442	289	148	20
75-79	3684	3395	3100	2796	2486	2199	1973	1724	1495	1300	1114	932	741	549	389	207	38
70-74	3450	3172	2912	2681	2429	2195	1957	1746	1517	1286	1099	907	750	587	406	209	49
65-69	3202	2924	2664	2425	2184	1961	1764	1564	1350	1169	990	821	669	494	335	171	29
50-64	3020	2774	2586	2360	2138	1945	1787	1601	1420	1210	1055	862	680	514	356	202	39
18-49	558	507	474	440	397	363	321	297	267	229	205	171	132	103	74	49	4

Number of patients at risk, stratified by Age at 1 year baseline check (years)




85 and over	2383	2019	1729	1448	1186
80-84	2433	2148	1866	1601	1350
75-79	2484	2199	1973	1724	1495
70-74	2426	2195	1957	1746	1517
65-69	2177	1961	1764	1564	1350
50-64	2137	1945	1787	1601	1420
18-49	397	363	321	297	267

Number of patients at risk, stratified by Age at 1 year baseline check (years)



85 and over	4339	3782	3243	2811	2385
80-84	3788	3425	3108	2760	2439
75-79	3684	3395	3100	2796	2486
70-74	3450	3172	2912	2681	2429
65-69	3202	2924	2664	2425	2184
50-64	3020	2774	2586	2360	2138
18-49	558	507	474	440	397

Number of patients at risk, stratified by Age at 1 year baseline check (years)




85 and over	1186	962	782	612	484	344	239	121	19
80-84	1350	1128	936	748	588	442	289	148	20
75-79	1495	1300	1114	932	741	549	389	207	38
70-74	1517	1286	1099	907	750	587	406	209	49
65-69	1348	1169	990	821	669	494	335	171	29
50-64	1420	1210	1055	862	680	514	356	202	39
18-49	267	229	205	171	132	103	74	49	4

Number of patients at risk, stratified by Age at 1 year baseline check (years)


Cumulative incidence of Myocardial infarction , stratified by Sex in Group 3 .

The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Female	9258	8360	7511	6732	5929	5258	4636	4037	3460	2938	2470	1996	1615	1200	821	422	75
Male	12783	11619	10576	9541	8529	7572	6761	5944	5125	4346	3711	3057	2429	1833	1267	685	123

Number of patients at risk, stratified by Sex




Female	5920		5258		4636		4037		3460
Male	8517		7572		6761		5944		5125

Number of patients at risk, stratified by Sex



Female	9258		8360		7511		6732		5929
Male	12783		11619		10576		9541		8529

Number of patients at risk, stratified by Sex




Female	3460	2938	2470	1996	1615	1200	821	422	75
Male	5123	4346	3711	3057	2429	1833	1267	685	123

Number of patients at risk, stratified by Sex

Cumulative incidence of Myocardial infarction , stratified by OAP use (Total) in Group 3 .


The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,

C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Yes	7673	7019	6431	5834	5207	4659	4146	3626	3145	2639	2260	1828	1460	1096	747	404	74
No	14368	12960	11656	10439	9251	8171	7251	6355	5440	4645	3921	3225	2584	1937	1341	703	124

Number of patients at risk, stratified by OAP use (Total)




Yes	5198	4659	4146	3626	3145
No	9239	8171	7251	6355	5440

Number of patients at risk, stratified by OAP use (Total)



Yes	7673	7019	6431	5834	5207
No	14368	12960	11656	10439	9251


Number of patients at risk, stratified by OAP use (Total)




Yes	3144	2639	2260	1828	1460	1096	747	404	74
No	5439	4645	3921	3225	2584	1937	1341	703	124

Number of patients at risk, stratified by OAP use (Total)


Cumulative incidence of Myocardial infarction , stratified by Number of additional risk factors in Group 3 .
The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,
C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Number of patients at risk, stratified by Number of additional risk factors



Number of patients at risk, stratified by Number of additional risk factors




Number of patients at risk, stratified by Number of additional risk factors




Number of patients at risk, stratified by Number of additional risk factors


Cumulative incidence of Myocardial infarction, stratified by Chronic use of anticoagulation medication in Group 3.
The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,
C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Number of patients at risk, stratified by Chronic use of anticoagulation medication



Number of patients at risk, stratified by Chronic use of anticoagulation medication



Number of patients at risk, stratified by Chronic use of anticoagulation medication






Number of patients at risk, stratified by Chronic use of anticoagulation medication

Stroke (total)


Cumulative incidence of Stroke (total) , stratified by Age at 1 year baseline check (years) in Group 3 .

The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Cumulative incidence of Stroke (total) , stratified by Sex in Group 3 .

The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Female	9258	8433	7621	6897	6117	5420	4797	4200	3605	3065	2582	2084	1679	1246	851	438	80
Male	12783	11701	10712	9684	8687	7746	6941	6092	5254	4479	3816	3136	2492	1879	1316	724	129

Number of patients at risk, stratified by Sex




Female	6108		5420		4797		4200		3605
Male	8676		7746		6941		6092		5254

Number of patients at risk, stratified by Sex



Female	9258		8433		7621		6897		6117
Male	12783		11701		10712		9684		8687

Number of patients at risk, stratified by Sex




Female	3603	3065	2582	2084	1679	1246	851	438	80
Male	5252	4479	3816	3136	2492	1879	1316	724	129

Number of patients at risk, stratified by Sex


Cumulative incidence of Stroke (total) , stratified by OAP use (Total) in Group 3 .

The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Yes	7673	7078	6522	5926	5314	4767	4251	3730	3239	2730	2342	1890	1518	1132	782	418	74
No	14368	13056	11811	10655	9490	8399	7487	6562	5620	4814	4056	3330	2653	1993	1385	744	135

Number of patients at risk, stratified by OAP use (Total)




Yes	5305		4767		4251		3730		3239
No	9479		8399		7487		6562		5620

Number of patients at risk, stratified by OAP use (Total)



Yes	7673		7078		6522		5926		5314
No	14368		13056		11811		10655		9490

Number of patients at risk, stratified by OAP use (Total)




Yes	3238	2730	2342	1890	1518	1132	782	418	74
No	5617	4814	4056	3330	2653	1993	1385	744	135


Number of patients at risk, stratified by OAP use (Total)

Cumulative incidence of Stroke (total) , stratified by Number of additional risk factors in Group 3 .


The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Number of patients at risk, stratified by Number of additional risk factors



Number of patients at risk, stratified by Number of additional risk factors




Number of patients at risk, stratified by Number of additional risk factors




Number of patients at risk, stratified by Number of additional risk factors

Cumulative incidence of Stroke (total) , stratified by Chronic use of anticoagulation medication in Group 3 .
The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,
C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Yes	2847	2572	2306	2063	1821	1589	1404	1225	1021	869	712	582	457	340	237	123	24
No	19194	17562	16027	14518	12983	11577	10334	9067	7838	6675	5686	4638	3714	2785	1930	1039	185

Number of patients at risk, stratified by Chronic use of anticoagulation medication




Yes	1820	1589	1404	1225	1021
No	12964	11577	10334	9067	7838

Number of patients at risk, stratified by Chronic use of anticoagulation medication



Yes	2847	2572	2306	2063	1821
No	19194	17562	16027	14518	12983

Number of patients at risk, stratified by Chronic use of anticoagulation medication




Yes	1021	869	712	582	457	340	237	123	24
No	7834	6675	5686	4638	3714	2785	1930	1039	185

Number of patients at risk, stratified by Chronic use of anticoagulation medication

Cardiovascular mortality


Cumulative incidence of Cardiovascular mortality, stratified by Age at 1 year baseline check (years) in Group 3.

The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




85 and over	4339	3854	3370	2959	2546	2174	1883	1587	1311	1077	874	695	545	389	268	139	20
80-84	3788	3466	3184	2867	2559	2265	1989	1713	1453	1220	1021	820	647	489	323	170	25
75-79	3684	3426	3152	2866	2568	2294	2074	1830	1590	1396	1205	1010	810	602	429	231	42
70-74	3450	3201	2962	2741	2495	2264	2032	1818	1585	1349	1156	955	791	621	438	224	51
65-69	3202	2948	2706	2474	2235	2007	1810	1614	1392	1210	1027	851	696	517	356	183	30
50-64	3020	2801	2619	2403	2193	2005	1848	1663	1483	1275	1111	907	716	543	378	218	41
18-49	558	512	481	451	410	376	334	308	278	241	215	180	140	111	81	54	6

Number of patients at risk, stratified by Age at 1 year baseline check (years)




85 and over	2544	2174	1883	1587	1311
80-84	2554	2265	1989	1713	1453
75-79	2566	2294	2074	1830	1590
70-74	2492	2264	2032	1818	1585
65-69	2228	2007	1810	1614	1392
50-64	2192	2005	1848	1663	1483
18-49	410	376	334	308	278

Number of patients at risk, stratified by Age at 1 year baseline check (years)



85 and over	4339	3854	3370	2959	2546
80-84	3788	3466	3184	2867	2559
75-79	3684	3426	3152	2866	2568
70-74	3450	3201	2962	2741	2495
65-69	3202	2948	2706	2474	2235
50-64	3020	2801	2619	2403	2193
18-49	558	512	481	451	410

Number of patients at risk, stratified by Age at 1 year baseline check (years)




85 and over	1310	1077	874	695	545	389	268	139	20
80-84	1453	1220	1021	820	647	489	323	170	25
75-79	1590	1396	1205	1010	810	602	429	231	42
70-74	1585	1349	1156	955	791	621	438	224	51
65-69	1390	1210	1027	851	696	517	356	183	30
50-64	1483	1275	1111	907	716	543	378	218	41
18-49	278	241	215	180	140	111	81	54	6

Number of patients at risk, stratified by Age at 1 year baseline check (years)


Cumulative incidence of Cardiovascular mortality , stratified by Sex in Group 3 .

The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Female	9258	8464	7688	6978	6209	5522	4908	4309	3711	3166	2678	2172	1753	1308	899	469	82
Male	12783	11744	10786	9783	8797	7863	7062	6224	5381	4602	3931	3246	2592	1964	1374	750	133

Number of patients at risk, stratified by Sex




Female	6200		5522		4908		4309		3711
Male	8786		7863		7062		6224		5381

Number of patients at risk, stratified by Sex



Female	9258		8464		7688		6978		6209
Male	12783		11744		10786		9783		8797


Number of patients at risk, stratified by Sex



Female	3710	3166	2678	2172	1753	1308	899	469	82
Male	5379	4602	3931	3246	2592	1964	1374	750	133


Number of patients at risk, stratified by Sex

Cumulative incidence of Cardiovascular mortality , stratified by OAP use (Total) in Group 3 .
 The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,
 C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Yes	7673	7095	6560	5982	5377	4835	4324	3804	3309	2793	2405	1950	1566	1180	818	442	77
No	14368	13113	11914	10779	9629	8550	7646	6729	5783	4975	4204	3468	2779	2092	1455	777	138

Number of patients at risk, stratified by OAP use (Total)




Yes	5368	4835	4324	3804	3309
No	9618	8550	7646	6729	5783

Number of patients at risk, stratified by OAP use (Total)



Yes	7673	7095	6560	5982	5377
No	14368	13113	11914	10779	9629


Number of patients at risk, stratified by OAP use (Total)



Yes	3308	2793	2405	1950	1566	1180	818	442	77
No	5781	4975	4204	3468	2779	2092	1455	777	138


Number of patients at risk, stratified by OAP use (Total)

Cumulative incidence of Cardiovascular mortality , stratified by Number of additional risk factors in Group 3 .
The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,
C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




5	25	25	20	16	12	11	10	10	10	9	9	7	6	4	3	1
4	292	265	234	209	189	168	153	134	115	100	87	74	64	50	39	22
3	2045	1855	1672	1525	1350	1202	1087	939	792	664	560	447	358	268	198	14
2	7395	6744	6158	5568	4964	4387	3921	3444	2971	2535	2159	1748	1374	1042	720	384
1	12284	11319	10390	9443	8491	7617	6798	6006	5204	4459	3794	3140	2542	1906	1312	701

Number of patients at risk, stratified by Number of additional risk factors




5	12	11	11	10
4	189	168	153	134
3	1349	1202	1087	939
2	4958	4387	3921	3444
1	8478	7617	6798	6006

Number of patients at risk, stratified by Number of additional risk factors



5	25	25	20	16	12
4	292	265	234	209	189
3	2045	1855	1672	1525	1350
2	7395	6744	6158	5568	4964
1	12284	11319	10390	9443	8491


Number of patients at risk, stratified by Number of additional risk factors



5	10	10	9	9	7	6	4	3	1
4	115	100	87	74	64	50	39	22	5
3	792	664	560	447	358	268	198	109	14
2	2969	2535	2159	1748	1374	1042	720	384	76
1	5203	4459	3794	3140	2542	1906	1312	701	119


Number of patients at risk, stratified by Number of additional risk factors

Cumulative incidence of Cardiovascular mortality , stratified by Chronic use of anticoagulation medication in Group 3 .
 The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,
 C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Yes	2847	2583	2327	2087	1848	1623	1439	1266	1056	901	742	613	483	360	248	127	24
No	19194	17625	16147	14674	13158	11762	10531	9267	8036	6867	5867	4805	3862	2912	2025	1092	191

Number of patients at risk, stratified by Chronic use of anticoagulation medication




Yes	1847	1623	1439	1266	1056
No	13139	11762	10531	9267	8036

Number of patients at risk, stratified by Chronic use of anticoagulation medication



Yes	2847	2583	2327	2087	1848
No	19194	17625	16147	14674	13158

Number of patients at risk, stratified by Chronic use of anticoagulation medication







Yes	1056	901	742	613	483	360	248	127	24
No	8033	6867	5867	4805	3862	2912	2025	1092	191

Number of patients at risk, stratified by Chronic use of anticoagulation medication


Composite end-point

Cumulative incidence of Composite end-point , stratified by Age at 1 year baseline check (years) in Group 3 .
The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,
C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Cumulative incidence of Composite end-point , stratified by Sex in Group 3 .

The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Female	9258	8331	7450	6657	5848	5166	4540	3940	3365	2853	2388	1920	1550	1145	779	398	73
Male	12783	11579	10507	9451	8428	7468	6653	5823	5012	4238	3610	2957	2341	1759	1217	664	119

Number of patients at risk, stratified by Sex




Female	5839	5166	4540	3940	3365
Male	8416	7468	6653	5823	5012

Number of patients at risk, stratified by Sex



Female	9258	8331	7450	6657	5848
Male	12783	11579	10507	9451	8428


Number of patients at risk, stratified by Sex



Female	3364	2853	2388	1920	1550	1145	779	398	73
Male	5010	4238	3610	2957	2341	1759	1217	664	119


Number of patients at risk, stratified by Sex

Cumulative incidence of Composite end-point , stratified by OAP use (Total) in Group 3 .
 The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,
 C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Yes	7673	7004	6396	5783	5150	4599	4083	3561	3084	2584	2205	1774	1417	1053	715	383	71
No	14368	12906	11561	10325	9126	8035	7110	6202	5293	4507	3793	3103	2474	1851	1281	679	121

Number of patients at risk, stratified by OAP use (Total)




Yes	5141	4599	4083	3561	3084
No	9114	8035	7110	6202	5293

Number of patients at risk, stratified by OAP use (Total)



Yes	7673	7004	6396	5783	5150
No	14368	12906	11561	10325	9126


Number of patients at risk, stratified by OAP use (Total)



Yes	3083	2584	2205	1774	1417	1053	715	383	71
No	5291	4507	3793	3103	2474	1851	1281	679	121


Number of patients at risk, stratified by OAP use (Total)

Cumulative incidence of Composite end-point , stratified by Number of additional risk factors in Group 3 .
The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,
C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




5	25	23	18	14	11	9	8	8	7	6	5	4	2	2	1
4	292	254	218	195	169	149	133	115	95	81	69	58	48	39	30
3	2045	1814	1586	1418	1235	1088	964	820	689	569	481	382	305	225	163
2	7395	6641	5971	5305	4684	4106	3642	3165	2707	2287	1936	1552	1214	919	619
1	12284	11178	10164	9176	8177	7281	6445	5655	4878	4146	3505	2879	2319	1717	1182

Number of patients at risk, stratified by Number of additional risk factors




5	11	10	9	8	8
4	169	149	133	115	95
3	1234	1088	964	820	689
2	4677	4106	3642	3165	2707
1	8164	7281	6445	5655	4878

Number of patients at risk, stratified by Number of additional risk factors



5	25	23	18	14	11
4	292	254	218	195	169
3	2045	1814	1586	1418	1235
2	7395	6641	5971	5305	4684
1	12284	11178	10164	9176	8177


Number of patients at risk, stratified by Number of additional risk factors



5	8	8	7	6	5	4	2	2	1
4	95	81	69	58	48	39	30	18	4
3	689	569	481	382	305	225	163	86	12
2	2705	2287	1936	1552	1214	919	619	328	70
1	4877	4146	3505	2879	2319	1717	1182	628	105


Number of patients at risk, stratified by Number of additional risk factors

Cumulative incidence of Composite end-point , stratified by Chronic use of anticoagulation medication in Group 3 .
The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,
C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Yes	2847	2547	2256	2001	1759	1527	1335	1160	959	809	667	548	430	320	222	112	21
No	19194	17363	15701	14107	12517	11107	9858	8603	7418	6282	5331	4329	3461	2584	1774	950	171

Number of patients at risk, stratified by Chronic use of anticoagulation medication




Yes	1757	1527	1335	1160	959
No	12498	11107	9858	8603	7418

Number of patients at risk, stratified by Chronic use of anticoagulation medication



Yes	2847	2547	2256	2001	1759
No	19194	17363	15701	14107	12517

Number of patients at risk, stratified by Chronic use of anticoagulation medication




Yes	959	809	667	548	430	320	222	112	21
No	7415	6282	5331	4329	3461	2584	1774	950	171

Number of patients at risk, stratified by Chronic use of anticoagulation medication

Overall mortality


Cumulative incidence of Overall mortality , stratified by Age at 1 year baseline check (years) in Group 3 .

The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




85 and over	4339	3854	3370	2959	2546	2174	1883	1587	1311	1077	874	695	545	389	268	139	20
80-84	3788	3466	3184	2867	2559	2265	1989	1713	1453	1220	1021	820	647	489	323	170	25
75-79	3684	3426	3152	2866	2568	2294	2074	1830	1590	1396	1205	1010	810	602	429	231	42
70-74	3450	3201	2962	2741	2495	2264	2032	1818	1585	1349	1156	955	791	621	438	224	51
65-69	3202	2948	2706	2474	2235	2007	1810	1614	1392	1210	1027	851	696	517	356	183	30
50-64	3020	2801	2619	2403	2193	2005	1848	1663	1483	1275	1111	907	716	543	378	218	41
18-49	558	512	481	451	410	376	334	308	278	241	215	180	140	111	81	54	6

Number of patients at risk, stratified by Age at 1 year baseline check (years)




85 and over	2544	2174	1883	1587	1311
80-84	2554	2265	1989	1713	1453
75-79	2566	2294	2074	1830	1590
70-74	2492	2264	2032	1818	1585
65-69	2228	2007	1810	1614	1392
50-64	2192	2005	1848	1663	1483
18-49	410	376	334	308	278

Number of patients at risk, stratified by Age at 1 year baseline check (years)



85 and over	4339	3854	3370	2959	2546
80-84	3788	3466	3184	2867	2559
75-79	3684	3426	3152	2866	2568
70-74	3450	3201	2962	2741	2495
65-69	3202	2948	2706	2474	2235
50-64	3020	2801	2619	2403	2193
18-49	558	512	481	451	410

Number of patients at risk, stratified by Age at 1 year baseline check (years)




85 and over	1310	1077	874	695	545	389	268	139	20
80-84	1453	1220	1021	820	647	489	323	170	25
75-79	1590	1396	1205	1010	810	602	429	231	42
70-74	1585	1349	1156	955	791	621	438	224	51
65-69	1390	1210	1027	851	696	517	356	183	30
50-64	1483	1275	1111	907	716	543	378	218	41
18-49	278	241	215	180	140	111	81	54	6

Number of patients at risk, stratified by Age at 1 year baseline check (years)


Cumulative incidence of Overall mortality , stratified by Sex in Group 3 .

The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Female	9258	8464	7688	6978	6209	5522	4908	4309	3711	3166	2678	2172	1753	1308	899	469	82
Male	12783	11744	10786	9783	8797	7863	7062	6224	5381	4602	3931	3246	2592	1964	1374	750	133

Number of patients at risk, stratified by Sex




Female	6200		5522		4908		4309		3711
Male	8786		7863		7062		6224		5381

Number of patients at risk, stratified by Sex



Female	9258		8464		7688		6978		6209
Male	12783		11744		10786		9783		8797


Number of patients at risk, stratified by Sex



Female	3710	3166	2678	2172	1753	1308	899	469	82
Male	5379	4602	3931	3246	2592	1964	1374	750	133


Number of patients at risk, stratified by Sex

Cumulative incidence of Overall mortality , stratified by OAP use (Total) in Group 3 .
The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,
C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Yes	7673	7095	6560	5982	5377	4835	4324	3804	3309	2793	2405	1950	1566	1180	818	442	77
No	14368	13113	11914	10779	9629	8550	7646	6729	5783	4975	4204	3468	2779	2092	1455	777	138

Number of patients at risk, stratified by OAP use (Total)




Yes	5368	4835	4324	3804	3309
No	9618	8550	7646	6729	5783

Number of patients at risk, stratified by OAP use (Total)



Yes	7673	7095	6560	5982	5377
No	14368	13113	11914	10779	9629

Number of patients at risk, stratified by OAP use (Total)




Yes	3308	2793	2405	1950	1566	1180	818	442	77
No	5781	4975	4204	3468	2779	2092	1455	777	138

Number of patients at risk, stratified by OAP use (Total)


Cumulative incidence of Overall mortality , stratified by Number of additional risk factors in Group 3 .

The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




5	25	25	20	16	12	11	10	10	10	9	7	6	4	3	1
4	292	265	234	209	189	168	153	134	115	100	87	74	64	50	22
3	2045	1855	1672	1525	1350	1202	1087	939	792	664	560	447	358	268	198
2	7395	6744	6158	5568	4964	4387	3921	3444	2971	2535	2159	1748	1374	1042	720
1	12284	11319	10390	9443	8491	7617	6798	6006	5204	4459	3794	3140	2542	1906	1312

Number of patients at risk, stratified by Number of additional risk factors




5	12	11	11	10	10
4	189	168	153	134	115
3	1349	1202	1087	939	792
2	4958	4387	3921	3444	2971
1	8478	7617	6798	6006	5204

Number of patients at risk, stratified by Number of additional risk factors



5	25	25	20	16	12
4	292	265	234	209	189
3	2045	1855	1672	1525	1350
2	7395	6744	6158	5568	4964
1	12284	11319	10390	9443	8491


Number of patients at risk, stratified by Number of additional risk factors



5	10	10	9	9	7	6	4	3	1
4	115	100	87	74	64	50	39	22	5
3	792	664	560	447	358	268	198	109	14
2	2969	2535	2159	1748	1374	1042	720	384	76
1	5203	4459	3794	3140	2542	1906	1312	701	119


Number of patients at risk, stratified by Number of additional risk factors

Cumulative incidence of Overall mortality , stratified by Chronic use of anticoagulation medication in Group 3 .
The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,
C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Yes	2847	2583	2327	2087	1848	1623	1439	1266	1056	901	742	613	483	360	248	127	24
No	19194	17625	16147	14674	13158	11762	10531	9267	8036	6867	5867	4805	3862	2912	2025	1092	191

Number of patients at risk, stratified by Chronic use of anticoagulation medication




Yes	1847	1623	1439	1266	1056
No	13139	11762	10531	9267	8036

Number of patients at risk, stratified by Chronic use of anticoagulation medication



Yes	2847	2583	2327	2087	1848
No	19194	17625	16147	14674	13158

Number of patients at risk, stratified by Chronic use of anticoagulation medication



Yes	1056	901	742	613	483	360	248	127	24
No	8033	6867	5867	4805	3862	2912	2025	1092	191

Number of patients at risk, stratified by Chronic use of anticoagulation medication

EPID Research Oy	Confidential	252
------------------	--------------	-----





1.4.4 Cumulative incidence of primary outcomes for group 4

Myocardial infarction

Cumulative incidence of Myocardial infarction , stratified by Age at 1 year baseline check (years) in Group 4 .


The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,

C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Cumulative incidence of Myocardial infarction , stratified by Sex in Group 4 .

The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Female	8041	7275	6555	5881	5190	4609	4068	3537	3047	2593	2185	1762	1427	1065	720	375	68
Male	11153	10147	9256	8369	7484	6664	5962	5247	4548	3853	3300	2713	2162	1628	1135	617	109

Number of patients at risk, stratified by Sex



Female	5182		4609		4068		3537		3047
Male	7473		6664		5962		5247		4548

Number of patients at risk, stratified by Sex



Female	8041		7275		6555		5881		5190
Male	11153		10147		9256		8369		7484

Number of patients at risk, stratified by Sex




Female	3047		2593		2185		1762		1427		1065		720		375		68
Male	4546		3853		3300		2713		2162		1628		1135		617		109

Number of patients at risk, stratified by Sex


Cumulative incidence of Myocardial infarction , stratified by OAP use (Total) in Group 4 .

The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,
C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Yes	7382	6760	6200	5628	5029	4497	4000	3503	3042	2553	2190	1773	1416	1061	721	393	73
No	11812	10662	9611	8622	7645	6776	6030	5281	4553	3893	3295	2702	2173	1632	1134	599	104

Number of patients at risk, stratified by OAP use (Total)




Yes	5020	4497	4000	3503	3042
No	7635	6776	6030	5281	4553

Number of patients at risk, stratified by OAP use (Total)



Yes	7382	6760	6200	5628	5029
No	11812	10662	9611	8622	7645


Number of patients at risk, stratified by OAP use (Total)



Yes	3041	2553	2190	1773	1416	1061	721	393	73
No	4552	3893	3295	2702	2173	1632	1134	599	104


Number of patients at risk, stratified by OAP use (Total)

Cumulative incidence of Myocardial infarction, stratified by Number of additional risk factors in Group 4.
The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




5	23	23	18	14	12	11	10	9	9	8	7	6	5	3	3	1
4	225	196	173	152	130	119	104	88	75	62	52	44	34	27	20	2
3	1673	1493	1317	1193	1047	920	823	705	595	496	422	334	270	202	150	12
2	6307	5695	5156	4606	4082	3613	3212	2809	2430	2053	1749	1405	1108	831	560	295
1	10966	10015	9147	8285	7403	6610	5881	5173	4486	3826	3254	2685	2171	1628	1122	603

Number of patients at risk, stratified by Number of additional risk factors




5	12	11	10	9	9
4	130	119	104	88	75
3	1046	920	823	705	595
2	4076	3613	3212	2809	2430
1	7391	6610	5881	5173	4486

Number of patients at risk, stratified by Number of additional risk factors



5	23	23	18	14	12
4	225	196	173	152	130
3	1673	1493	1317	1193	1047
2	6307	5695	5156	4606	4082
1	10966	10015	9147	8285	7403

Number of patients at risk, stratified by Number of additional risk factors






5	9	9	8	7	6	5	3	3	1
4	75	62	52	44	34	27	20	10	2
3	595	496	422	334	270	202	150	81	12
2	2429	2053	1749	1405	1108	831	560	295	61
1	4485	3826	3254	2685	2171	1628	1122	603	101

Number of patients at risk, stratified by Number of additional risk factors

Stroke (total)


Cumulative incidence of Stroke (total) , stratified by Age at 1 year baseline check (years) in Group 4 .

The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Cumulative incidence of Stroke (total) , stratified by Sex in Group 4 .


The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Number of patients at risk, stratified by Sex



Number of patients at risk, stratified by Sex




Number of patients at risk, stratified by Sex




Number of patients at risk, stratified by Sex

Cumulative incidence of Stroke (total) , stratified by OAP use (Total) in Group 4 .


The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Number of patients at risk, stratified by OAP use (Total)



Number of patients at risk, stratified by OAP use (Total)




Number of patients at risk, stratified by OAP use (Total)




Number of patients at risk, stratified by OAP use (Total)

Cumulative incidence of Stroke (total) , stratified by Number of additional risk factors in Group 4 .
The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,
C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




5	23	22	18	14	11	10	9	9	8	6	5	3	2	1
4	225	201	178	158	140	128	114	101	92	78	66	55	46	35
3	1673	1506	1347	1220	1080	958	868	745	626	521	450	350	279	210
2	6307	5739	5221	4704	4185	3707	3311	2896	2506	2129	1816	1469	1151	867
1	10966	10094	9263	8422	7567	6774	6031	5316	4605	3938	3346	2756	2232	1668

Number of patients at risk, stratified by Number of additional risk factors




5	11	10	9	9
4	140	128	114	101
3	1079	958	868	745
2	4179	3707	3311	2896
1	7555	6774	6031	5316

Number of patients at risk, stratified by Number of additional risk factors



5	23	22	18	14	11
4	225	201	178	158	140
3	1673	1506	1347	1220	1080
2	6307	5739	5221	4704	4185
1	10966	10094	9263	8422	7567

Number of patients at risk, stratified by Number of additional risk factors




5	9	9	8	8	6	5	3	2	1
4	92	78	66	55	46	35	26	12	3
3	626	521	450	350	279	210	155	86	12
2	2503	2129	1816	1469	1151	867	591	315	62
1	4604	3938	3346	2756	2232	1668	1155	624	107

Number of patients at risk, stratified by Number of additional risk factors

Cardiovascular mortality


Cumulative incidence of Cardiovascular mortality, stratified by Age at 1 year baseline check (years) in Group 4.

The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




85 and over	3698	3283	2878	2532	2192	1869	1623	1357	1126	925	743	584	456	328	228	116	18
80-84	3132	2877	2649	2390	2139	1904	1671	1434	1221	1025	864	694	547	416	275	145	19
75-79	3122	2911	2678	2436	2189	1959	1769	1565	1372	1201	1050	872	707	523	372	203	35
70-74	3009	2796	2598	2408	2192	1998	1795	1607	1408	1201	1027	861	710	557	393	198	47
65-69	2891	2664	2449	2240	2020	1816	1640	1464	1262	1094	932	769	632	469	321	169	28
50-64	2805	2601	2433	2236	2033	1857	1714	1547	1382	1191	1043	852	676	512	358	207	38
18-49	537	493	462	432	393	359	319	293	265	230	208	173	134	107	78	54	6

Number of patients at risk, stratified by Age at 1 year baseline check (years)




85 and over	2190	1869	1623	1357	1126
80-84	2135	1904	1671	1434	1221
75-79	2187	1959	1769	1565	1372
70-74	2189	1998	1795	1607	1408
65-69	2013	1816	1640	1464	1262
50-64	2032	1857	1714	1547	1382
18-49	393	359	319	293	265

Number of patients at risk, stratified by Age at 1 year baseline check (years)



85 and over	3698	3283	2878	2532	2192
80-84	3132	2877	2649	2390	2139
75-79	3122	2911	2678	2436	2189
70-74	3009	2796	2598	2408	2192
65-69	2891	2664	2449	2240	2020
50-64	2805	2601	2433	2236	2033
18-49	537	493	462	432	393

Number of patients at risk, stratified by Age at 1 year baseline check (years)




85 and over	1125	925	743	584	456	328	228	116	18
80-84	1221	1025	864	694	547	416	275	145	19
75-79	1372	1201	1050	872	707	523	372	203	35
70-74	1408	1201	1027	861	710	557	393	198	47
65-69	1260	1094	932	769	632	469	321	169	28
50-64	1382	1191	1043	852	676	512	358	207	38
18-49	265	230	208	173	134	107	78	54	6

Number of patients at risk, stratified by Age at 1 year baseline check (years)


Cumulative incidence of Cardiovascular mortality , stratified by Sex in Group 4 .

The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Female	8041	7370	6710	6101	5440	4844	4309	3777	3264	2789	2367	1917	1547	1160	790	414	73
Male	11153	10255	9437	8573	7718	6918	6222	5490	4772	4078	3500	2888	2315	1752	1235	678	118

Number of patients at risk, stratified by Sex



Female	5432		4844		4309		3777		3264
Male	7707		6918		6222		5490		4772

Number of patients at risk, stratified by Sex



Female	8041		7370		6710		6101		5440
Male	11153		10255		9437		8573		7718


Number of patients at risk, stratified by Sex



Female	3263	2789	2367	1917	1547	1160	790	414	73
Male	4770	4078	3500	2888	2315	1752	1235	678	118


Number of patients at risk, stratified by Sex

Cumulative incidence of Cardiovascular mortality , stratified by OAP use (Total) in Group 4 .
The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,
C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Yes	7382	6834	6322	5768	5189	4666	4172	3675	3200	2704	2333	1895	1522	1144	791	430	76
No	11812	10791	9825	8906	7969	7096	6359	5592	4836	4163	3534	2910	2340	1768	1234	662	115

Number of patients at risk, stratified by OAP use (Total)




Yes	5180		4666		4172		3675		3200
No	7959		7096		6359		5592		4836

Number of patients at risk, stratified by OAP use (Total)



Yes	7382		6834		6322		5768		5189
No	11812		10791		9825		8906		7969


Number of patients at risk, stratified by OAP use (Total)



Yes	3199	2704	2333	1895	1522	1144	791	430	76
No	4834	4163	3534	2910	2340	1768	1234	662	115


Number of patients at risk, stratified by OAP use (Total)

Cumulative incidence of Cardiovascular mortality , stratified by Number of additional risk factors in Group 4 .
 The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,
 C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




5	23	23	19	15	12	11	10	10	9	9	7	6	4	3	1
4	225	203	183	161	144	130	116	102	93	79	68	57	47	36	27
3	1673	1519	1370	1253	1116	992	901	777	656	551	471	370	297	224	168
2	6307	5762	5268	4768	4256	3782	3385	2975	2586	2203	1886	1527	1205	908	625
1	10966	10118	9307	8477	7630	6847	6118	5403	4691	4024	3433	2842	2306	1738	1201

Number of patients at risk, stratified by Number of additional risk factors




5	12	11	11	10
4	144	130	116	102
3	1115	992	901	777
2	4250	3782	3385	2975
1	7618	6847	6118	5403

Number of patients at risk, stratified by Number of additional risk factors



5	23	23	19	15	12
4	225	203	183	161	144
3	1673	1519	1370	1253	1116
2	6307	5762	5268	4768	4256
1	10966	10118	9307	8477	7630

Number of patients at risk, stratified by Number of additional risk factors







5	10	10	9	9	7	6	4	3	1
4	93	79	68	57	47	36	27	13	3
3	656	551	471	370	297	224	168	93	13
2	2584	2203	1886	1527	1205	908	625	335	64
1	4690	4024	3433	2842	2306	1738	1201	648	110


Number of patients at risk, stratified by Number of additional risk factors

Composite end-point

Cumulative incidence of Composite end-point , stratified by Age at 1 year baseline check (years) in Group 4 .
The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,
C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Cumulative incidence of Composite end-point , stratified by Sex in Group 4 .
 The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,
 C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Female	8041	7247	6500	5815	5119	4530	3984	3456	2967	2519	2115	1697	1372	1016	683	354	66
Male	11153	10116	9201	8292	7398	6577	5874	5147	4451	3763	3216	2632	2089	1568	1091	596	105

Number of patients at risk, stratified by Sex




Female	5111		4530		3984		3456		2967
Male	7387		6577		5874		5147		4451

Number of patients at risk, stratified by Sex



Female	8041		7247		6500		5815		5119
Male	11153		10116		9201		8292		7398

Number of patients at risk, stratified by Sex




Female	2966	2519	2115	1697	1372	1016	683	354	66
Male	4449	3763	3216	2632	2089	1568	1091	596	105

Number of patients at risk, stratified by Sex


Cumulative incidence of Composite end-point , stratified by OAP use (Total) in Group 4 .

The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,
C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Yes	7382	6747	6167	5581	4975	4440	3940	3442	2984	2501	2138	1722	1376	1019	690	372	70
No	11812	10616	9534	8526	7542	6667	5918	5161	4434	3781	3193	2607	2085	1565	1084	578	101

Number of patients at risk, stratified by OAP use (Total)




Yes	4966	4440	3940	3442	2984
No	7532	6667	5918	5161	4434

Number of patients at risk, stratified by OAP use (Total)



Yes	7382	6747	6167	5581	4975
No	11812	10616	9534	8526	7542


Number of patients at risk, stratified by OAP use (Total)



Yes	2983	2501	2138	1722	1376	1019	690	372	70
No	4432	3781	3193	2607	2085	1565	1084	578	101


Number of patients at risk, stratified by OAP use (Total)

Cumulative incidence of Composite end-point , stratified by Number of additional risk factors in Group 4 .
The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,
C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




5	23	22	17	13	11	10	9	8	8	8	6	5	4	2	2	1
4	225	194	169	150	128	117	102	87	74	61	50	42	33	26	19	10
3	1673	1481	1295	1162	1013	890	794	676	568	471	405	317	254	189	138	75
2	6307	5673	5112	4546	4019	3547	3149	2738	2362	1993	1693	1357	1065	800	534	281
1	10966	9993	9108	8236	7346	6543	5804	5094	4406	3749	3176	2607	2104	1555	1081	582

Number of patients at risk, stratified by Number of additional risk factors




5	11	10	9	8	8
4	128	117	102	87	74
3	1012	890	794	676	568
2	4013	3547	3149	2738	2362
1	7334	6543	5804	5094	4406

Number of patients at risk, stratified by Number of additional risk factors



5	23	22	17	13	11
4	225	194	169	150	128
3	1673	1481	1295	1162	1013
2	6307	5673	5112	4546	4019
1	10966	9993	9108	8236	7346

Number of patients at risk, stratified by Number of additional risk factors




5	8	8	7	6	5	4	2	2	1
4	74	61	50	42	33	26	19	10	2
3	568	471	405	317	254	189	138	75	11
2	2360	1993	1693	1357	1065	800	534	281	59
1	4405	3749	3176	2607	2104	1555	1081	582	98

Number of patients at risk, stratified by Number of additional risk factors

Overall mortality


Cumulative incidence of Overall mortality, stratified by Age at 1 year baseline check (years) in Group 4.

The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




85 and over	3698	3283	2878	2532	2192	1869	1623	1357	1126	925	743	584	456	328	228	116	18
80-84	3132	2877	2649	2390	2139	1904	1671	1434	1221	1025	864	694	547	416	275	145	19
75-79	3122	2911	2678	2436	2189	1959	1769	1565	1372	1201	1050	872	707	523	372	203	35
70-74	3009	2796	2598	2408	2192	1998	1795	1607	1408	1201	1027	861	710	557	393	198	47
65-69	2891	2664	2449	2240	2020	1816	1640	1464	1262	1094	932	769	632	469	321	169	28
50-64	2805	2601	2433	2236	2033	1857	1714	1547	1382	1191	1043	852	676	512	358	207	38
18-49	537	493	462	432	393	359	319	293	265	230	208	173	134	107	78	54	6

Number of patients at risk, stratified by Age at 1 year baseline check (years)




85 and over	2190	1869	1623	1357	1126
80-84	2135	1904	1671	1434	1221
75-79	2187	1959	1769	1565	1372
70-74	2189	1998	1795	1607	1408
65-69	2013	1816	1640	1464	1262
50-64	2032	1857	1714	1547	1382
18-49	393	359	319	293	265

Number of patients at risk, stratified by Age at 1 year baseline check (years)



85 and over	3698	3283	2878	2532	2192
80-84	3132	2877	2649	2390	2139
75-79	3122	2911	2678	2436	2189
70-74	3009	2796	2598	2408	2192
65-69	2891	2664	2449	2240	2020
50-64	2805	2601	2433	2236	2033
18-49	537	493	462	432	393

Number of patients at risk, stratified by Age at 1 year baseline check (years)




85 and over	1125	925	743	584	456	328	228	116	18
80-84	1221	1025	864	694	547	416	275	145	19
75-79	1372	1201	1050	872	707	523	372	203	35
70-74	1408	1201	1027	861	710	557	393	198	47
65-69	1260	1094	932	769	632	469	321	169	28
50-64	1382	1191	1043	852	676	512	358	207	38
18-49	265	230	208	173	134	107	78	54	6

Number of patients at risk, stratified by Age at 1 year baseline check (years)


Cumulative incidence of Overall mortality , stratified by Sex in Group 4 .

The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Female	8041	7370	6710	6101	5440	4844	4309	3777	3264	2789	2367	1917	1547	1160	790	414	73
Male	11153	10255	9437	8573	7718	6918	6222	5490	4772	4078	3500	2888	2315	1752	1235	678	118

Number of patients at risk, stratified by Sex




Female	5432	4844	4309	3777	3264
Male	7707	6918	6222	5490	4772

Number of patients at risk, stratified by Sex



Female	8041	7370	6710	6101	5440
Male	11153	10255	9437	8573	7718


Number of patients at risk, stratified by Sex



Female	3263	2789	2367	1917	1547	1160	790	414	73
Male	4770	4078	3500	2888	2315	1752	1235	678	118


Number of patients at risk, stratified by Sex

Cumulative incidence of Overall mortality , stratified by OAP use (Total) in Group 4 .
 The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,
 C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Yes	7382	6834	6322	5768	5189	4666	4172	3675	3200	2704	2333	1895	1522	1144	791	430	76
No	11812	10791	9825	8906	7969	7096	6359	5592	4836	4163	3534	2910	2340	1768	1234	662	115

Number of patients at risk, stratified by OAP use (Total)




Yes	5180	4666	4172	3675	3200
No	7959	7096	6359	5592	4836

Number of patients at risk, stratified by OAP use (Total)



Yes	7382	6834	6322	5768	5189
No	11812	10791	9825	8906	7969

Number of patients at risk, stratified by OAP use (Total)




Yes	3199	2704	2333	1895	1522	1144	791	430	76
No	4834	4163	3534	2910	2340	1768	1234	662	115

Number of patients at risk, stratified by OAP use (Total)


Cumulative incidence of Overall mortality , stratified by Number of additional risk factors in Group 4 .

The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




5	23	23	19	15	12	11	10	10	10	9	9	7	6	4	3	1
4	225	203	183	161	144	130	116	102	93	79	68	57	47	36	27	3
3	1673	1519	1370	1253	1116	992	901	777	656	551	471	370	297	224	168	13
2	6307	5762	5268	4768	4256	3782	3385	2975	2586	2203	1886	1527	1205	908	625	64
1	10966	10118	9307	8477	7630	6847	6118	5403	4691	4024	3433	2842	2306	1738	1201	648

Number of patients at risk, stratified by Number of additional risk factors




5	12	11	11	10	10
4	144	130	116	102	93
3	1115	992	901	777	656
2	4250	3782	3385	2975	2586
1	7618	6847	6118	5403	4691

Number of patients at risk, stratified by Number of additional risk factors



5	23	23	19	15	12
4	225	203	183	161	144
3	1673	1519	1370	1253	1116
2	6307	5762	5268	4768	4256
1	10966	10118	9307	8477	7630

Number of patients at risk, stratified by Number of additional risk factors



5	10	10	9	9	7	6	4	3	1
4	93	79	68	57	47	36	27	13	3
3	656	551	471	370	297	224	168	93	13
2	2584	2203	1886	1527	1205	908	625	335	64
1	4690	4024	3433	2842	2306	1738	1201	648	110

Number of patients at risk, stratified by Number of additional risk factors





EPID Research Oy	Confidential	273
------------------	--------------	-----

1.4.5 Cumulative incidence of primary outcomes for group 5

Myocardial infarction


Cumulative incidence of Myocardial infarction , stratified by Age at 1 year baseline check (years) in Group 5 .

The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Cumulative incidence of Myocardial infarction , stratified by Sex in Group 5 .

The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Female	4548	4101	3650	3250	2845	2489	2189	1905	1615	1368	1140	928	745	549	372	196	32
Male	4394	3951	3561	3170	2803	2457	2179	1902	1655	1429	1224	1030	834	628	450	244	42

Number of patients at risk, stratified by Sex



Female	2842	2489	2189	1905	1615
Male	2798	2457	2179	1902	1655

Number of patients at risk, stratified by Sex



Female	4548	4101	3650	3250	2845
Male	4394	3951	3561	3170	2803


Number of patients at risk, stratified by Sex




Female	1615	1368	1140	928	745	549	372	196	32
Male	1655	1429	1224	1030	834	628	450	244	42

Number of patients at risk, stratified by Sex


Cumulative incidence of Myocardial infarction , stratified by Number of additional risk factors in Group 5 .
The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,
C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Number of patients at risk, stratified by Number of additional risk factors



Number of patients at risk, stratified by Number of additional risk factors



Number of patients at risk, stratified by Number of additional risk factors




Number of patients at risk, stratified by Number of additional risk factors

Stroke (total)

Cumulative incidence of Stroke (total) , stratified by Age at 1 year baseline check (years) in Group 5 .


The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.



85 and over	2643	2327	2015	1767	1522	1283	1110	922	755	628	500	382	296	202	139	74	11
80-84	1773	1622	1480	1334	1177	1047	904	774	647	543	454	366	295	226	148	84	12
75-79	1401	1281	1177	1057	937	818	742	659	575	504	438	372	296	220	149	84	12
70-74	1196	1107	1017	930	852	773	698	630	558	480	413	358	296	233	179	90	22
65-69	1075	994	916	835	748	667	600	541	480	422	354	298	244	182	127	64	10
50-64	854	794	731	662	607	554	507	463	412	359	322	279	217	165	115	72	12


Number of patients at risk, stratified by Age at 1 year baseline check (years)

B



85 and over	2643	2327	2015	1767	1522
80-84	1773	1622	1480	1334	1177
75-79	1401	1281	1177	1057	937
70-74	1196	1107	1017	930	852
65-69	1075	994	916	835	748
50-64	854	794	731	662	607


Number of patients at risk, stratified by Age at 1 year baseline check (years)



85 and over	1521	1283	1110	922	755
80-84	1176	1047	904	774	647
75-79	935	818	742	659	575
70-74	849	773	698	630	558
65-69	747	667	600	541	480
50-64	607	554	507	463	412

Number of patients at risk, stratified by Age at 1 year baseline check (years)

D




85 and over	754	628	500	382	296	202	139	74	11
80-84	647	543	454	366	295	226	148	84	12
75-79	575	504	438	372	296	220	149	84	12
70-74	558	480	413	358	296	233	179	90	22
65-69	480	422	354	298	244	182	127	64	10
50-64	412	359	322	279	217	165	115	72	12

Number of patients at risk, stratified by Age at 1 year baseline check (years)


Cumulative incidence of Stroke (total) , stratified by Sex in Group 5 .

The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Female	4548	4142	3718	3353	2965	2603	2297	2018	1714	1446	1210	981	784	579	394	211	34
Male	4394	3983	3618	3232	2878	2539	2264	1971	1713	1490	1271	1074	860	649	463	257	45

Number of patients at risk, stratified by Sex




Female	2962	2603	2297	2018	1714
Male	2873	2539	2264	1971	1713

Number of patients at risk, stratified by Sex



Female	4548	4142	3718	3353	2965
Male	4394	3983	3618	3232	2878


Number of patients at risk, stratified by Sex



Female	1713	1446	1210	981	784	579	394	211	34
Male	1713	1490	1271	1074	860	649	463	257	45


Number of patients at risk, stratified by Sex

Cumulative incidence of Stroke (total) , stratified by Number of additional risk factors in Group 5 .
The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,
C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




5	4	4	4	3	2	2	2	1	1	1	0	0	0	0
4	56	50	42	38	34	31	28	24	23	20	14	10	6	6
3	602	525	458	402	347	298	267	220	191	157	137	107	86	68
2	2805	2529	2271	2040	1796	1564	1383	1197	1026	886	757	623	490	371
1	5475	5017	4561	4102	3664	3247	2881	2547	2186	1872	1572	1314	1059	783

Number of patients at risk, stratified by Number of additional risk factors




5	2	2	2	1	1
4	34	31	28	24	23
3	347	298	267	220	191
2	1795	1564	1383	1197	1026
1	3657	3247	2881	2547	2186

Number of patients at risk, stratified by Number of additional risk factors



5	4	4	4	3	2
4	56	50	42	38	34
3	602	525	402	347	298
2	2805	2529	2271	2040	1796
1	5475	5017	4561	4102	3664

Number of patients at risk, stratified by Number of additional risk factors




5	1	1	1	1	0	0	0	0	0
4	23	20	14	10	9	6	6	2	1
3	191	157	137	107	86	68	47	23	3
2	1025	886	757	623	490	371	258	139	21
1	2186	1872	1572	1314	1059	783	546	304	54

Number of patients at risk, stratified by Number of additional risk factors


Cardiovascular mortality

Cumulative incidence of Cardiovascular mortality , stratified by Age at 1 year baseline check (years) in Group 5 .


The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Number of patients at risk, stratified by Age at 1 year baseline check (years)



Number of patients at risk, stratified by Age at 1 year baseline check (years)




Number of patients at risk, stratified by Age at 1 year baseline check (years)




Number of patients at risk, stratified by Age at 1 year baseline check (years)

Cumulative incidence of Cardiovascular mortality , stratified by Sex in Group 5 .


The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.



Number of patients at risk, stratified by Sex



Number of patients at risk, stratified by Sex




Number of patients at risk, stratified by Sex




Number of patients at risk, stratified by Sex

Cumulative incidence of Cardiovascular mortality , stratified by Number of additional risk factors in Group 5 .
The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,
C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




5	4	4	4	3	2	2	1	1	1	1	0	0	0	0
4	56	50	43	38	35	31	29	24	23	20	14	10	6	2
3	602	529	466	411	357	309	278	232	201	168	144	113	93	75
2	2805	2543	2290	2065	1817	1585	1407	1225	1053	915	786	649	516	390
1	5475	5032	4586	4136	3701	3287	2926	2589	2230	1917	1619	1361	1100	818

Number of patients at risk, stratified by Number of additional risk factors




5	2	2	2	1	1
4	35	31	29	24	23
3	357	309	278	232	201
2	1816	1585	1407	1225	1053
1	3694	3287	2926	2589	2230

Number of patients at risk, stratified by Number of additional risk factors



5	4	4	4	3	2
4	56	50	43	38	35
3	602	529	466	411	357
2	2805	2543	2290	2065	1817
1	5475	5032	4586	4136	3701

Number of patients at risk, stratified by Number of additional risk factors







5	1	1	1	1	0	0	0	0	0
4	23	20	14	10	9	6	6	2	1
3	201	168	144	113	93	75	53	27	4
2	1052	915	786	649	516	390	273	148	21
1	2230	1917	1619	1361	1100	818	571	314	56

Number of patients at risk, stratified by Number of additional risk factors


Composite end-point

Cumulative incidence of Composite end-point , stratified by Age at 1 year baseline check (years) in Group 5 .
The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards,
C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Cumulative incidence of Composite end-point , stratified by Sex in Group 5 .

The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Female	4548	4083	3622	3218	2814	2459	2154	1871	1584	1338	1108	895	717	527	355	191	31
Male	4394	3938	3540	3139	2772	2425	2145	1862	1612	1387	1187	995	799	599	429	233	40

Number of patients at risk, stratified by Sex




Female	2811	2459	2154	1871	1584
Male	2767	2425	2145	1862	1612

Number of patients at risk, stratified by Sex



Female	4548	4083	3622	3218	2814
Male	4394	3938	3540	3139	2772


Number of patients at risk, stratified by Sex



Female	1584	1338	1108	895	717	527	355	191	31
Male	1612	1387	1187	995	799	599	429	233	40


Number of patients at risk, stratified by Sex

Cumulative incidence of Composite end-point, stratified by Number of additional risk factors in Group 5.
The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




5	4	4	4	3	2	2	1	1	1	0	0	0	0	0	0
4	56	47	39	36	31	29	25	21	19	17	11	8	7	4	2
3	602	517	436	376	318	269	232	192	166	137	120	93	75	60	42
2	2805	2496	2214	1952	1699	1468	1288	1106	945	813	694	566	451	340	235
1	5475	4957	4469	3990	3536	3116	2752	2413	2065	1757	1469	1223	983	722	503

Number of patients at risk, stratified by Number of additional risk factors




5	2	2	2	1	1
4	31	29	25	21	19
3	318	269	232	192	166
2	1698	1468	1288	1106	945
1	3529	3116	2752	2413	2065

Number of patients at risk, stratified by Number of additional risk factors



5	4	4	4	3	2
4	56	47	39	36	31
3	602	517	436	376	318
2	2805	2496	2214	1952	1699
1	5475	4957	4469	3990	3536

Number of patients at risk, stratified by Number of additional risk factors




5	1	1	1	0	0	0	0	0	0
4	19	17	11	8	7	4	4	2	1
3	166	137	120	93	75	60	42	19	3
2	945	813	694	566	451	340	235	124	20
1	2065	1757	1469	1223	983	722	503	279	47


Number of patients at risk, stratified by Number of additional risk factors

Overall mortality


Cumulative incidence of Overall mortality , stratified by Age at 1 year baseline check (years) in Group 5 .
The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Number of patients at risk, stratified by Age at 1 year baseline check (years)



Number of patients at risk, stratified by Age at 1 year baseline check (years)




Number of patients at risk, stratified by Age at 1 year baseline check (years)



Number of patients at risk, stratified by Age at 1 year baseline check (years)


Cumulative incidence of Overall mortality , stratified by Sex in Group 5 .

The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




Female	4548	4161	3750	3388	3003	2639	2341	2058	1750	1484	1248	1019	816	605	414	219	35
Male	4394	3997	3639	3265	2909	2575	2301	2013	1758	1537	1316	1115	902	684	489	272	47

Number of patients at risk, stratified by Sex




Female	3000	2639	2341	2058	1750
Male	2904	2575	2301	2013	1758

Number of patients at risk, stratified by Sex



Female	4548	4161	3750	3388	3003
Male	4394	3997	3639	3265	2909

Number of patients at risk, stratified by Sex




Female	1749	1484	1248	1019	816	605	414	219	35
Male	1758	1537	1316	1115	902	684	489	272	47

Number of patients at risk, stratified by Sex


Cumulative incidence of Overall mortality , stratified by Number of additional risk factors in Group 5 .

The follow-up time in different panels is A: from the 1-year baseline check to the end of study, B: from the 1-year baseline check to 1 year onwards, C: from the 1-year baseline check +1 year to 1 year onwards, D: from the 1-year baseline check +2 years to the end of study.




5	4	4	4	3	2	2	1	1	1	0	0	0	0
4	56	50	43	38	35	31	29	24	23	20	14	10	6
3	602	529	466	411	357	309	278	232	201	168	144	113	93
2	2805	2543	2290	2065	1817	1585	1407	1225	1053	915	786	649	516
1	5475	5032	4586	4136	3701	3287	2926	2589	2230	1917	1619	1361	1100

Number of patients at risk, stratified by Number of additional risk factors




5	2	2	2	1	1
4	35	31	29	24	23
3	357	309	278	232	201
2	1816	1585	1407	1225	1053
1	3694	3287	2926	2589	2230

Number of patients at risk, stratified by Number of additional risk factors



5	4	4	4	3	2
4	56	50	43	38	35
3	602	529	466	411	357
2	2805	2543	2290	2065	1817
1	5475	5032	4586	4136	3701

Number of patients at risk, stratified by Number of additional risk factors



5	1	1	1	1	0	0	0	0	0
4	23	20	14	10	9	6	6	2	1
3	201	168	144	113	93	75	53	27	4
2	1052	915	786	649	516	390	273	148	21
1	2230	1917	1619	1361	1100	818	571	314	56

Number of patients at risk, stratified by Number of additional risk factors